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ABSTRACT (GERMAN) 
Eine der größten Herausforderungen für die Formulierungsentwicklung in der 
pharmazeutischen Technologie ist die häufig schlechte Wasserlöslichkeit von 
Wirkstoffen (WS). Nur ein im Körper gelöst vorliegender WS wird seine Wirkung 
voll entfalten können. Nach der oralen Gabe einer festen Arzneiform und deren 
Disintegration im Gastrointestinaltrakt (GIT) muss der WS so schnell in Lösung 
gehen können, dass er während der Passagezeit durch den GIT absorbiert wer-
den kann. Besonders in den letzten Jahrzehnten wurden vielfältige Technologien 
entwickelt, um Lösungsansätze hierfür zu finden. Zwei gängige Techniken, die 
Herstellung einer festen Dispersion mit einhergehender Amorphisierung des WS, 
sowie die Erzeugung von Einschlussverbindungen (EV) mit Cyclodextrinen (CD), 
wurden im Rahmen dieser Arbeit untersucht. Die festen Dispersionen oder gege-
benenfalls feste Lösungen wurden hierbei mit den Methoden der Schmelzextrusi-
on (SE) und Schmelzgranulation (SG) mit einem Zweischneckenschmelzextruder 
erhalten. Das sehr schlecht wasserlösliche Antimykotikum Itraconazol (ITR) dien-
te in der vorliegenden Arbeit als Modellarzneistoff. Während üblicherweise ther-
moplastische Polymere als Matrixsubstanzen in Schmelzprozessen dienen, wurde 
hier vorwiegend β-Cyclodextrin (βCD) als Träger verwendet. Zudem lag der Fo-
kus darauf, möglichst auf ternäre Zusätze zu verzichten und eine reine ITR-βCD-
Formulierung zu gewinnen. Wie in Schmelzprozessen üblich, wurde vollständig 
auf die Zugabe von potentiell toxischen Lösungsmitteln verzichtet. Aber auch die 
Zugabe von Wasser, welches die mikrobielle Anfälligkeit einer Formulierung er-
höhen kann, wurde vermieden. All dies ermöglichte einen kontinuierlichen, kos-
tengünstigen und ökologisch attraktiven Herstellungsprozess. 
Die Entwicklung einer solchen Formulierung und nicht zuletzt die Entwicklung 
des dazugehörigen stabilen Schmelzprozesses ist in der Literatur bisher nicht o-
der nur sehr marginal beschrieben worden und wird in den meisten Reviews nicht 
behandelt. Trotz der patentierten Anwendung von βCD als Träger in Schmelzpro-
zessen werden EV mit WS fast ausschließlich im wässrigen Milieu gewonnen. Fes-
te EV entstehen nachfolgend durch Gefriertrocknung oder vergleichbare Verfah-
ren. Die Kombination von Schmelzprozessen und CD-EV ist zudem bis auf sehr 
wenige Ausnahmen nur im Beisein von Polymeren untersucht worden. Sowohl die 
komplett flüssigkeitsfreie Erzeugung von EV als auch die polymerfreie SE oder 
SG wurden bislang nicht umfassend charakterisiert, obwohl sich viele formulie-
rungstechnische Vorteile in einer solchen Methodik vereinen. Daher lag es im be-
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sonderen Interesse, synergistische oder additive Effekte dieser beiden Technologien 
auf die grundsätzlichen Eigenschaften des Produkts sowie vor allem auf die Löslich-
keit beziehungsweise Lösungsgeschwindigkeit von ITR in-vitro zu untersuchen. 
In der vorliegenden Arbeit konnte gezeigt werden, dass zum einen unter Zuhil-
fenahme einer eigens hierfür entwickelten Düsengeometrie eine stabile SE mög-
lich war und zum anderen, dass gleichwertige Produkte mit einer stabilen SG er-
halten werden konnten, die einfacher handzuhaben war. Es wurde ein optimales 
Temperaturprofil für die Herstellung des Schmelzgranulats gefunden, dessen Ma-
ximaltemperatur ca. 10 °C über dem Schmelzpunkt (Tm) von ITR lag. Dieses ver-
einte die Amorphisierung des ITR mit einer fast quantitativen WS-Freisetzung 
nach 120 min in 0,1 N HCl. Anhand der kombinierten Auswertung mehrerer Me-
thoden war es möglich, auf das Vorhandensein von EV im Schmelzgranulat zu 
schließen. Auch die Verarbeitung deutlich unter dem Tm von ITR zeigte auf-
schlussreiche Ergebnisse, da sich dabei mit ca. 86 % die höchste relative Verbes-
serung der Freisetzung über 4 h nachweisen ließ. Da ITR hier vollständig kristal-
lin vorlag, war der Nachweis von EV vor allem durch die Infrarotspektroskopie 
durchführbar.  
Zudem wurden weitere Optimierungsansätze untersucht. Für Vergleichszwecke 
kamen polymerische Zusätze sowie ein Zuckeralkohol zum Einsatz. Des Weiteren 
wurden Sempera®-Kapseln, ein deutsches orales ITR-Marktprodukt, als Referenz 
analysiert. Einzig ein geringer Hydroxypropylmethylcellulose-Zusatz in der SG 
war in der Lage, die Freisetzungsgeschwindigkeit des ITR im Vergleich zum binä-
ren Schmelzgranulat zu erhöhen. Jedoch zeigte sich in diesem ternären System 
Segregation der Pulvermischung während der Fütterung des Schmelzextruders. 
Mit dem zur Verfügung stehenden Equipment war die Stabilität dieses Optimie-
rungsansatzes nicht ausreichend gesichert. Eine kontrollierte Substanzenzufüh-
rung über mehrere Fütterstationen könnte diese festgestellte Problematik jedoch 
beheben. Darüber hinaus wurden Stabilitätsuntersuchungen bei Stressbedingun-
gen (40 °C/75 % relative Luftfeuchte) über sechs Monate bei fast allen herge-
stellten Proben durchgeführt. Hierbei konnte kein substantieller Qualitätsabfall 
der Produkte beobachtet werden. 
Im Kontext dieser Arbeit konnte dargestellt werden, dass der entwickelte 
Schmelzgranulierungsprozess ein neuartiger, innovativer Ansatz für eine kontinu-
ierliche Verarbeitung von CDs ist, um simultan wasserfrei EV zu erzeugen.  
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ABSTRACT  
One of the major challenges in the field of pharmaceutical technology is the 
poor aqueous solubility of active pharmaceutical ingredients (APIs). Most of the 
time, the API can only come to full effect in the body if it is dissolved in physio-
logical fluids. After oral administration of a solid dosage form and the following 
disintegration in the gastrointestinal tract (GIT), the dissolution kinetics of the 
API need to be fast enough so that API molecules can be absorbed during GIT 
passage. Especially in the last decades, a plethora of techniques were developed 
to resolve this. Two well-established technologies were combined in this project. 
Firstly, the manufacture of solid dispersions during which the API was trans-
formed to its amorphous state and secondly, the formation of inclusion complex-
es (ICs) with cyclodextrins (CDs). For obtaining the solid dispersions or, if appli-
cable, solid solutions, hot-melt extrusion (HME) and hot-melt granulation (HMG) 
were employed. Thereby, a melt twin-screw extruder was utilised. Throughout 
this thesis, the poorly water-soluble antifungal drug itraconazole (ITR) served as 
model API. Traditionally, the matrix component in melt processes is a thermo-
plastic polymer. Different from this, in this project, β­cyclodextrin (βCD) was in-
vestigated as carrier in HME and HMG. Moreover, the focus was put on trying to 
avoid ternary additives in the formulation as the overall aim was a binary product 
of ITR and βCD. As customary in melt processes, no potentially toxic liquid was 
added during manufacturing. Furthermore, the use of water was omitted since 
this can alter the microbiological susceptibility of the formulation. All of this en-
sured a continuous, cost-effective and ecologically attractive manufacturing process.  
The development of such a formulation as well as the development of the sta-
ble melt process have only been described marginally in the literature. Most re-
views do not even cover the possibility of this special application. Even though 
βCD has been patented for the use as matrix substance in HME, nearly all ICs 
are formed in an aqueous milieu. Solid ICs are successively obtained by freeze 
drying or comparable techniques. With only very few exceptions, the combination 
of melt processes and ICs with CDs has only been investigated in the presence of 
polymers. Both, the completely dry formation of ICs, as well as polymer-free 
melt processes have not been comprehensively characterised. This is surprising 
as both techniques unite diverse advantages for the formulation. Consequently, 
in this project, there was a strong interest to investigate synergistic and additive 
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effects that both of these technologies would have on the solubility or rather sol-
ubility rate of ITR in-vitro and on the general product. 
In this present work, it was shown that it was possible to achieve a stable SE-
process with βCD as matrix. For this, a self-developed die geometry was utilised. 
Also it was presented that products with the same quality could be obtained by a 
stable HMG procedure which was simpler to operate. An optimal HMG tempera-
ture profile was found. The maximum temperature was approximately 10 °C 
higher than the melting point (Tm) of ITR. By this, amorphisation of ITR was 
achieved as well as nearly quantitative ITR dissolution in 0.1 N HCl after 
120 min. By using the combined results of different methods, it was possible to 
conclude the presence of ICs in the melt granules. Processing below ITR Tm also 
yielded informative results as the relatively highest increase in ITR dissolu-
tion over 4 h (86 %) was determined for such a sample. Since ITR was complete-
ly crystalline in this specimen, ICs could be verified by infrared spectroscopy. 
Additionally, different optimisation approaches were investigated. Polymeric 
additives as well as a sugar alcohol were examined. Moreover, Sempera® cap-
sules, an oral ITR formulation on the German market, was analysed as reference. 
Merely the minor addition of hydroxypropyl methylcellulose in HMG resulted in 
faster ITR dissolution compared to the binary product. However, during this HMG 
procedure, segregation of the powder blend occurred in the feeding system of 
the extruder. The available equipment did not allow sufficient and reproducible 
stability of this optimisation approach. Nonetheless, this phenomenon could 
probably be resolved by applying a more controllable feeding system with sepa-
rate feeding units. Finally, a stability study was conducted at elevated condi-
tions (40 °C/75 % relative humidity) for six months. Nearly all manufactured 
samples were subjected to this stability investigation. No substantial loss in 
product quality was seen.  
In this thesis, it became obvious that the developed HMG process is a novel and 
innovative approach for the continuous processing of CDs during which solvent-
free IC formation can be achieved. 
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I. Introduction and Definition of Objectives 
I.1. Introduction  
Since recent years the pharmaceutical industry faces new obstacles in regard to 
the development of innovative, acceptable formulations. The main objection for 
pharmaceutical technologists probably is the increasing amount of active phar-
maceutical ingredients (APIs) with poor aqueous solubility. This can lead to inad-
equate dissolution and, consequently, bioavailability. Due to advanced high 
throughput screening techniques, these days, new APIs, also called new chemical 
entities (NCEs), are often developed backwards by identifying a target and then 
creating a molecule for interaction. By this, the amount of NCEs with high lipo-
philicity oftentimes increases. It is estimated that over 40 % of marketed drugs 
are poorly water-soluble as well as about 60 % of NCEs, coming directly out of 
the synthesis laboratories [1]. These poorly soluble NCEs can be categorised ac-
cording to the Biopharmaceutics Classification System (BCS) by assigning them 
either in class II or class IV [2]. APIs categorised into BCS class IV possess poor 
aqueous solubility as well as insufficient intestinal permeability, whereas BCS 
class II compounds exhibit good permeability properties.  
BCS class II APIs are most applicable for solubility enhancement by formulation 
design opposing to BCS class IV drugs that are more likely candidates for chang-
es on the chemical level, such as addition of functional groups or synthesising 
them as pro-drugs [3]. For BCS class II compounds, the rate limiting step re-
garding bioavailability is either their absolute solubility or their dissolution rate as 
it is proposed that after being dissolved in the gastrointestinal tract (GIT), ab-
sorption is rapidly following [4]. Therefore, formulation design of BCS class II 
drugs has to be carried out carefully to overcome the deficiency in aqueous solu-
bility. Depending on the desired dosage form, different techniques can be used for 
this solubility enhancement, such as micronisation, nanosizing, crystal engineer-
ing, solid dispersions by hot-melt extrusion (HME), hot-melt granulation (HMG) 
and formation of inclusion complexes (ICs) with cyclodextrins (CDs) [5]. 
Even though formulation research constantly brings forward innovative ap-
proaches for non-invasive systemic drug delivery such as dermal, pulmonary or 
nasal application, the most common for drug administration still is the oral route 
which also shows highest patient adherence [6]. Solid forms comprise the largest 
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share of oral formulations, since they combine different positive properties both 
for the patient as well as for the pharmaceutical manufacturer, like simple ad-
ministration or cost-effective transportation.  
After oral administration of a solid form, the API needs to dissolve in the GIT 
and will then most likely be absorbed in the small intestine before it can take ef-
fect [7]. The oral bioavailability of APIs can vary strongly between different pa-
tients but also for each individual itself due to e.g. change in gastric pH or liquid 
in the GIT. The formulation comprises an additional factor which could possibly 
be responsible for therapeutic failure. Many medications already on the market 
show insufficient and fluctuating bioavailabilities. For instance, when administer-
ing diclofenac or glibenclamide, the oral bioavailability is strongly dependent on 
the formulation and situated between 30 - 80 % and 50 - 90 %, respectively [7]. 
When no alternatives are at disposal, patients have to cope with the risk of either 
inadequate API efficacy or on the other hand, more adverse reactions. By guar-
anteeing that the absorbed API shows the desired therapeutic effect, doses may 
have to be determined higher than necessary with improved formulation design. 
This shows that, although much research has been and still is conducted in the 
field of solubility and dissolution rate enhancement of orally administered drugs, 
there is definitely room for improvement. Most inquisitions only deal with one 
single solubility enhancing technique. Combinational approaches are rarely re-
ported and reviews usually discuss procedures as stand-alones [1,5,8]. 
Over the years, pharmaceutical production has constantly become more regu-
lated which on the one hand is positive for the consumer as it further ensures 
product quality but on the other hand, regulatory, manufacturing and maintain-
ing costs have risen for the pharmaceutical companies. As the development of 
new formulations and NCEs is very costly and patent protection often expires al-
ready a few years after the medication has entered the market, the originator 
company has only limited time to earn the necessary turnover from the product. 
A key factor in ensuring this is to keep manufacturing processes as cost-effective 
and simple as possible whereby at the same time upholding high product quality. 
Traditionally, pharmaceutical production was carried out in batch mode. Recent-
ly, continuous manufacturing has become more and more important as it has 
been recognised by the Food and Drug Administration (FDA) of the United States 
of America (US) [9]. HME and HMG are processes eligible for this. By applying 
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these techniques, it is technically possible to operate production endlessly, re-
sulting in cost savings. With the proper downstream equipment, it is theoretically 
possible to obtain the final dosage form directly after HME/HMG. Moreover, ana-
lytical tools can be applied to monitor product quality throughout the whole pro-
cedure. This is an advantage compared to most batch processes where ordinarily 
samples of specified size are drawn during manufacturing for in-process controls. 
In batch production mode, there is rarely the possibility of a full-batch control, 
especially in volume production where millions of units are produced in a few 
hours. 
Taking all of the points previously mentioned into account, it becomes clear 
that important aspects regarding the future of pharmaceutical technology can be 
identified. First of all, solubility enhancing formulation design should be available 
not only for innovative dosage forms but also for the most utilised oral solids. By 
this, satisfactory oral bioavailability may be ensured for BCS class II drugs and oth-
er substances that show deficiencies in that area. The chosen techniques to achieve 
this should not be applied as solitaries but rather be combinatorically investigated to 
expose synergistic and additive effects for the joint product. Secondly, the thereby 
invented formulations should be producible in a cost-effective, quality-upholding 
manner, in the best case by a continuous manufacturing process. 
In consequence, this thesis presents an innovative approach in the development 
of a solid, oral formulation and optimisation thereof which conflates all of these 
identified needs. The present project targets the solid dispersion technique by HME 
and HMG combined with the encapsulation by CDs to improve the aqueous solubil-
ity of a model BCS class II API. Furthermore, this combinational approach will be 
attempted simultaneously during continuous hot-melt procedures.  
I.2. Objectives 
The present work aims at developing a novel oral solid formulation for the BCS 
class II model compound itraconazole (ITR). The oral bioavailability of ITR shows 
great variability and is situated at an average 55 % for the marketed capsule-
based formulation Sporanox® [10]. Here, ITR spray-coated neutral pellets with 
an ITR mass fraction (drug load) of approximately 22 % are prepared in multi-
stage batch production (see section III.1.2.). In this thesis, emphasis will be put 
on continuously preparing a formulation with ITR that exhibits higher drug load 
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than the marketed counterpart. To pursue advances in ITR dissolution, two solu-
bility enhancing methods will be intertwined. Solid dispersions will be prepared 
by hot-melt procedures within a melt-twin screw extruder (mTSE). Thereby, the 
API can become trapped in a usually polymeric matrix in its amorphous state, re-
sulting in strong dissolution improvement. Apart from the traditional use of pol-
ymers as matrices, CDs will be investigated as matrix to additionally enhance ITR 
solubility by forming ICs within the mTSE.  
Generally, inclusion complex formation (ICF) occurs in the presence of water, 
mostly in solution [11]. Thus, the merging of these two techniques, utilisation of 
an mTSE as well as solvent-free formation of solid ICs during HME or HMG are 
innovative approaches in formulation design. Through this combinational ap-
proach, possible additional and synergistic effects on API solubility and the gen-
eral product can be investigated. To ensure cost-effectiveness, unmodified βCD 
will be utilised predominantly, as it is a considerably inexpensive sustainable ex-
cipient.  
Based on this overall aim of the current study, the following chronological tar-
gets can be ascertained: 
Firstly, a stable operating mTSE process has to be developed and optimised to 
yield products with sufficient characteristics. This includes the exhibition of ICs as 
well as enhanced ITR dissolution. To detect solid ICs, data of different analytical 
tools will be interpreted in a self-constructed coordinated scheme. Preformulation 
studies will be carried out and evolved into a final hot-melt procedure. The 
melt-processed product will be characterised thoroughly.  
Secondly, the developed formulation will be compared with the marketed for-
mulation, alternative methods of ICF as well as varying hot-melt matrix or ter-
nary components to put the formulation’s results into a wider scientific perspec-
tive. The products’ storage stability will be evaluated to gain insights into their 
behaviours at different storage conditions and, moreover, to identify differences 
between the examined alternatives.  
Finally, it will be possible to assess the newly developed formulation’s future 
perspectives and to choose the most promising formulation design approach of 
all the diverse investigated specimen.   
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II. Theoretical Background 
The subsequent chapter gives insights into the necessary theoretical facts for 
the deeper understanding of this thesis.  
II.1. Solubility and Solubility Rate Enhancement of Ac-
tive Pharmaceutical Ingredients 
As mentioned, different strategies can be taken for improving the solubility of 
poorly soluble substances such as BCS class II compounds. For full comprehen-
sion, a schematic view of the different BCS classes is shown in Figure II.1.. 
 
Figure II.1. - Schematic representation of the four different divisions in the Bio-
pharmaceutics Classification System according to [3]. 
This project concentrates on the solubility and dissolution rate enhancements of 
the BCS class II model drug ITR. Recently, Butler and Dressman further divided 
BCS class II in class IIa and class IIb in their so-called “Developability Classifica-
tion System” (DCS) [12]. Hereby, class IIa substances show dissolution rate lim-
ited absorption in the body whereas class IIb drugs are absorbed solubility lim-
ited. This means that a class IIa API will most likely achieve complete oral ab-
sorption even when its saturation solubility is reached in the intestines without 
the need for complex formulation technologies. Class IIb drugs tend to only show 
full absorption if the formulation design achieves an already solubilised form. 
Generally, class IIb APIs prove the greater challenge in formulation develop-
ment [12]. According to Butler, ITR belongs to DCS class IIb [13]. 
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Table II.1. gives a detailed overview of different techniques for solubility en-
hancement, categorised according to either physical or chemical modifications on 
the drug in question.  
Table II.1. - Different approaches for enhancing drug solubility or enlarging the 
available surface area for improving dissolution rate, combined and modified 
after [14,15]. 
Physical modifications Particle size by 
           Micronisation 
           Nanosuspensions 
 Crystal engineering 
           Creation of polymorphs 
           Creation of co-crystals 
           Creation of pseudopolymorphs, including solvates 
 Complexation, solubilisation and delivery systems 
           With surfactants  
                     Micelles 
                     Emulsions and microemulsions 
                     Self-emulsifying systems 
           With cyclodextrins 
           Liposomes and niosomes 
           Further micro/nanoparticles 
 Drug dispersion in different carriers (mostly polymeric) 
           Eutectic mixtures 
           Solid dispersions (non–molecular) 
           Solid solutions 
Chemical modifications Soluble pro-drugs 
 Salts 
 Changes in lipophilic/hydrophilic moieties in synthesis 
The first step in understanding solubility enhancement is the definition of solu-
bility. The Pharmacopoeia Europaea (Ph. Eur.) defines solubility as the saturated 
concentration of a solute (e.g. drug) in regard to the volume of a given sol-
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vent (e.g. gastric fluids) between 15 - 25 °C [16]. This illustrates that the solu-
bility of a substance is a constant at specific conditions. Thus, the term solubility 
enhancement can somewhat be misleading as true solubility enhancement is 
generally only possible by changing the substance on a molecular level such as 
by altered synthesis or by changing the crystal habit (see Table II.1.). In most 
other cases, it is only the solubility/dissolution rate (DR) which is improved, such 
as by enlarging the surface area of the API. An exception to this is the creation of 
a supersaturated solution. By using different excipients, the API is kept from pre-
cipitating in a solution where its concentration exceeds its actual solubility. Ex-
amples for these excipients are surfactants or CDs. The modified Noyes-Whitney 
equation (equation 1) explains the relationship between important factors rele-
vant for dissolution of poorly soluble compounds in the GIT [17]. 
DR = 
dX
dt
 = 
A ∙ D
h
 ∙ (Cs - 
Xd
V
 )               equation 1 
Here, dX is the amount of dissolved drug during a specified time period dt, A is 
the surface area of the API, D the diffusion coefficient, h the effective boundary 
layer thickness, CS the saturation concentration of the API in the gastric condi-
tions, V the volume of the surrounding fluid and Xd the amount of drug already 
dissolved in this fluid. Figure II.2. shows a simplified model of how a drug is ab-
sorbed after being orally ingested. The solid dosage form has to disintegrate and 
subsequently release the API which can then become dissolved. At all times, a 
certain amount of drug will deteriorate in the gastric environment, possibly by 
enzymatic reactions or hydrolysis. Therefore, the release from the dosage form, 
the dissolution and the absorption of the API have to occur fast enough or else all 
of the drug will be metabolised without significant absorption and effect. 
 
Figure II.2. - Following the simplified different occurrences after administering 
a solid oral dosage form, modified after [7,17]. 
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The dissolved drug molecules are passing the intestinal wall, where most ab-
sorption takes place. From there, the drug can enter the blood circulation and 
reach its target site. Simultaneously, the drug undergoes metabolism in the liver 
and in the gut wall. The degree of these metabolisms is strongly dependent on 
drug properties. As mentioned, for BCS class II or rather DCS class IIa drugs, 
the absorption rate is often controlled by the dissolution rate [3]. They have to 
dissolve during GIT passage so that they can still reach the absorptive sites. 
From there, absorption is generally very fast. This explains why so many of the 
techniques mentioned in Table II.1. utilise an enhancement of surface area. This 
improves the wettability of the drug and consequently the dissolution rate (see 
equation 1). For DCS class IIb drugs like ITR, additional techniques such as com-
plexation, solubilisation or amorphisation may be necessary to achieve a super-
saturated state or improve solubility. By this, the (supersaturated) solution ena-
bles API molecules to reach the absorptive sites. 
Usually, the above-named applications are singularly employed. In this project, 
an innovative approach was sought out: the combination of two of these well-
established methods to possibly detect synergistic and additive effects on the 
solubility and dissolution rate of ITR. Solid dispersion technique is known to im-
prove ITR’s bioavailability [13]. Apart from this, there is an oral solution on the 
market employing ICF with CDs [10]. Therefore, encapsulation by βCD was uti-
lised to create a supersaturated API system. Moreover, βCD served as matrix 
component in which ITR was supposed to be delicately dispersed. This dispersion 
was attempted by using HME and HMG processes. Besides the ability to create 
solid dispersions and solutions by HME/HMG, there is the possibility of API amor-
phisation which can further enhance drug solubility. The following subsections 
will focus on these applications that were carried out within this work.  
II.2. Solid Dispersions by Hot-Melt Extrusion and Hot-
Melt Granulation 
II.2.1. Solid Dispersions  
In 1971, Chiou and Riegelman defined a solid dispersion as a dispersion of one 
or more APIs in an inert carrier or matrix system in the solid state. They only re-
ferred to systems that were prepared by melting, solvent or melting-solvent 
methods [18]. However, due to the development of new technologies, especially 
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in the field of nanoparticles, the line between solid dispersions and other formu-
lation approaches has become blurred. In recent times, solid dispersion mostly 
refers to a glassy solution of a drug in an amorphous carrier with high glass tran-
sition temperatures (Tg) [19]. The matrix substance in these formulations is in 
almost all cases polymeric. Nonetheless, different subtypes of solid dispersions 
are known and are presented in Table II.2.. 
Table II.2. - Different subtypes of solid dispersions according to [20]. 
Subtype of Solid Dispersion Carrier API Phases 
I Eutectics crystalline crystalline 2 
II 
Amorphous precipitates in 
crystalline matrix 
crystalline amorphous 2 
III Solid solutions    
a Continuous vs. discontinuous crystalline molecularly dispersed 1 or 2 
b Substitutional vs. interstitial crystalline molecularly dispersed 1 or 2 
IV Glass suspension amorphous crystalline 2 
V Glass suspension amorphous amorphous 2 
VI Glass solution amorphous molecularly dispersed 1 
Whereas for the carrier, where only the crystalline and the amorphous state are 
recognised, the drug can also be molecularly dispersed or rather “dissolved” in 
the matrix. If the solubilising capability of a matrix is large enough to dissolve all 
API molecules, the result is a solid solution with only one phase with one Tg 
where the Tgs of the sole components cannot be distinguished anymore. Eutec-
tics are mixtures of very fine crystals of the components. If the carrier is highly 
water-soluble and the eutectic mixture is given into an aqueous environment, the 
carrier will rapidly dissolve, causing a large surface of the freed API particles. 
This increases the dissolution rate [15]. The same mechanism can be assumed 
for type II solid dispersions.  
For solid solutions, two different categories with two subcategories each are 
known. These depend either on the miscibility of the substances (type IIIa, see 
Table II.2.), or on the API’s position in the crystal lattice (type IIIb). In a contin-
uous solid solution, all components are completely miscible whereas in a discon-
tinuous solid solution, there are only proportions in which a true solid solution 
can be reached. In other ratios, the components are not miscible. A substitution-
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al solid solution is based on the theory that the solute drug substitutes for matrix 
molecules in the crystal lattice. In interstitial systems, the drug solutes will be 
situated in the interstitial spaces between matrix molecules [15]. In glass sus-
pensions or solutions, the drug molecules can be either homogenously dispersed 
in the carrier or situated in API-rich regions. If the drug was turned amorphous 
during manufacturing of solid dispersions or solutions, the saturation solubility 
will most likely increase. The main disadvantage of the amorphisation, however, 
is the fact that often, products are only metastable. As the crystalline state is 
mostly energetically favourable, amorphous systems tend to recrystallise directly 
after production or during storage. This recrystallisation is especially common 
when drug clusters are present in type V solid dispersions [20]. The chosen car-
rier can help to immobilise the drug molecules, hindering recrystallisation, e.g. 
due to viscosity or interactions with the API [20]. 
II.2.2. Hot-Melt Extrusion  
As previously mentioned, for the preparation of solid dispersions, two technolo-
gies are recognised, melting and solvent methods. There are important disad-
vantages regarding the solvent method. Generally, it is time consuming due to 
long processing. Furthermore, drying steps are often necessary. With this, high 
costs arise as well as insecurity about product quality. As organic solvents are 
used frequently, it is crucial that no residuals of these often poisonous substanc-
es stay in the formulation [1,18]. Moreover, the use of toxic components could 
endanger personnel during production.  
In the last decades, a particular melting technique, HME, has been gaining 
more and more ground in the creation of solid dispersions and solutions in the 
pharmaceutical field. It has been regularly applied industrially for at least a cen-
tury. In the beginning, HME was employed in the plastics as well as in the food 
industry. Up to date, more than half of all plastic products are processed by HME. 
Examples for these products include pipes, bags, tape, fibres or sheets. The first 
industrial use of HME was in the mid-nineteenth century for the fabrication of 
plastic insulation of wires [21,22]. This already indicates that HME is a well-
known and established technology in the field of polymer science. Nonetheless, 
its application in the pharmaceutical industry only dates back a few decades. Es-
pecially in the last twenty years, HME has advanced to being a platform technol-
ogy when it comes to the development of solid dosage forms [23]. 
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Figure II.3. shows the issued patents for the pharmaceutical employment of 
HME between 1983 and 2006 as well as an international scope where these pa-
tents were issued. Germany and the US together hold over 50 % of the market. 
But it is obvious that HME is a field that is internationally focused on. 
Figure II.3. - Patents regarding the pharmaceutical utilisation of HME issued be-
tween 1983 and 2006; a) shown in numbers per year and b) shown in percent-
age by country/continent; according to [21]. 
Extrusion in general is a procedure where raw material is fabricated into a 
product with consistent shape and density. These uniform properties are 
achieved by forcing the material through a die at specified conditions [24]. 
Whereas in wet extrusion, a liquid binder is used to agglutinate the material so 
that it forms a new shape after being deformed in the die, HME is a solvent-free 
technique. Here, the deformation is caused by applying controlled heat to the 
material. This is a strong advantage against solvent methods. The HME proce-
dure can be divided into four different operations. Firstly, the material has to be 
fed to the extruder through a feeding system, also called a hopper. Secondly, it 
has to be transported through the extruder barrel while being mixed, grinded 
and kneaded. If necessary, ventilation ports for vapour discharge can be applied 
here. Thirdly, the material has to be pressed through the die and lastly, the 
product leaving the die, now called extrudate, has to be downstream processed, 
e.g. by calendering, cutting or shaping in moulds [25]. 
HME is carried out utilising either melt-single screw extruders (mSSE), melt-
twin screw extruders (mTSE), melt-multi screw extruders or ram extruders. This 
means that either one lone screw is rotating in the heated barrel or two or more 
screws which can be co- or counter-rotating and (non)intermeshing. In ram ex-
trusion, a piston is used to press the material through the die. Hereby, the aris-
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ing pressures are often very high [21,23]. Each of these set-ups has its own ad-
vantages and disadvantages. The most commonly applied is the mTSE with in-
termeshing co-rotating screws. This has positive effects on the mixing capability 
of the system. Additionally, intermeshing screws exhibit a so-called self-wiping 
effect which eliminates stagnation in the barrel and allows a more confined resi-
dence time of the material during HME. In this project, an intermeshing co-
rotating mTSE set-up was employed. Figure II.4. shows a schematic view of this 
typical mTSE system.  
 
Figure II.4. - Scheme of typical HME procedure with an mTSE, adapted from [26]. 
The API and the matrix can either be pre-blended or fed into the mTSE by two 
separate hoppers. The zone of the powder entry is customarily not heated to 
avoid blockages. The other barrel zones are usually separately heated so that the 
ingredients follow a specified temperature profile along the barrel. Thereby, the 
material is melted, plasticised, mixed and compressed. The energy input is not 
only caused by the heated barrel but also due to shear and frictional forces by 
the screws and barrel walls [27]. In most cases, the screws can be assembled by 
combining different screw elements, such as kneading or conveying elements. 
The screw configuration has a large impact on the energy input during HME and 
thus, is also mostly chosen individually. The same applies for the chosen screw 
speed. The torque of the mTSE as well as the actual screw speed can be moni-
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tored. At the end of the barrel the die is located. Different kinds of dies can be 
employed such as flat dies, circular dies or annular dies. Generally, the chosen 
die structure predicts the shape of the resulting product [27]. After leaving the 
die, the finished extrudate can be cooled under defined conditions or simply be 
air-cooled. Afterwards, downstream equipment can be used such as pelletisers or 
grinding equipment. The whole process of HME from feeding to the final formula-
tion can be applied in a continuous fashion. Even though the classic solid disper-
sion or solution prepared by HME only necessitates an API as well as the matrix, 
other excipients can be added to the formulation to optimise product stability. 
Possible substances can e.g. belong to the classes of plasticisers, anti-oxidants or 
thermal lubricants [21]. 
The main disadvantage of HME is the thermal stress which is applied to the ma-
terial [24]. Highly thermo-labile components cannot be processed by HME. None-
theless, by the application of mTSE, the mean residence time of the substances 
in the barrel is kept relatively short. In some cases, this can allow the operation 
with generally thermo-labile molecules. The advantages of this technique out-
reach the disadvantages by far. Reproducible, continuous manufacturing with 
simple equipment are only a few. No solvents are needed in this process. Addi-
tionally, HME enables constant monitoring and documentation of the process. 
Different parameters which are chosen at the beginning of the procedure are 
recorded continually such as feed rate, temperatures in the barrel, pressure at 
the die, extrudate temperature or the torque. This contributes to the FDA’s pro-
cess analytical technology (PAT) initiative. Hereby, products in pharmaceutical 
processes should be constantly monitored in-line, e.g. by employing UV spec-
troscopy, near infra-red spectroscopy (NIR) or Raman spectroscopy [24,27]. 
Pharmaceutically, HME is mainly used for solid dosage forms such as granules, 
pellets, spheres, tablets, capsules, transdermal and transmucosal films or im-
plants [28–32]. Dominantly, polymers are used as matrices in these case stud-
ies. Very often, the target under investigation is not immediate drug release but 
rather modified or sustained drug delivery systems. Hereby, the choice of matrix 
is especially important as it usually controls the dissolution rate of the drug. 
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II.2.3. Hot-Melt Granulation 
Another hot-melt process is HMG. Per definition, HMG is construed as an ag-
glomeration process where a molten or softened binder (hydrophilic or hydro-
phobic) is added to fine solid particles [33]. Solid bridges can form when the 
molten material solidifies. Generally, the meltable binder should exhibit a Tm be-
tween 50 - 100 °C and should be present in the mixture in an amount of 
10 - 30 % [34]. Applications for HMG are similar to HME, since the choice of 
binder can influence the drug release from the produced granules. Mostly, HMG 
is carried out by utilising high-shear mixers or fluidising granulators. The applica-
tion of extruders is not impractical, albeit not the most common technique [34]. 
Recently, HMG is gaining more interest, as it can be operated as a continuous 
manufacturing process, e.g. by applying an mTSE. Shah and Repka stated that 
high shear mixers and fluidised bed granulators are inferior to mTSE regarding 
the flow mechanics and heat transfer in the barrel. The heat transfer within 
mTSE is easier to control and localise. Furthermore, the high uniformity allows 
simpler up-scaling [23]. Richter explained that it is possible to perform HMG with 
an mTSE by removing the die from the extruder barrel. By this, the material is 
granulated without rising pressure [35]. 
Batra et al. investigated the behaviour of different polymeric binders in HMG to 
achieve favourable compactibility of the produced granules [36]. They differenti-
ated HME and HMG according to the following premises:  
i.  in HME, the polymer content is usually > 60 % due to the for-
mation of solid dispersions/solutions, whereas in HMG, it should 
be around 10 %, 
ii. in HME, the API can be miscible in the polymer, 
iii. in HMG, the process is carried out above Tg of the polymer and 
below Tm of the drug, whereas in HME, it is possible to operate 
the procedure while both substances are molten/softened, 
iv. HME products are usually extrudate strands [36]. 
Richter investigated two different polymeric binders with the same mTSE used 
in this project (see section III.2.1.3.) with a commercial granulation kit. She 
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found that processing below Tg resulted in unstable processes and thus, agreed 
with the postulations of Batra et al. [35,36].  
It has to be noted that the procedure communicated as HMG in this thesis does 
not meet the conditions mentioned above. The ratio between API and matrix was 
always in the favour of the matrix. Additionally, processes were partly carried out 
above Tm of the model drug ITR and, depending on the used carrier, below Tg/m 
of this component. No specified molten binder was used in this project. The mol-
ten API mostly served this purpose. Furthermore, in most experiments, no poly-
meric carrier was used as matrix system but rather the oligosaccharide βCD. 
These facts all indicate that no HMG was carried out in its traditional sense. How-
ever, for the lack of a better term for the innovative processes developed, they 
will still be referred to as HMG throughout this study whenever the mTSE was 
operated without a die. 
II.3. Inclusion Complexes with Cyclodextrins 
In addition to the HME/HMG technologies, in this work, the complexation with 
CDs was employed for solubility and dissolution rate enhancement of ITR. As 
stated, this oftentimes results in super-saturated drug systems. This subsection 
will focus on the improvement of oral bioavailability of APIs by ICF with CDs. The 
chemical structure and properties of the used CDs will be explained in more de-
tail in section III.1.3.. It should be noted that the pharmaceutical application of 
CDs is not only limited to the enhancement of API solubility. Moreover, CDs can 
be used for taste masking, masking odours, increasing product stability or de-
creasing tissue irritation [37]. Over 30 different pharmaceutical formulations are 
marketed world-wide containing CDs, not only for oral delivery but also for a va-
riety of other administrative routes [38]. However, it has to be added that one of 
the main advantages of CDs is also an important drawback when it comes to the 
application to CDs in generic formulations. The strong ability of CDs to enhance 
drug dissolution often results in CD-formulations failing in bioequivalence studies 
by outperforming the original medication. This decelerates the presence of CDs 
not only in original but also generic drug products [39]. 
CDs are sustainable excipients derived from starch through bacterial fermenta-
tion. They consist of D-glucopyranose monomers that are α-1,4-linked so that 
they form a cyclic structure. Due to the chair formation of the glucose units, the 
Theoretical Background 
 
 
16 
CD molecules are shaped like truncated cones with a narrow and a wider edge. 
Here, primary hydroxyl (narrow edge) and secondary hydroxyl groups (wider 
edge) are located [40]. The inside of the central CD cavity is more lipophilic than 
their outer surface. This allows CDs to form ICs with a variety of drugs. In an IC, 
one (or rarely even more) drug molecule becomes incorporated in the central CD 
cavity [41]. This encapsulation occurs without the formation of covalent bonds. 
In aqueous solution, the API molecules that are included in the CD cavity are in 
equilibrium with the API molecules which are freely present [38]. In nearly all 
cases, ICF is performed with the aid of water or another solvent such as ethanol. 
However, there are reports that ICF with organic solvents yields inferior results 
to the use of water [42]. Carrier et al. reviewed the utilisation of CDs for enhanc-
ing oral bioavailability and investigated 28 different case studies. All presented 
ICs were prepared in an aqueous environment. Different ICF methods included 
freeze-drying, spray-drying, co-precipitation and grinding of a CD/API aqueous 
paste in a mortar [37]. Very often, ICs are proclaimed as solid systems or solid 
complexes. But, mostly this only refers to the final dosage form which was de-
rived from an aqueous system of drug and CD [43,44]. A rare, truly solvent-free 
approach of creating ICs was attempted by Hassan et al. and Al-Marzouqi et al. 
who utilised supercritical carbon dioxide in a pressurised chamber to include ITR 
into βCD [45,46].  
The driving forces for ICF have been extensively studied, however, to the best 
of the author’s knowledge, only regarding ICF in solution. Nonetheless, it is still 
proclaimed that the complex mechanisms behind ICF are not fully understood. In 
2002, Liu and Guo reviewed the literature about this issue and concluded that 
important driving forces for ICF in solution were electrostatic interactions, hydro-
phobic interactions, hydrogen bonding, charge-transfer interactions and Van-der-
Waals forces. Moreover, they reviewed the release of cavity-bond high-energy 
water, release of conformational strain of the CD rings and the so-called “enthal-
py-entropy compensation” [47]. With their findings, they continued the conclu-
sion by Matsui et al. from 1985 who stated that the various intermolecular inter-
actions act concurrently [48]. Although these results hold great value for the 
general understanding of CD chemistry, they do not fully apply for the investi-
gated ICs in this work which were formed without further addition of solvents. As 
this manner of ICF by the combination of HME/HMG with CDs as matrix compo-
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nents is a fairly new and innovative approach to create ICs, next to none re-
search has been conducted in this field.  
The present thesis concentrates on in-vitro evaluations of solid formulations in-
tended for oral use. Consequently, understanding of the behaviour of a solid IC 
after oral administration is needed. Figure II.5. shows a simplified scheme of API 
absorption after intake of an IC. For the purpose of the scheme, it is not im-
portant how the IC is comprised. It could be any solid dosage form such as a 
capsule or a tablet. 
 
Figure II.5. - Scheme of drug absorption after oral administration of a solid IC, 
modified and combined from [17,40,41]. 
After intake, the dosage form has to disintegrate. The solid IC will most likely 
dissolve in the GIT fluids. There is a constant equilibrium between dissolved drug 
molecules and complex molecules. For simplification, the complex in Figure II.5. 
is depicted as the composition of one drug molecule and one CD molecule with 
the drug inhabiting the perfect centre of the cavity. In reality, the complex can 
also consist of a varying amount of CD and drug molecules or be a non-inclusion 
complex where the API can be located at the outer CD surface. Right after disin-
tegration, the equilibrium will be switched to the side of the IC as it generally 
shows better aqueous solubility than the pure drug. The complex passes the GIT 
until it reaches the specified absorptive sites for the drug. Due to the high hydro-
philicity and large size, CDs as well as ICs can only marginally pass biological 
membranes [38]. 
Most biological membranes exhibit an aqueous outer layer, also referred to as 
the unstirred water layer (UWL). The drug molecules need to diffuse through this 
barrier before they can further diffuse through the lipophilic membrane itself. 
Normally, CDs can only enhance the API absorption when the main hurdle of the 
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restricted bioavailability is the UWL and not the lipophilic membrane barrier. This 
also explains the fact that CDs only show little effect on the bioavailability of 
BCS class I and III drugs in contrast to BCS class II and IV [41,49]. In the 
scheme in Figure II.5. it is shown that the equilibrium in the UWL is switching to 
the free drug. This is simply caused by the fact that dissolved drug molecules 
further pass the intestinal wall which subsequently enhances the gradient of the 
equilibrium in the direction of the API. When formulating oral CD medications, 
care has to be taken in using an excess amount of CDs as this is known to rather 
decrease drug absorption in the GIT because not enough free drug molecules are 
able to pass the biological membrane [41]. 
Main driving forces for the exclusion of the drug from the IC have been de-
scribed as dilution in the bodily fluids or competitive displacement (e.g. when 
substances in the GIT such as bile salts compete with the drug for the CD cavi-
ty). Additionally, drug-plasma binding, tissue uptake or CD elimination have also 
been postulated to be responsible for the rapid release of the API from the 
IC [49,50]. However, the latter three are most likely more dominant for paren-
teral IC application. Especially the dilution phenomenon is of great value in oral 
administration of solid CD formulations. If dilution occurs too early in the GIT, 
precipitation of the drug is possible. This is particularly the case if the drug:CD 
relationship in the formulation is non-linear [51]. Drug precipitation could further 
stall or decrease drug absorption as the drug molecules are not able to further 
reach their absorptive sites. 
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III. Material and Methods 
III.1. Material 
This section provides information about all investigated sample compounds. De-
tails about the utilised analyser substances are located in the appendix (see sec-
tion VII.2.). 
III.1.1. Itraconazole  
ITR is a triazole agent that inhibits the 14-α-demethylase, an enzyme that is 
found in fungal cells. It is responsible for converting lanosterol to ergosterol, a 
substance that is crucial for satisfactory function of the fungal cell membranes. 
Without functioning ergosterol synthesis, fungal cell proliferation is hindered. In 
addition to that, further mechanisms have been postulated about ITR’s fungistat-
ic - at high doses proclaimed fungicidal - effects. These are e.g. accumulation of 
intracellular hydrogen peroxide due to interactions with fungal cytochrome c oxi-
dative and peroxidative enzymes, inhibition of purine uptake or interactions with 
membrane phospholipids. ITR is efficient against a broad spectrum of fungal 
pathogens (e.g. dermatophytes, dimorphic fungi, Aspergilles spp. and yeasts) 
and used in antifungal therapy since the 1980’s [52,53]. Its high therapeutic effi-
cacy is due to the lipophilic nature of the azole ring which is affiliated with en-
hanced tissue penetration, a longer serum half-life and improved interaction with 
the target enzymes [54]. Typical daily doses range from 50 - 400 mg dependent 
on the infested areas as well as on fungal species. Due to the risk of increased 
adverse effects like rare but severe hepatic toxicity at higher doses, if not neces-
sary on medical grounds, 400 mg/d should not be exceeded [53,55]. 
Recently, ITR has been identified as a Hedgehog signalling pathway (Hh) inhibi-
tor. Hh is suspected to support growth in different tumour species. 
Ptch+/-p53-/- mice that had allograft medulloblastomas treated with ITR showed 
suppression of tumour growth at serum levels that were comparable to patients 
undergoing antifungal therapy [56]. Searching for ITR as cancer treatment in the 
national database of the US government for clinical trials revealed that in the end 
of 2017, various clinical studies were recruiting or had already been finished, 
dealing with basal cell cancer, non-small cell lung cancer, oesophageal cancer, 
metastatic prostate cancer, metastatic breast cancer and others [57]. 
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ITR is commercially available as oral capsules (see section III.1.2.) or in liquid 
form as oral and i.v. solution [58]. Figure III.1. shows ITR’s chemical structure.  
 
Figure III.1. - Chemical structure of ITR [59]. 
Important physico-chemical and pharmacokinetic characteristics are given 
in Table III.1.. As BCS class II compound with limited bioavailability, ITR is at-
tractive for solubility enhancement research. The high Tm (see Table III.1.) and 
thermostability contribute to extensive research being conducted in the field of 
hot-melt processes [60–62]. Another research motif is the formation of ICs with 
CDs due to ITR’s lipophilic nature and suitability as guest molecule [63–65]. 
Table III.1. - Physico-chemical properties of ITR [52]. 
Molecular weight 705.633 g/mol 
Physical State  solid, white powder 
Volume of distribution 796 ± 185 L 
Plasma protein binding 99.8 % 
Half life 21 h 
Bioavailability approximately 55 % when taken with full meal 
Melting point 166.2 °C 
Water solubility practically insoluble, BCS class II 
logP 5.66 
pKa 3.70, weak base, ionised at low pH 
Therefore, ITR was used as model BCS class II compound in this project. ITR 
batches ITFP12008 and IRFP13005 (Lee Pharma Ltd., India) were obtained via 
F. & A. Pharma-Handels-GmbH, Germany. x50 (average particle size) was deter-
mined by laser diffraction (see section III.2.2.7.) as 5.9 ± 0.1 µm. 
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III.1.2. Sempera®/Sporanox® Capsules 
The German brand for the aforementioned ITR oral capsule formulation is Sem-
pera®, a product of Janssen-Cilag GmbH. Internationally, the formulation is often 
marketed as Sporanox® (Janssen Pharmaceuticals) [52]. In subsequent sections, 
Sempera® only refers to samples investigated in this project, whereas the term 
Sporanox® will be used affiliated to literature references. Yet, both formulations 
share nearly the same composition, as the only difference between them is the 
use of glucose syrup in Sempera® which is unlikely to have an influence on API 
dissolution. Therefore, the determined and literature related results will be corre-
lated in this thesis.  
The proposed manufacturing process of Sporanox® capsules is shown in 
Figure III.2.. The scheme is based on US Patents 5,633,015 and 
US 6,663,901 B1 that describe the production of the capsules [66,67]. First, a 
solution of methylene chloride and denaturated ethanol is prepared, ITR and hy-
droxypropyl methylcellulose (HPMC) 2910 (5 mPa · s) are added and dissolved 
completely. Neutral sugar spheres in the range of 600 - 700 µm are given into a 
fluidised bed granulator with Wurster bottom spray insert and coated with the 
ITR/HPMC 2910 solution at approximately 55 °C. After a short drying 
step (10 - 20 min) in the fluidised bed granulator, the coated pellets are trans-
ferred into a vacuum tumble drier for preferably 36 h at approximately 80 °C. 
The vacuum tumble drier is rotating at about 2 - 3 rpm. After a sieving step to 
separate agglomerated spheres, the pellets are given into a fluidised bed granu-
lator with Wurster insert again and coated with a sealing solution of polyethylene 
glycol (PEG) 20000 in methylene chloride/denaturated ethanol at approximately 
55 °C. After a 10 min drying step and cooling down of the pellets, they are re-
moved from the fluidised bed granulator and automatically filled into hard gelatin 
capsules with a dose of 100 mg ITR [66].  
The long vacuum drying step was later renewed and the possibility of drying 
under microwave conditions was introduced as the general limits for residual 
methylene chloride in dosage forms became stricter [67]. By applying this drying 
system, according to US 6,663,901 B1, drying time can be reduced to 1 h in-
stead of 36 h.  
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Figure III.2. - Manufacturing flow chart for Sporanox® capsules according to pa-
tents US 5,633,015 and US 6,663,901 B1 [66,67]. 
Even though the marketed formulation used in this project was the German 
product Sempera® which contains glucose syrup without un-disclosed information 
in which part of the process this excipient is employed, it can be assumed that 
the general manufacturing procedure will be closely related to the available, pa-
tented Sporanox® operation. Sempera® capsules used in this work (PZN 3853714; 
Batch FIL7Y00, FKL9F00) were acquired through a German pharmacy.  
III.1.3. β-Cyclodextrin and Hydroxypropyl-β-Cyclodextrin 
CDs are chemical entities that have been first reported by Villiers in 1891 and 
were characterised by Schardinger in the beginning of the 20th century during 
which period they were called “Schardinger dextrins”. In the following decades, 
their chemical structure and other properties were extensively studied all around 
the globe [68]. They are cyclic oligosaccharides, in the case of βCD, consisting of 
seven α-(1,4)-linked D-glucopyranose units presenting the chair formation as 
shown in Figure III.3.. Also known “parent” CDs are α-cyclodextrin and 
γ­cyclodextrin which are composed of six and eight α-(1,4)-linked 
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D-glucopyranose units, respectively. CDs are gained in the bacterial fermentation 
of starch when certain enzymes, namely cyclomaltodextrin glucanotransferases 
which can be found e.g. in strains of B. macerans, detach fragments of the 
starch polysaccharide helix and connect the two ends to a cyclic product. These 
natural enzymes yield mixtures of CDs that are challenging to separate und puri-
fy, e.g. by selective precipitation. The development of selective cyclomaltodextrin 
glucanotransferases has significantly improved the manufacturing of CDs over 
the years and enabled their wide-spread use [68–70]. As presented in 
Figure III.3., the three-dimensional structure of βCD appears as a truncated, 
open cone. The reason is the chair conformation of the glucose units.  
 
Figure III.3. - Chemical structure of βCD; ID = inner cavity diameter; OD = out-
er molecule diameter; h = height; for gaining hydroxypropyl­βCD, the visible H 
atoms might be etherified with hydroxypropyl groups in varying ratios from 
0 - 3 per each glucose unit; adapted from [41,49]. 
Primary hydroxy groups of the molecule are located on the narrow end of the 
cone and secondary hydroxy groups on the wider edge. This phenomenon can 
also be seen for other CDs. Due to this, the surface of the CDs is strongly hydro-
philic. The centre of the cone, the cavity, is more lipophilic because of the posi-
tioning of mostly skeletal carbons and oxygens from the ether groups [41,71]. 
From this structural particularity, positive properties of CDs arise. First of all, the 
cyclic structure causes a resistance to non-enzymatic hydrolysis and secondly, 
CDs exhibit the capability of creating non-covalent ICs with lipophilic substances 
such as APIs. These ICs oftentimes result in improved aqueous solubility and bi-
oavailability of the drug as well as decreased volatility, less local irritation and 
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improved general stability [51,70]. This has caused CDs to be widely used in 
pharmaceutical applications, but also in the food and cosmetics industry where 
they can be employed to improve the product’s shelf life or mask unwanted 
tastes and odours.  
βCD is the most commonly applied CD due to its accessibility and low 
price (around 5 US$/kg) [11,68]. Very often, it exhibits the highest attraction to 
different APIs for including them into the cavity which is shown by the highest 
average inclusion complex stability constant or complexation efficiency [49]. 
Nevertheless, there is a drawback in the application of βCD which is its aqueous 
solubility of approximately 18.4 ± 0.2 g/L at 25 °C [49]. Compared to APIs this 
appears genuinely high but when considering the water solubilities of αCD and 
γCD (129.5 ± 0.7 g/L and 249.2 ± 0.2 g/L, respectively [49]), the limitation be-
comes obvious. This is supposed to be caused by very strong intramolecular hydro-
gen bonding in βCD and deems it unfit for parenteral administration [70,71]. 
The strategy to overcome this problem is the substitution of βCD. Even the ad-
dition of lipophilic moieties causes the new molecule to present a higher aqueous 
solubility by relaxing the intramolecular hydrogen bonds. This may also influence 
the toxicological profile and stability, possibly due to a decrease in crystallini-
ty [11,70,72]. Substitution is generally possible at every terminal hydroxy func-
tion in the βCD molecule. One example for a frequently used βCD derivative is 
2-hydroxypropyl-β-cyclodextrin (HPβCD) which presents favourable toxicological 
properties and can be administered parenterally. Doses of 8 g of HPβCD per day 
for two weeks were well tolerated [73]. Even though some minor organic histo-
pathological and biochemical changes were observed mostly in animal toxicology 
studies, all were reversible and considered non-threatening for humans. In clini-
cal investigations of the oral use in humans the main adverse effect reported was 
reversible diarrhoea [74]. βCD and HPβCD are both represented in the current 
Ph. Eur. [75,76] and βCD is included in the GRAS (generally regarded as safe)-
list of the FDA. The maximum “acceptable oral daily intake” (ADI) of βCD is set 
to 5 mg/kg bw (body weight) by the Joint FAO (Food and Agriculture Organisa-
tion)/WHO (World Health Organisation) Committee of Food Additives (JECFA). 
This is not mainly due to CD-related health risks but by evaluation of toxic resid-
ual components from synthesis [70,77]. The oral “no observed adverse effect 
levels” (NOAEL) of βCD for adult humans was proposed 500 mg/day by the Eu-
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ropean Medicines Agency (EMA) in 2014. However, in October 2017, the revision 
of the annex to the European Commission guideline on “Excipients in the label-
ling and package leaflet of medicinal products for human use” newly stated that 
“Based on animal studies and human experience, harmful effects of CDs are not 
to be expected at doses below 20 mg/kg bw per day.” [78,79]. 
HPβCD is the present CD in the marketed solution of Sporanox® where it is 
used to encapsulate ITR. In this FDA approved formulation, when high dose 
therapy is applied, up to 16 g of HPβCD are consumed daily [10]. After oral ad-
ministration, the amount of absorbed βCD is considerably low because most of it 
passes stomach and small intestine intact and is then metabolised by bacteria in 
the colon. HPβCD in contrast is mostly excreted intact in the faeces as it is non-
absorbable and non-metaboliseable [73]. Table III.2. gives an overview of im-
portant characteristics of both βCD and HPβCD.  
Table III.2. - Characteristics of the two applied CDs in this work, βCD and 
HPβCD, according to [41,49,77,80]. 
 βCD HPβCD 
Molecular weight, g/mol 1134.978 1399 
Height, nm 0.78 not reported 
Inner diameter, nm 0.62 (partially shielded) 0.62  
Outer diameter, nm 1.54 not reported  
Solubility in water, g/L at 25 °C 18.4 ± 0.2 > 600 
Melting range, °C 255 - 265 > 300 * 
ADI level, mg/kg bw 5 no set limit 
x50, µm; see section III.2.2.7. 77.2 ± 1.4 98.4 ± 2.2 
Molar degree of substitution X 0.63** 
* described as decomposition temperature, no melting range given, ** derived from the correlat-
ing Certificate of Analysis  
As explained in section II.3., the use of CDs oftentimes improves the aqueous 
solubility and bioavailability of APIs. βCD presents the most favourable cavity 
size and often strongest IC stability constants. The high melting range of about 
260 °C and thus, thermostability, generally qualify it for being employed in melt 
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processes. Additionally, the utilisation of βCD as sole matrix in the creation of a 
melt process has only been investigated very marginally. To the author’s best 
knowledge, only one reference is available where HME with βCD was conducted. 
However, the focus of that work was on another CD derivative and the develop-
ment of the process itself was not highlighted [81]. All of these argumentations 
give reason that βCD was investigated as first-choice matrix in this study. How-
ever, to examine an alternative, HPβCD was evaluated as it is already employed 
in marketed formulations with ITR. The used qualities of βCD (Kleptose®; 
Batch EE459) and HPβCD (Kleptose HPB®; Batch E0288) were kindly donated by 
Roquette Frères, France.  
III.1.4. Soluplus® 
Soluplus® (SOLU), a newly developed solubilising polymer especially designed 
to create solid solutions and dispersions by HME was launched by BASF SE, Ger-
many in 2009. It has been used frequently in HME research ever since, particu-
larly regarding formulations with BCS class II compounds due to their poor aque-
ous solubility [82,83]. Its structural formula is given in Figure III.4.. SOLU is a 
graft copolymer composed of polyvinyl caprolactam and polyvinyl acetate side 
chains attached to a polyethylene glycol backbone in the ratio of 57:30:13 [20]. 
It has a molecular weight of approximately 118 000 g/mol. SOLU shows excellent 
extrudability and has a Tg around 70 °C. 
 
Figure III.4. - Chemical structure of Soluplus® [84]. 
Many APIs have plasticising effects on SOLU, enabling HME at lower tempera-
tures than for the pure excipient (around 120 – 180 °C depending on screw con-
figuration) [84]. No SOLU degradation has been reported for hot-melt processes 
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up to 220 °C [20]. Thus, SOLU can stand ITR Tm (around 167 °C) and is there-
fore often employed in ITR-HME research [85–87]. In this project, SOLU was 
used as an alternative matrix especially in regard to its solubilisation capability. 
x50 value was determined as described in section III.2.2.7. to be 
303.1 ± 5.2 µm. SOLU (Batch 84414368EO) was kindly donated by BASF SE, 
Germany. 
III.1.5. Polyethylene Glycol 6000 
PEG 6000 consists of polyethylene oxide monomers connected via ether links. 
Its monomeric chemical structure is shown in Figure III.5.. The number 6000 
stands for the average molecular weight in g/mol and corresponding to that, for 
the physical state of the substance.  
 
Figure III.5. - Chemical structure of PEG [88]. 
PEGs are viscous liquids with a molecular weight up to 600, semisolid up to 
1000 g/mol and solid wax-like between 1000 and 20000 g/mol. They are phar-
maceutically employed for many different applications, e.g. as solvents, ointment 
bases, plasticisers, lubricants or suppository bases [89]. There is a long history 
of research about solid dispersions and solutions with PEG 6000 studied as wa-
ter-soluble matrix. Hereby, the focus is often based on the determination of the 
solubility enhancing properties of PEG 6000. Possible explanations include inter-
actions of encapsulation, improvement of wettability and enhancing the dissolu-
tion rate by maintaining the reduced particle size of the API within the ma-
trix [90–94]. 
In this project, PEG 6000 was examined as alternative matrix in binary formu-
lations and furthermore as ternary additive to powder blends of βCD and ITR to 
investigate influences mostly regarding ITR dissolution rate. As previous experi-
ments with the used mTSE system had shown, best content uniformity during 
feeding was acquired if the applied PEG 6000 by Clariant SE, Germany, was used 
as a milled fine powder (PF quality; Batch DEA4005506; 75 - 95 % 
< 90 µm [95]). 
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III.1.6. Xylitol 
Xylitol is a sugar alcohol with five carbons. Industrially, it is manufactured by us-
ing a catalytic reduction process. By this hydrogenation, D-xylose, its correspond-
ing sugar, is converted into the primary alcohol [96]. Xylitol can be used as a non-
cariogenic sweetener [97] but is also investigated as crystalline matrix in HME to 
evaluate its potential for API dissolution enhancement [98]. The chemical composi-
tion of xylitol is given in Figure III.6.. It presents as a crystalline, white powder 
with an aqueous solubility of 664 g/L [97] and a reported Tm of about 91 °C [99]. 
Kaizawa et al. reported a decomposition temperature for xylitol of 200 °C [100]. 
This allows its utilisation in hot-melt processes up to that temperature.  
 
Figure III.6. - Chemical structure of xylitol [101]. 
In this project, xylitol (Xylisorb 90; Batch E270R; Roquette Frères) was mainly 
used as ternary additive in HMG formulations to assess the influence a combina-
tion of βCD and xylitol might have on ITR dissolution and possible ICF. x50 was 
determined according to section III.2.2.7. to be 149.9 ± 4.7 µm. 
III.1.7. Hydroxypropyl Methylcellulose  
HPMC is derived from purified pulp by caustic soda treatment and etherification 
with chloromethane and propylene oxide at high temperatures. Afterwards, the 
material is washed, dried and pulverised [102]. The result is a water-soluble, 
non-ionic cellulose ether. The chemical structure of HPMC is shown in Fig-
ure III.7.. The used HPMC quality (Metolose® 65SH) exhibited a substitution level 
of 1.8 regarding the average number of substituted hydroxy groups of each an-
hydrous monomeric glucose unit with a methoxy group and 0.15 regarding the 
average number of hydroxypropoxy groups added to each anhydrous glucose 
monomer which corresponds with the United States Pharmacopeia (USP) substi-
tution 2906. A 2 % aqueous solution of the used HPMC material has a reported 
viscosity of 3000 - 5600 mPa · s at 20 °C [102].  
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Figure III.7. - Chemical structure of Metolose® 65SH [103]. 
HPMC is a commonly used excipient in pharmaceutical formulations and is uti-
lised for many different applications, such as hydrogel tabletting matrix for sus-
tained API release, coating of solid dosage forms, viscosity enhancer, stabiliser in 
suspensions or even capsule shell material due to not being of animal 
origin [104–107]. HPMC has a proclaimed melting range of 280 - 300 °C. Thus, it 
is often investigated as matrix in hot-melt processes [108,109]. Rambali et al. 
investigated a combination of HPMC and HPβCD in an HME process with 
ITR [110]. Apart from this, HPMC is the chosen polymer for the ITR solution that 
is spray-coated on the starter pellets for the marketed product Sporanox®. There 
is high scientific interest in the interaction of ITR and HPMC. Very often, third 
substances are added to further optimise these formulations. Rajarajan et al. ex-
amined a spray-drying procedure with HPMC, PEG and ITR [111]. The HPMC 
quality utilised in this work (Metolose® 65SH-4000; Lot 5095611; Shin-Etsu 
Chemical Company Ltd., Japan) has already been studied in hot-melt proce-
dures [106]. The x50 value was determined according to section III.2.2.7. as 
69.0 ± 0.2 µm. 
In this project, HPMC was investigated as an alternative matrix in the binary 
hot-melt process. Also, ternary mixtures of HPMC, βCD and ITR were investigat-
ed to determine if the combination of the two glucose-based substances would 
further enhance properties of the developed formulation such as processability or 
ITR dissolution. 
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III.2. Methods 
In the present chapter, the techniques used in this project are divided into pre-
parative (see section III.2.1.) and analytical methods (see section III.2.2.). 
III.2.1. Preparative Methods 
In the context of this thesis, preparative methods describe all techniques that 
were used in the manufacturing of blends or samples. 
 Preparation of Powder Blends III.2.1.1.
As only one feeding station was used for all HMG and HME runs, the excipients 
had to be blended with the API prior to being filled into the feeding vessel. For all 
cases, a Turbula® shaker-mixer T2C (Willy A. Bachhofen AG, Switzerland) with a 
rotation speed of 42 rpm was employed. This blender is a three-dimensional 
free-fall mixer that uses translational, rotational and inversion forces. During 
mixing the powder constantly changes directions in a rhythmical pulsing mo-
tion [112]. The utilised plastic blending vessels were coated with Sprayflon 
Plus 3® (Saint-Gobain Performance Plastics Pampus GmbH, Germany), a pressur-
ised gas polytetrafluoroethylene formulation, prior to weighing-in of powder, as 
previous studies had shown an anti-adhesive effect and improved content uni-
formity for powder blends during mixing and mTSE feeding. 
For weighing-in of the substances, a double sandwich method was used where 
total excipient and API amounts were equally divided into three or two parts, re-
spectively. About 10 - 20 % of the blending vessel’s volume was filled. For all 
ternary mixtures the weighing-in protocol was ternary substance/ex-
cipient/API/excipient/API/excipient/ternary substance. Binary βCD/ITR blends for 
HMG and HME were prepared in singular (n = 1) and were composed as given in 
Table III.3.. Alternative HME or HMG mixtures were also singularly prepared and 
their respective compositions are given in the corresponding results sections. 
Table III.3. - Composition of binary βCD/ITR powder mixtures. 
 Stoichiometric Ratio Weight Proportion 
βCD 1 62 parts 
ITR 1 38 parts 
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Standard blending time was set to 20 min. After that, the physical mix-
tures (PM) were spread upon a white paper (DIN A3) and divided into three 
parts, left side, middle and right side. Ten samples were drawn (three from the 
left and right side each and four from the middle) and evaluated for ITR content 
(see section III.2.2.3.). If content homogeneity did not deviate more than 5 %, 
PM was considered ready for further processing. If homogeneity was not met af-
ter 20 min of blending, a second blending step of 20 min was added. ITR content 
was evaluated again and if PM was still not in specification as mentioned above, 
it was discarded. Time between content evaluation and further processing was 
kept as short as possible to prevent segregation. 
 Kneading and Wet Granulation III.2.1.2.
For comparative purposes, ICs were prepared by the kneading method, also 
called “slurry” which is the preferred method of forming ICs with βCD [80]. The 
method used in this project was based on the proposed technique by the βCD’s 
manufacturer [80] and slightly altered. Three parts of βCD were given into a 
mortar and manually mixed with one part of demineralised (dem.) water using a 
pestle until it reached a homogenous pasty state. If visual homogeneity was not 
reached by then, a few more droplets of dem. water were given into the mortar 
as generally suggested [80]. ITR was added gradually. If the mixture’s viscosity 
did not allow the kneading process, dem. water was appended to the mixture at 
this stage again. The material was kneaded for 30 min and dried at 70 °C for 
10 h in an oven (Memmert GmbH + Co. KG, Germany). The dried “slurry” was 
manually grinded in a mortar and sieved (< 425 µm) before analysis.  
To investigate the influence of a combination of HMG and a kneading process, a 
wet granulation was conducted. The above-mentioned process was manually re-
peated in a stainless steel bowl. The granulation end-point was defined as a ho-
mogenous state when the newly built agglomerates would stick together after 
slight manual compression but disintegrate after release. After reaching the 
granulation end-point, the granulate was given through a 1 mm sieve and dried 
at 70 °C in an oven (Memmert GmbH + Co. KG). In previous experiments it was 
determined that feeding of the mTSE was only feasible at residual moisture of 
around 15 % and lower. Thus, drying was continued until this specification was 
met. The wet-granulate was then directly transferred into the hopper and hot-
melt-granulated. 
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 Hot-Melt Extrusion and Hot-Melt Granulation III.2.1.3.
All HMG and HME experiments were performed using the Pharma 11 Twin 
Screw Extruder (Thermo Fisher Scientific GmbH, Germany) which will be de-
scribed in more detail in the subsequent sections.  
III.2.1.3.1. Pharma 11 Twin Screw Extruder 
An image of the Pharma 11 Twin Screw Extruder without its feeding unit is 
shown in Figure III.8.. The horizontal extruder barrel is divided into different 
parts. Firstly, the powder entry zone (funnel at the right side) which cannot be 
heated and is permanently water-cooled to prevent blockages. Second, seven 
separately controllable heating zones throughout the barrel that are connected to 
the water-cooling system and reach a maximum temperature of 280 °C. And 
lastly, the die at the left end of the extruder which is independently heated up to 
280 °C but not cool-able.  
 
Figure III.8. - Set-up of the Pharma 11 Twin Screw Extruder without feeder; 
image used with copyright permission of Thermo Fisher Scientific. 
The pressure control unit is connected to the nozzle head as well and can reach 
a maximum of 100 bar. The two screws are co-rotating within the barrel which 
allows sufficient mixing and inhabits a self-wiping aspect [27]. The ultimate 
screw speed is 1000 rpm. During the HMG/HME process, it is possible to monitor 
the screw torque to avoid motor damage. The highest tolerable torque is 
12 Nm (6 Nm per screw). The higher the torque, the more energy is needed by 
the screws to mix the material and the more energy goes into the final extru-
date. Thus, it holds importance in evaluating the HME/HMG procedure itself and 
will be taken into account for each HME/HMG process presented in this thesis.  
Material and Methods 
 
 
33 
In general, the upper barrel is completely closed and material within must fol-
low the barrel down to the die before again coming into contact with air. As pre-
liminary studies showed, the water from within the CD cavities started to evapo-
rate at about 100 °C, vaporised and left through the feedstock access, causing 
fresh powder entering mTSE to become moist und obstruct the powder entry. 
Therefore it was necessary to use the Pharma 11 mTSE ventilation port system. 
Here, a special component with a hole in it was installed in the upper barrel di-
rectly next to the powder entrance so that the water vapour could exit there. The 
chosen feeding system is essential for the HME/HMG process as blend segrega-
tion and insufficient content uniformity can occur within the hopper. As pharma-
ceutical feedstock often lacks good flowability, many different hopper systems 
are available such as vessels with built-in rotating agitator paddles, side stuffers 
or with two transporting screws of varying dimensions for conveying specific ma-
terials [21].  
There are two different main feeding categories recognised, gravimetric and 
volumetric feeding [113]. In gravimetric feeding a specified mass of excipient or 
mixture is fed into the extruder during a given time, e.g. 2 kg/h. These feeders 
have an installed scale that allows self-adjusting e.g. by adapting the rotation 
rate of the conveying screws to permanently stay within the appropriate feed 
rate limits. These feeders are mostly used industrially for pharmaceutical prod-
ucts as they allow more detailed oversight of the process. In volumetric feeding, 
the feeder set-up is the same with the exception of the built-in scale. The feed 
rate is often presented as a percentage of feeder capability, e.g. 50 % means 
that the conveying elements and agitator paddles are working at half of their 
maximum aptitude. This type of hopper has to be calibrated for each new feed-
stock as flowability will always differ for materials and freshly prepared PMs. Dif-
ferent filling levels are fed for a specified amount of time in a weighing vessel at 
full power. That way, it is possible to correlate the feeding capability to a 
throughput in kg/h [114]. Still, the process monitoring of volumetric feeding has 
drawbacks since it is much harder to detect changes in feed rate upon instant. To 
avoid segregation in PMs, it is possible to use two or more separate feeders, 
each only feeding one substance. By doing so, it is conceivable that excipients 
are added to the extrusion process at later process points, e.g. addition of ther-
mosensitive APIs after the highest temperature has already passed. 
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Throughout this project, the Pharma 11 Volumetric Mini Twin Feeder (MT-S 
HYP, Brabender Technologie GmbH & Co. KG, Germany) was employed. This 
feeder has a stirring mixing wheel for destroying powder bridges and two con-
veying screws to ensure feedstock flow. It belongs to the category of starve-
feeders which are most common when applying an mTSE as the formulation is 
given directly onto the rotating screws causing instant processing with the avoid-
ance of material build-up in the powder entry zone [115]. A schematic view of 
the used hopper is shown in Figure III.9.. 
 
Figure III.9. - Outline of the used feeding system; the whole feeding unit (left) 
and inside view of the feeding vessel, showing two conveying screws and the 
agitator paddle wheel (right). Images are adapted from [114]. 
As it is critical to calibrate the feed rate when using this type of hopper, prior to 
each HMG/HME experiment, PMs to be processed were given into the feeder and 
after the conveying screws were completely filled, material was fed at 100 % 
feeding capability for 1 - 2 min, weighed and projected to the throughput in g/h. 
This was done three times each for low and high filling levels. The arithmetic 
mean of these six measurements was set as the maximum possible feeding 
rate (100 %). From this, the necessary feed rate in % was derived for the de-
sired throughput in g/h. During HMG and HME, the amount of yielded product 
was weighed regularly to oversee the throughput and if necessary, the feed rate 
was adjusted. Moreover, powder samples were drawn periodically amidst feeding 
to analyse the API content with the aim to evaluate possible segregation within 
the feeder.  
Also of importance for a successful HME/HMG process is the screw design as 
mechanical shear forces impact the material, especially in kneading zones. This 
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can influence the finished products [116]. For all experiments, the standard 
screw design was utilised as shown in Figure III.10.. The screw diameter (D) was 
11 mm and length (L) 440 mm, resulting in a L/D ratio of 40 which is an im-
portant parameter for a possible up-scaling. 
 
Figure III.10. - Applied standard screw design; a) forward conveying elements, 
b) discharge screw conveyors, c) kneading/mixing elements, on the right as a 
single element and on the left as a finished kneading/mixing zone block with its 
elements shifted between 30° and 60°, adapted from [117]. 
The most common screw element is the conveying element. The standard 
screw design only uses forward conveyors. The discharge screw conveyors are 
special elements. They are channel-specific (α and β for each screw respectively) 
as they need to build up the pressure when the material reaches the die. They do 
not necessarily have to be used when working without a die, but in this project, 
they were always kept at the end of the screws for comparative purposes. 
Kneading zones are where most mechanical shear forces are brought upon the 
material. They are arranged of single mixing elements which are shifted in their 
offset angle. The higher the offset angle, the smaller the conveying power of the 
element and the greater the mixing capability. A 90° offset angle is solely viable 
for mixing. In general, a kneading zone is composited in a way that the first ele-
ments are shifted by 30°, the middle elements by 60° and the last by 90° to 
maintain forward conveying together with strong mixing properties. The first 
kneading zone of the utilised standard screw design (c, right in Figure III.10.) 
consists of 12 single mixing elements, the first three shifted by 30°, the next five 
by 60° and the last four by 90°. For the second kneading zone (Figure III.10., 
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c, left) three, three and four elements are shifted by 30°, 60° and 90° respec-
tively [117]. The applied screw speeds are given in the corresponding results 
sections. 
In HME processes, the die is a critical component as this is where the pressure 
builds up when the material is conveyed towards the narrowing structure. In this 
study, the standard Pharma 11 Twin Screw Extruder die (diameter 2 mm) was 
utilised next to a variable die (Thermo Fisher Scientific) with a flexible nozzle 
head that could be equipped with insets with varying diameter. The Thermo Fish-
er Scientific 3 mm inset and a self-built 6 mm inset were investigated. Further-
more, a 6 mm conical die was developed and tested in this work. The develop-
ment of this die with a special inner structure will be presented in sec-
tion IV.2.1.2.. 
When HMG was conducted, the die was removed completely from the mTSE 
and the material was allowed to fall freely from the extruder. By doing so, the 
material is only kneaded and mixed without the addition of high pressure [35]. 
To ensure a reproducible material exit, an in-house built granulation heel slide 
was applied to the end of the barrel (see Figure III.11.). After the extru-
dates/granules had left the die/granulation heel slide, they were air-cooled and 
stored in plastic containers until further processing. 
 
Figure III.11. - Granulation heel slide attached to the end of the Pharma 11 
Twin Screw Extruder barrel. 
The utilised mTSE is structured in seven separately heatable zones plus - if ap-
plied - the heatable die. When creating temperature profiles, it is very important 
to avoid too large differences between neighbouring zones as temperature stabil-
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ity might suffer. That is why usually the barrel temperatures rise from powder 
entry to the die. Sometimes it might be necessary to solely lower the tempera-
ture of the die if e.g. the extruded material is too liquid after having melted and 
thoroughly kneaded and would simply leak from the die. The temperature pro-
files used in this project are presented in the corresponding experimental sec-
tions as firstly, they were strongly dependent on the materials used and second-
ly, constitute an important factor in the process optimisation. Prior to further 
analysis, for comparative purposes, all HMG and HME samples were manually 
crushed and sieved (< 425 µm). 
III.2.2. Analytical Methods  
All techniques used in this work for characterising samples and products are 
summarised as analytical methods and described in the subsequent sections. 
III.2.2.1. Phase Solubility Analyses and Data Interpretation 
Phase solubility measurements (PSM) were first introduced to the scientific 
canon by Higuchi and Connors in 1965 [118]. Since then, this technique has of-
ten been employed as the foundation of CD inclusion research. The purpose of 
PSM is to determine the influence the CD has on the guest molecule (mostly 
APIs) in regard to its solubilisation. Furthermore, the stability constant and the 
complexation efficiency (CE) of the IC can be derived from this. Lastly, PSM can 
help to further understand the complex stoichiometry [71]. In PSM, an excess 
amount of drug is given into specified aqueous solutions of the CD in ques-
tion (e.g. 0.001 mol/L, 0.002 mol/L, 0.003 mol/L). Solutions are then kept in mo-
tion (for example by shaking) for a certain amount of time at constant tempera-
ture until equilibrium is reached and later evaluated for dissolved API content.  
CD concentration ([CD]t) plotted against the dissolved API concentration (Dt) 
yields the phase solubility diagram (PSD) which classifies the type of IC into two 
categories A and B, with several subtypes respectively (see Figure III.12.). Cate-
gory A is defined by an increased amount of dissolved drug the more CD is pre-
sent in the solution. The profile of subtype AN shows a negative deviation from 
linearity at higher [CD]t, whereas subtype AP then presents a positive deviation 
from linearity, indicating that CD is more effective at high [CDt]. AL type profiles 
show a linear enhancement of Dt and are reported as first order regarding CD. 
This means that one CD molecule complexes one or more molecules of 
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drug [71]. If the slope of the AL type diagram is larger than unity, higher order 
ICs are assumed in respect to the drug. 
 
Figure III.12. - Model phase-solubility profiles of main categories A and B and 
their applicable subcategories; y-axis presents the concentration of dissolved 
drug, x-axis presents the concentration of the aqueous CD solution; adapted 
from [71,119]. 
Although this phenomenon can also occur if the PSD slope is less than one, in 
general, 1:1 ICs are considered as more common [119]. AP systems are first-
order complexes in regard to the drug. One drug molecule forms ICs with one or 
more CD molecules. The so-formed ICs have to be fitted to different mathemati-
cal models to evaluate the most probable complex stoichiometry. Explanations 
for AN profiles include chaotropic or kosmotropic properties of the solubiliser, 
changed viscosity, surface tension or conductivity.  
B type profiles are yielded when the formed IC shows limited aqueous solubili-
ty. BS profiles become present when, at one point, Dt exceeds its maximum solu-
bility. ICs begin to precipitate while remaining excess drug dissolves or becomes 
complexed. As long as precipitation, dissolution and complexation are in balance, 
a plateau is seen in the PSD. After all solid drug particles have been included, 
further precipitation decreases the amount of Dt. Profiles of subtype Bi show in 
general the same phenomena as BS diagrams but as the ICs are very poorly sol-
uble in water, the linear increase of dissolved drug at low [CD]t (BS diagram) 
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does not occur [71]. As mentioned above, all of these generated phase-solubility 
profiles can be used to determine the stability constant (K) of the IC. Since the 
most common IC is of the stoichiometry 1:1, the stability constant K1:1 is most 
often evaluated to gain information about the IC. As the plotting of Dt against 
[CD]t would reveal a straight line if 1:1 ICs were formed, according to Higuchi 
and Connors [118], K1:1 can be determined by equation 2. 
K1:1 =  
Slope
D0 (1-Slope)
                 equation 2 
Here, Slope stands for the generated slope from the PSD and D0 is the solubility 
of the drug without the presence of CD in the solution. Applying equation 2 to 
the PSD, D0 should be of the same value as the intercept of the linear equa-
tion (Dint) as the intercept per definition presents the Dt at zero [CD]t. However, 
it is reported that especially for poorly water-soluble drugs (< 0.1 mM), such as 
ITR, there often is a deviation between D0 and Dint (D0 > Dint) that is not correlat-
able to any other drug property. These kinds of drugs often generate A-L type 
profiles as shown in Figure III.12., resulting in a too large value for K1:1. In some 
cases, Dint and K1:1 might become negative which is generally impossible. Postu-
lated reasons for this include the physico-chemical non-ideality of water mole-
cules, self-association of drug molecules and the fact that CDs also have the abil-
ity to form non-inclusion complexes or self-aggregate [119,120]. Charged CDs 
have been reported to result in PSD where DInt > D0 which then causes K1:1 to ap-
pear too small (A+L) [119].  
All these occurrences give reason to suspect that K1:1 actually rather is a com-
bination of different stability constants of various reactions in the aqueous solu-
tion. To overcome this variability in the stability constant and gain a reliable var-
iable for further conclusions, CE is of interest. By calculating CE, the molar ratio 
of CD and drug necessary to gain a 1:1 IC as well as the increase in formulation 
bulk can be assessed which is of great importance for a final dosage form [121]. 
CE can be derived without taking D0 or Dint into account and is calculated accord-
ing to equation 3 where Slope describes the slope of the linear equation from the 
PSD [122]. 
CE = D0 * K1:1 = 
[
D
CD
]
[CD]
=
Slope
(1-Slope)
              equation 3 
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From CE it is possible to calculate the drug : CD ratio by using the following 
equation 4 [121]. 
D:CD = 1 :  (1 + 
1
CE
)               equation 4 
The increase in formulation bulk (IFB) can be derived from equation 5 where 
MWdrug and MWCD mean the molecular weights of drug and CD [121]. Multiplying 
IFB with the drug dose per administration yields the new formulation bulk size. 
IFB = 
MWCD
MWdrug
 * (1 + 
1
CE
)               equation 5 
In this study, βCD solutions in dem. water and 0.1 N HCl besides HPβCD solu-
tions in 0.1 N HCl in the range between approximately 0.001 M and 0.0018 M 
were spiked with an excess amount of ITR. They were agitated at ambient condi-
tions until equilibrium was reached after seven days, filtered through 0.2 µm fil-
ters (Chromafil® Extra PET-20/25, Macherey-Nagel GmbH & Co. KG, Germany) 
and analysed as described in section III.2.2.3.. Each measurement was conduct-
ed at least in triplicate and K1:1, CE and IFB were derived from these analyses. 
III.2.2.2. Thermal Analysis 
Many important characteristics of solid samples can be determined by thermo-
sensitive measurement techniques. By exposing the sample to constant or vary-
ing temperatures and tracking different measurands such as sample weight or 
heat flow against a reference, temperature or changes over time allow conclu-
sions about different properties, like substance identity, crystallinity, thermal 
stability and water content [123,124] In this project, two of these techniques, 
differential scanning calorimetry (DSC) and thermal gravimetry (TGA), were em-
ployed.  
III.2.2.2.1. Differential Scanning Calorimetry 
DSC is the most common thermal technique due to its rapidity, uncomplicated 
sample preparation and the multitude of detectable events, such as melting, 
(re)crystallisation or Tgs. All these events can be evaluated quantitatively. The 
power compensation DSC which was applied during this work consists of two 
identical small furnaces that are separately heated, cooled or held isothermally 
according to the same associated measurement specification. The differences in 
the energy flow needed to keep both sample and reference at the same tempera-
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ture is measured in mW or J/s. This energy variation plotted against either tem-
perature or time yields the DSC curve [124]. Changes in the energy flow can be 
endothermic or exothermic depending on the occurring phase transitions in the 
sample, e.g. melting results in an endothermic peak, recrystallisation yields exo-
thermic signals. Samples are weighed in sealed aluminium pans that can be 
closed air-tight or present a pierced lid to allow pressure compensation. This 
way, residual water can exit the pan during analysis. The reference usually con-
sists of an empty aluminium pan. To avoid oxidation processes, the whole DSC 
apparatus is often flushed with nitrogen or helium gas [125].  
Throughout this project, DSC measurements were used to gain insight into the 
thermal behaviour of the studied sample. Of utmost importance was the state of 
ITR regarding its amorphousness or possible ICF. The occurrence of a melting 
peak at the corresponding Tm of ITR (166.2 °C, see section III.1.1.) was always 
examined. DSC traces were also evaluated for any other appearing signal. DSC 
analyses were conducted using Perkin Elmer PYRISTM Diamond DSC and 
DSC 7 (both Perkin Elmer Inc., US). Measurements were evaluated with PYRISTM 
Software Version 9.0.2.0193 (Perkin Elmer Inc.). If not marked otherwise, the 
accurate sample amount equivalent to 1 - 2 mg of ITR was weighed in an alu-
minium pan and sealed with a pierced aluminium pan. The reference was pre-
pared likewise with two empty aluminium pans. During analysis, the sample was 
flushed with 20 mL/min nitrogen gas. 
The exact temperature range and heating rate are given collectively with the 
results shown in the corresponding sections. They were always individually cho-
sen according to the properties to be examined, e.g. the investigation of the de-
composition temperature called for higher maximum temperatures than the ex-
amination of loss of βCD cavity water or ITR Tm.  
III.2.2.2.2. Thermal Gravimetry 
TGA is a simple way of determining the water content of solids. Water can play 
an important role in recrystallisation processes. Additionally, the water content in 
melt-extrudates/melt-granules allows conclusions about the HME/HMG proce-
dure. During the measurement, the sample is exposed to rising temperatures 
over time. Sample weight is monitored constantly and can be used to calculate 
the water loss during heating. This method yields results similar to those ob-
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tained by Karl-Fischer titration and was therefore regarded as suitable for the 
desired purposes in this work [126].  
A STA 6000 (Perkin Elmer Inc.) with ceramic pots and a constant flow of nitro-
gen (20 mL/min) was employed for all experiments and sample analysis was 
conducted with the PYRISTM Software (Version 9.0.2.0193, Perkin Elmer Inc.). 
For each evaluation, 15 – 20 mg of sample were given into the ceramic pot, held 
at 35 °C for 2 min and then heated to 750 °C at 10 K/min. The percentage of 
weight loss between 50 and 150 °C displayed the water content of the measur-
and as this allowed complete vaporisation of surface as well as βCD cavity water 
but sample degradation was avoided. Notwithstanding, some measurements, es-
pecially in the beginning of the experimental preformulation phase, were con-
ducted using different parameters. In case of different settings, the used meth-
odology is given together with the data shown. 
III.2.2.3. Itraconazole Content Evaluation 
Being the model API in this project, the development of a quantification method 
for ITR was necessary. This was firstly managed by using UV spectroscopy. But, 
the utilisation of additional substances, such as SOLU, made it impossible to use 
the method described in the following subsection. UV absorption interferences 
forced the development of a further method. Consequently, high performance 
liquid chromatography (HPLC) was selected. 
III.2.2.3.1. UV-Spectroscopy 
In 2011, Parikh et al. proposed a simple and reproducible UV-method with high 
recovery for ITR quantification at 262 nm where methanol was the only solvent 
employed. This method was also applicable for ITR quantification from a market-
ed formulation [127]. As a UV scan of ITR in methanol yielded an absorption 
maximum at 253 nm (Helios Omega, Thermo Fisher Scientific GmbH, Germany), 
this was subsequently chosen as the corresponding wavelength for all UV spec-
troscopy experiments. βCD did not show interference at this wavelength. ITR 
stock solutions in methanol (0.15 mg/mL) were prepared prior to each analysis, 
diluted with either methanol or 0.1 N HCl (only for dissolution testing) to gain a 
calibration curve in the appropriate range. Samples were diluted accordingly. 
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III.2.2.3.2. High Performance Liquid Chromatography 
HPLC is a known technique for drug quantification that uses the hydro-
philic/lipophilic interactions of the API with either the mobile phase or the sta-
tionary column. Depending on these interactions, the evaluated substance will 
elute earlier or later from the column and pass an appropriate detection system. 
By this, it is possible to analyse samples where different ingredients show UV ab-
sorption at the same wavelength which would not be possible by UV spectrosco-
py. Adapting the experimental set-up described by Trinadha Rao et al. [128], the 
used HPLC method is given in the appendix (see section VII.3.). Stock solutions 
were prepared as described in the previous subsection and diluted with mobile 
phase. For every analysis, a fresh calibration curve was prepared and analysed. 
III.2.2.3.3. f1 and f2-Concept  
As stated, over the course of this study it was necessary to change the ITR 
quantification methodology from UV spectroscopy to HPLC. It had to be evaluat-
ed if measurements based on either UV spectroscopy or HPLC could be freely 
compared to each other and yielded the same results.  
For that reason, the dissolution profile comparisons according to the FDA’s 
guidance for industry were conducted in a modified way, namely by employing 
method A, the determination of the difference and similarity factors, f1 and f2, re-
spectively. This model independent approach results in two numbers describing 
the two products under investigation, in this varied case, the two quantification 
methods. f1 means the percentage of differences between two dissolution profiles 
and f2 concludes the percentage of similarity [129]. Mathematical operations for 
f1 and f2 are given in equation 6 and 7. 
f1 = {
[∑ n t=1  |Rt  - Tt| ]
[∑ n t=1 Rt]
} * 100                            equation 6 
f2 = 50 * log {[1+ (
1
n
) ∑ n  (Rt- Tt)
2
t=1 ]
- 0.5
* 100 }            equation 7 
n means the number of measuring time points, Rt stands for the amount of dis-
solution in per cent reached at a certain time point (t) for the reference formula-
tion (in this case UV spectroscopy) and Tt the corresponding dissolution value for 
the HPLC quantification.  
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According to the FDA guideline, some specifications are recommended when 
applying f1 and f2, such as are: 
1.  n = 12 for each R and T 
2.  same measuring time points as well as conditions for dissolution 
testing for R and T with at least three to four sampling times 
3.  only one sampling time point after 85 % of dissolution 
4. up to 15 min of dissolution, variation coefficients below 20 %, af-
ter that below 10 % 
Reaching f1 below 15 % and f2 above 50 % are the considered limits for regard-
ing two dissolution profiles as similar. As dissolution of amorphous ITR (aITR) 
prepared by rapid cooling after melting did not show dissolution above 85 % af-
ter 4 h (see recommendation 3), it was used as suitable sample. 12 units of aITR 
underwent dissolution testing according to section III.2.2.9. and were analysed 
by HPLC and UV spectroscopy each. Dissolution curve is given in the appen-
dix (see section VII.3.). Applying equation 6 and 7 yielded a f1 value of 1.91 % 
and a f2 value of 95.92 % which also proved the similarity between the dissolu-
tion curves. Both results were strongly below and above the respective limits. 
Only recommendation 4 could not be met as the variation coefficient exceeded 
20 % and 10 % respectively up to 60 min of dissolution but as this was true for 
both quantification methods, it could be disregarded. Even though the original 
f1/f2-concept is not meant for these method-comparative purposes, it could still 
function as groundwork for the conclusion that it was possible to use either UV 
spectroscopy or HPLC in ITR quantification as they yielded the same results. 
Thus, in this thesis, results of both techniques were evaluated together without 
any further mention of the specified quantification method.  
III.2.2.4. Quantification of Cyclodextrins 
Quantification of βCD and HPβCD was conducted by HPLC adapted from the 
proposed method of the current Ph. Eur. for βCD [76]. Here, reverse phase HPLC 
is employed coupled with a refractive index (RI) detector as UV absorption spec-
tra of CDs cannot be used for quantification due to lack of linearity. Both CDs 
could be investigated together. Stock solutions of either CD in bidistilled water 
were prepared prior to every analysis and further diluted with it for a calibration 
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curve. As HPβCD is specified by an average degree of substitution with methyl 
groups, it is not one defined substance. Therefore, HPLC chromatograms pre-
sented three HPβCD peaks (see Figure III.13.). Since every stock solution was 
prepared with the same raw material as had been used for HMG experiments, 
and integration of the third peak resulted in a linear calibration curve, quantifica-
tion of HPβCD was deemed possible. Further details about the HPLC method are 
given in the appendix (see section VII.3.). 
 
Figure III.13. - Model chromatogram taken from the ClarityTM soft-
ware (DataApex, Czech Republic) where voltage in mV is plotted against the run 
time in min; a) HPβCD peak used for quantification, b) βCD peak used for quan-
tification, c) injection signals. 
 
III.2.2.5. X-ray Powder Diffraction 
As of today, the gold standard in gaining valuable information about the crystal 
lattice of a molecule and its possible amorphousness is the x-ray powder diffrac-
tion (XRPD). Here, electrons derived at a cathode are accelerated by applying a 
voltage up to about 50 kV and move towards the anode. If a solid sample is 
brought into the electron’s trajectory, the x-rays are scattered at the molecule’s 
atoms according to Bragg’s Law and are reflected at a specified angle. This way, 
characteristic diffraction rings can be detected. The intensity of this reflection 
plotted against the measuring angle 2Theta (2θ) results in the powder diffracto-
gram which is specific for each pure substance and can be used for identification. 
Diffractograms of PMs are additions of the components and might show different 
patterns due to overlapping reflection angles. As amorphous powders lack long-
range order, no x-ray diffraction can be detected, resulting in so-called “ha-
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los (see Figure III.14.). Sometimes partially crystalline mixtures present a “halo” 
with some distinctive peaks [124].  
 
Figure III.14. - Exemplary diffractograms of a fully amorphous sample present-
ing a "halo", in this case a melt-extruded product (top) and a fully crystalline 
material, in this case a βCD/ITR powder blend (bottom). 
In this study, XRPD was used to investigate the crystal status of PMs and 
HME/HMG products, especially regarding ITR. For a fully comprehensive picture, 
the obtained results were evaluated together with those conducted by DSC anal-
ysis. Due to costs and expenditure of time, single measurements were carried 
out using Stadi P (Stoe and Cie GmbH, Germany) with either IP-PSD (Stoe and 
Cie GmbH, resolution of 0.02° 2θ) or MYTHEN 1K detector (DECTRIS AG, Swit-
zerland, resolution of 0.009° 2θ) and Cu-Kα1-radiation. Samples were fixated by 
Scotch® tape MagicTM (3M Deutschland GmbH, Germany) as commercial glues 
necessary for acetate foils caused sample alteration. Samples were evaluated 
from 2 - 80° 2θ while being rotated at 40 kV and 30 mA. Due to technical issues, 
some samples were evaluated using a Stadi P (Stoe and Cie GmbH) with the fol-
lowing experimental set-up: PSD detector (Stoe and Cie GmbH, resolution of 
0.06° 2θ) measuring range from 5 - 50.98° 2θ at 20 kV and 5 mA. 
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III.2.2.6. Attenuated Total Reflectance Fourier-Transform-Infrared 
Spectroscopy Implementation and Data Evaluation 
Attenuated total reflectance Fourier-transform infra-red spectrosco-
py (ATR-FT-IR) is a well-known technique for analysing solid samples [130]. A 
laser beam in the mid-infrared range (4000 - 200 cm-1) set on a molecule will 
result in the absorption of some frequencies depending on the nature of the mol-
ecule’s atoms and their chemical environment such as covalent bonding. This ab-
sorption causes the IR-active molecular regions to vibrate in specified ways, 
e.g. symmetrical or asymmetrical deformation (δs, δas) and symmetrical and 
asymmetrical stretching vibrations (νs,νas). Generally, more energy is needed for 
the stimulation of stretching vibrations. Thus, above 1500 cm-1, mostly stretch-
ing vibrations are detectable and deformation vibrations at lower wave num-
bers [131]. In organic molecules, many different atomic bonds are present which 
cause coupled vibrations that result in characteristic spectral patterns that are 
mostly used for the identification of substances [131]. By employing the ATR set-
up, no sample preparation is needed as the solid sample is firmly placed on the 
measuring device (e.g. a diamond or ZnSe crystal) and then analysed. Hereby, a 
laser beam that should be internally reflected by the crystal creates an evanes-
cent wave that expands into the sample and is absorbed at the characteristic la-
ser frequencies due to the chemical properties of the measurand. This causes an 
attenuated signal in the IR detector that can be used to generate a transmission 
spectrum [132]. 
ATR-FT-IR plays an important role in the detection of ICs. As a guest molecule 
enters the CD cavity, the corresponding functional groups will no longer have the 
same atomic environment as in a PM where both substance molecules, CD and 
guest, are merely blended together without much interaction. The comparison of 
IR-spectra of sole substances, their PM and suspected IC is therefore often used 
in proving the existing of the encapsulation. The effect that the inclusion will 
have on the absorption of infrared laser light is hard to predict and individual for 
each molecule. Changes in wave number to lower or lesser frequencies have 
been reported as well as the broadening/tightening of IR bands [133].  
All measurements were conducted at least in triplicate using a Spec-
trum 100 (Perkin Elmer Inc.) with MIRacle ATR unit (Pike Technologies, US). 
Each spectrum was derived from 32 scans against the corrected background with 
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a resolution of 4 cm-1 over the range of 4000 - 550 cm-1. Spectra were then au-
tomatically baseline corrected and analysed for the existence of peaks (limit 
0.5 % transmittance) by the SpectrumTM software (Version 6.3.4.0164, Perkin 
Elmer Inc.).  
III.2.2.6.1. Data Evaluation for Inclusion Complex Detection 
By employing ATR-FT-IR, differences in spectra were used to conclude interac-
tions between the CD and the guest when comparing PM and processed samples. 
As variabilities detected differ from API to API [133], an analysis regimen had to 
be chosen for ITR before investigating HMG and HME samples. Thus, the molecu-
lar structure of ITR was evaluated to specify wave numbers that correlate to 
functional groups. However, as many specific atomic bonds such as C-H or C-N 
are present multiple times in the ITR molecule, their association to the respective 
functional groups had to be based on literature review, evaluation of neighbour-
ing functional groups and the quantity of their appearance. Figure III.15. shows 
the constitutional structure of crystalline ITR with selected marked functional 
groups and their corresponding spectral band numbers chosen after evaluating 
the results of Kumar et al. [134] , Nesseem [135], Al-Badr et al. [136] and the 
provided tables by Rücker et al. [131]. 
 
Figure III.15. - Chemical structure of ITR with corresponding wave numbers. 
Especially the piperazine ring system, given its position in the middle of the 
molecule, was of interest regarding possible inclusion. As ATR-FT-IR bands were 
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complicated to determine with often arising C-H, C-C and C-N atomic bondings, 
ATR-FT-IR spectrum of pure piperazine was also evaluated to better correlate 
this functional ring within ITR [137]. Combining the allocations of the functional 
groups, first conclusions of which part of ITR (head (left) or tail (right) part) is 
entering the CD cavity during ICF could be drawn. It has to be remembered 
though that different ATR-FT-IR wave bands can overlap, particularly when ICF 
of less than 100 % is achieved in the investigated sample. Apart from this, it is 
important to recognise the existence of aITR in melt processed samples which 
can influence the ATR-FT-IR spectrum. aITR prepared by melting with successive 
rapid cooling was studied by ATR-FT-IR as positive control. Some peaks disap-
peared when comparing aITR to ITR (e.g. ~ 898 and 852 cm-1) due to changes in 
the atomic structure caused by loss of crystal lattice. Those wave numbers were 
not further evaluated as any changes could solely be caused by amorphisation. 
To understand the spectral changes in more detail without subjectivity, twelve 
wave numbers originating from either ITR/aITR or βCD are given in Table III.4.. 
They had been identified as markers in evaluating possible ICF and were exam-
ined for shifts to higher or lower wave numbers or altogether disappearance. 
Table III.4. - Identified marker wave numbers for examining ICF, derived from 
analyses of either ITR (aITR) or βCD [92]; n = 5; standard deviation (sd) = ±. 
Wave Number, cm-1 Molecular Regions 
1697.80 ± 0.23 
(1698.87 ± 0.43) 
C=O, ITR 
1584.34 ± 0.17 
(1585.57 ± 0.07) 
C=N, ITR 
1551.43 ± 0.15 
(1552.49 ± 0.01) 
C=N, ITR 
1509.64 ± 0.29 
(1510.59 ± 0.10) 
aromatic C=C, ITR 
1451.26 ± 0.12 
(1450.87 ± 0.06) 
aromatic C=C, ITR 
1272.85 ± 0.45 
(1271.56 ± 0.04) 
piperazine, ITR 
1227.32 ± 0.28 
(1227.50 ± 0.14) 
dioxolane, ITR 
1185.03 ± 0.13 
(1182.59 ± 0.18) 
piperazine, ITR 
1140.53 ± 0.11 
(1137.71 ± 0.28) 
C-O-C, ITR 
1043.88 ± 0.50 
(1040.81 ± 0.66) 
aryl-Cl, ITR 
1025.78 ± 1.03 C-O, βCD 
824.10 ± 0.15 
(823.81 ± 0.49) 
di para benzene ring, ITR 
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Band intensity was not taken into account due to high variability and subse-
quently, insufficient explanatory grounds. The presented marker wave numbers 
were investigated for every sample analysed by ATR-FT-IR and always evaluated 
against a suitable control such as PM or PM with aITR (PMaITR). The detection of 
differences was used for concluding the possible existence of ICs. The detailed 
data evaluations are shown in the corresponding results sections. 
III.2.2.7. Laser Diffraction 
Particle size of raw materials and produced samples was determined by laser 
diffraction. Even though all self-processed samples were manually crushed and 
given through a 425 µm sieve prior to further analysis, the real mean particle 
size was still of interest. If differences in solving velocity become present in dis-
solution testing, the possibility of this effect being caused by a varying surface 
area of samples has to be taken into account. Raw material particle size can in-
fluence the blending procedure and therefore had to be evaluated as well.  
During laser diffraction measurements, the analysed particles will flex the light 
of a helium-neon-laser. The angle and intensity observed by this diffraction can 
be reverse correlated to the particle size. As not all particles will be of exactly the 
same size, diffraction patterns will overlap and can be evaluated based on the 
Fraunhofer theory. Laser diffraction experiments were conducted using a HELOS 
system with a RODOS module (Sympathec GmbH, Germany) and evaluated with 
the Windox Software Version 5.4.2.2 (Sympathec GmbH). Each determination 
was carried out in triplicate with a dispersion pressure of 3 bar and lens 
R5 (measuring range 0.5 µm - 875 µm).  
III.2.2.8. Scanning Electron Microscopy 
In order to gain information about the visual appearance of raw materials and 
processed samples, in this project, the method of scanning electron microsco-
py (SEM) was chosen. This technique allows a higher magnification and resolu-
tion compared to light microscopy [124].  
A bundled electron beam is induced by an electron gun, accelerated up to 30 kV 
and led through the objective lens towards the solid sample by a system of con-
denser lenses. Upon striking the sample, the electron beam enters and different 
interactions occur. Two of these are the most important, as they are detected in 
SEM. First, the low-energy secondary electrons which are emitted by atoms in 
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the sample after having been entered by the electron beam and second, the 
backscattering electrons which are reflected at the sample atom’s surface and 
can have high energies. Also emitted from the sample are x-rays which might be 
used for identification in SEM devices with specific detection equipment. In gen-
eral, signal converters and detectors such as scintillators are used for transform-
ing the observed electrons into a microscopic image of the sample. Electrocon-
ductive samples are suited best for SEM measurements as for them the chance 
of disturbances caused by electric charging is minimised. Most pharmaceutical 
measurands are not electroconductive, hence they are often coated with a thin 
layer of metal [125]. The whole analysis is performed under vacuum conditions. 
In this study, SEM images were generated using a Zeiss Ultra 55 Plus (Carl 
Zeiss NTS GmbH, Germany) applying a working voltage of 2 kV and utilising the 
SE-2 detector which visualises secondary electrons. Prior to analysis, samples 
were fixated on a sample holder by carbon stickers (Plano GmbH, Germany) and 
sputter coated with a Bal-Tec SCP 050 Sputter Coater (Leica Microsystems 
GmbH, Germany). This was conducted in an evacuated chamber at 50 mA for 
65 s with the use of argon 5.0., resulting in a thin gold layer upon the sample 
ensuring electroconductivity in SEM characterisation. 
III.2.2.9. Dissolution Testing  
In formulation development and determining product characteristics on a lab 
scale, dissolution testing is one of the most important tools to obtain first in-
sights into the drug’s in-vitro behaviour [138]. Dissolution testing means to mon-
itor the amount of dissolved API in a chosen medium over the course of a speci-
fied time. In the best case, these results then allow either the determination of 
an in-vivo-in-vitro-relationship (IVIVR) or in the best, but rarest case, an in-
vitro-in-vivo-correlation (IVIVC) which may be used for regulatory or quality con-
trol purposes [139]. Different apparatuses can be used for dissolution testing and 
are, inter alia, presented in the Ph. Eur. [140].  
The dissolution studies in this project were conducted with the Premi-
ere 5100 (Distek Inc., US), using Apparatus 2, the Paddle Apparatus, which is 
commonly used for investigating solids. The dissolution vessels were brought to 
the predefined temperatures by heating jackets (see Figure III.16). Sampling 
was conducted with an automatic sampler model 2230 (Distek Inc., US) at given 
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time points. Each sampler featured a 0.45 µm filter (FIL045-DK, Quality Lab Ac-
cessories L.L.C., US) to avoid removal of solid particles from the dissolution vessel. 
Dissolution media was not replaced during these experiments. However, for 
some first dissolution trials, samples were drawn manually and the medium was 
replaced. Results of these preliminary tests will be labelled accordingly.  
 
Figure III.16. - Exemplary dissolution vessel with heating jackets, rotating pad-
dle as well as automatic sampling device. 
Due to ITR being a weak base (pka 3.7), acid conditions are often described as 
suitable dissolution media, most commonly 0.1 N HCl with specified variations to 
approximate gastric conditions [109,141]. Generally, in dissolution tests, sink 
conditions should be applied. This means that the volume of dissolution medium 
is at least three times larger than needed for a saturated solution of the investi-
gated API. When working with poorly soluble BCS class II compounds it can be 
justifiable to employ non-sink conditions if the chosen dissolution method is dis-
criminatory and reproducible [139]. Also, as stated above, a true IVIVC for BCS 
class II APIs, especially those designed for immediate release like ITR, is ex-
tremely rare so that the importance of in-vitro dissolution testing rather lies in 
evaluating stability or batch consistency [139]. Thus, a compromise between gas-
tric resemblance and sink conditions was applied in this project. All dissolution pa-
rameters as well as the sampling time points are presented in Table III.5.. After 
dissolution testing was carried out, the samples were analysed for ITR content as 
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described in section III.2.2.3. within 48 hours. Sample stability for that time pe-
riod had previously been ascertained. 
Table III.5. - Dissolution testing parameters. 
General dissolution settings 
Dissolution medium 900 mL of 0.1 N HCl 
Medium temperature 37 ± 0.25 °C 
Paddle rotation speed 100 rpm 
Analysis time 4 h 
API analysis amount 
equivalent to 100 mg ITR, given directly into the dissolu-
tion vessel 
General sampling settings 
Sample amount 5 mL 
Sampling velocity 10 mL/min 
Sampling time points 2, 5, 10, 15, 30, 45, 60, 90, 120, 150, 180, 210, 240 min 
 
III.2.2.10. Storage Stability 
For evaluating the HMG products’ qualities against the marketed counterpart 
and alternative formulation approaches, they underwent stability testing over six 
months. This stability study was based on the suggestions of the ICH Guideline 
Q1A (R2) [142] at 25 °C/ambient humidity and 40 °C/75 %RH (accelerated 
study) (Climate chamber SB 111300, Weiss Klimatechnik GmbH, Germany). After 
HMG, the products were manually crushed in a mortar, given through a 425 µm 
sieve and separated into four customary plastic containers. Two were closed with 
a cap with a built-in drying agent (Gerresheimer AG, Germany), whereas the re-
maining two containers were left open to investigate the influence of the ambient 
moisture. For each sample and storage condition, a closed and an open canister 
were deposited.  
The samples were investigated according to the experimental plan given in Ta-
ble III.6.. All analytical methods were performed as reported in the associated 
sections. Due to time-consuming and partially costly analyses, DSC experiments, 
XRPD analysis, SEM imaging and TGA testing were carried out as single determi-
nations, content evaluations were conducted at least in triplicate, ATR-FT-IR 
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spectra were recorded at least in triplicate, and dissolution testing was carried 
out at least in duplicate for the investigated samples. 
Table III.6. - Analytical protocol for stability testing. 
Production 2 Weeks 1 Month 3 Months 6 Months 
DSC DSC DSC DSC DSC 
TGA TGA TGA TGA TGA 
βCD content βCD content βCD content βCD content βCD content 
ITR content ITR content ITR content ITR content ITR content 
Dissolution Dissolution Dissolution Dissolution Dissolution 
ATR-FT-IR ATR-FT-IR ATR-FT-IR ATR-FT-IR ATR-FT-IR 
SEM X X X SEM 
XRPD X X X X 
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IV. Results and Discussion 
The results obtained in the course of this project will be presented and dis-
cussed in the subsequent sections in a chronological order following the devel-
opment and optimisation of a hot-melt formulation consisting of βCD and ITR.  
IV.1. Phase Solubility Measurements Results 
As described in section III.2.2.1., PSM are frequently used as groundwork when 
investigating ICs with APIs and their possibly increased aqueous solubility, espe-
cially for the determination of complex stoichiometry and stability constants. All 
these information were of interest for the development of a binary formulation. A 
deeper knowledge about how simple the IC is formed in regard to how many CD 
molecules are necessary to encapsulate one ITR molecule is very important as it 
strongly influences the increase in formulation bulk. There are several literature 
references about PSM with ITR and βCD in different aqueous media. But, as 
these results were not always in perfect agreement, it was decided to not solely 
rely on those suggestions, but to self-conduct PSM. 
In the first experiments, ITR PSM were conducted for solutions of βCD in dem. 
water in the range between approximately 0.001 - 0.017 M. Higher βCD concen-
trations could not be evaluated. Because of the moderate water solubility of βCD 
itself, solutions up from 0.017 M were only preparable by ultrasonification. These 
solutions were not stable as precipitation of βCD crystals occurred within the 
seven day experiment time. Thus, they had to be excluded from data assess-
ment. As all dissolution experiments were carried out in 0.1 N HCl, PSM were al-
so conducted in this medium in the same concentration range. The utilised CD in 
the marketed ITR oral solution Sporanox® is HPβCD [10]. Due to this application 
it was expected that HPβCD would be able to substantially reach ITR solubilisa-
tion. This outlined HPβCD as an alternative matrix in the hot-melt process. Thus, 
the PSD for HPβCD and its corresponding IC constants were analysed. 
IV.1.1. Evaluation of Phase Solubility Diagrams and Discussion 
Results of the PSM studies are shown in Figure IV.1.. Obviously, PSD of βCD in 
dem. water resulted in very low amounts of dissolved ITR. A magnification of the 
PSD was necessary to examine if ITR concentration changed at all with rising 
βCD concentrations.  
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Figure IV.1. - PSD of ITR in βCD in dem. water, βCD in 0.1 N HCl and in HPβCD in 
0.1 N HCl; n = 3; linear equations and correlation coefficient (R2) are given next 
to the respective solubility profile; inserted graph in the upper left corner shows 
PSD of ITR in βCD in dem. water with adjusted y-axis; n = 8; error bars = sd. 
Consequently, PSD of HPβCD was not determined in dem. water, but only in 
0.1 N HCl. PSD of both CDs in 0.1 N HCl presented strong ITR solubility en-
hancements. Loftsson et al. determined K1:1 for 28 different drugs. The lowest 
correlation coefficient for which they assumed complex stoichiometry of 1:1 was 
0.967 for ergotamine with HPβCD [119]. Taking this into account, at least for the 
PSD in 0.1 N HCl, nearly linear relationships between ITR and βCD could be con-
firmed as shown by the correlation coefficients of 0.9700, and 0.9759 for βCD in 
0.1 N HCl and HPβCD in 0.1 N HCl. Furthermore, the slopes of all regression lines 
were lower than unity which suggested ICs in the stoichiometric ratio of 1:1. 
Consequently, at least for the PSD in 0.1 N HCl, ICs consisting of one ITR mole-
cule and one CD molecule could be assumed [71]. This is the most common type 
of IC [119]. Furthermore, evaluating the curve progression, AL-type diagrams, 
more precisely, A-L-type diagrams, could be recognised.  
PSM in dem. water showed a lesser correlation coefficient of 0.9451. The dia-
gram might have also been interpreted as AP-type, meaning that the solubility 
enhancing properties of βCD became more pronounced at higher CD concentra-
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tions. But as the quantified amounts of ITR were very low and always presented 
a quite high sd, this conclusion could not be regarded as substantial as for the 
other two analyses in 0.1 N HCl. This held particularly true because this experi-
ment was carried out eightfold without a distinctive result. Additionally, the oc-
currence of A-L-type diagrams for all three PSD was supported by the fact that 
the correlation coefficients rose to 0.9896, 0.9912 and 0.9853 for βCD and 
HPβCD in 0.1 N HCl and βCD in dem. water when excluding the first three de-
termined ITR concentrations at 0 M, 0.001 M and 0.002 M of the respective CD.  
Gökbulut et al. characterised the PSD of ITR and βCD in buffer solution pH 1.2 
as BS-types [143]. However, they tested βCD concentrations up to 100 mM which 
strongly exceeded CS of βCD (around 18 mM). As reported, βCD precipitation 
could have likely occurred at these high concentrations which would have caused 
false results. Yet, the interpretation of AL-type diagrams was in good agreement 
with the conclusions drawn by Alanazi et al. and Kumari et al. [144,145]. Alanazi 
et al. tested βCD concentrations up to 0.016 M in dem. water and 0.1 N HCl 
while Kumari et al. studied βCD in concentrations up to 0.015 M in dem. water. 
They obtained similar PSD as shown in this project. For the PSD of ITR with 
HPβCD, literature results seemed to be compliant about the existence of Ap-type 
diagrams as reported by Peeters et al. and Alanazi et al. [145,146]. Peeters et al. 
investigated HPβCD concentrations up to 40 wt/v % (around 0.29 M) at pH 2 and 
concluded ICs in the ratio of 1:2 ITR:HPβCD. Alanazi et al. evaluated concentra-
tions up to 0.04 M in 0.1 N HCl, also assuming higher order complexes. Even 
though Shah et al. reported AP-type diagrams of HPβCD and ITR in phosphate 
buffer pH 6.8, the experimental results shown rather suggested AL-type dia-
grams, because the correlation coefficient nearly reached unity (0.9912) for the 
concentration range up to 15 mM [147]. Although different media were used and 
the absolute amount of dissolved ITR differed extensively from the determination 
in this project, the general influence CDs seem to have on ITR was still comple-
mentary with literature results. For both PSM in 0.1 N HCl, D0 of 
ITR (8.174 x 10-6 ± 5.286 x 10-7 M) was clearly diverged from Dint which should 
have been the same value. Dint yielded negative results by the linear regression 
which is implausible. As previously reported, this is often observed for APIs with 
very low aqueous solubility such as ITR. Most of the time, it is not possible to de-
termine the exact complex stoichiometry as many different effects overlap in so-
lution and the system is constantly changing and interacting. Not only do CDs 
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form ICs, non-inclusion complexes are possible as well which might further en-
hance the API’s solubility or solubility rate. Recently, the IC stability constant K1:1 
is often understood as an interplay of many different stability constants in the 
solution such as dissociation and association constants, equilibrium between 
complexed and non-complexed API to only name a few [121]. For the purpose of 
this thesis, two important denouements needed to be taken from PSM. First of 
all, it was clearly shown that ITR solubility could be improved by using CDs. Sec-
ondly, it was necessary to evaluate if either βCD or HPβCD presented stronger 
ITR encapsulation under the same experimental conditions. From the shown PSD 
results, a complex with the stoichiometric ratio of 1:1 was supposed for all fur-
ther calculations.  
The stability constant (K1:1) for both y-axes intercepts (D0 and Dint), complexa-
tion efficiency (CE), drug to CD ratio (D:CD), the increase in formulation 
bulk (IFB) as well as the resulting formulation bulk for the three PSD were calcu-
lated according to equation 2-5 using D0, Dint and the slope from the linear re-
gression. Results are presented in Table IV.1..  
Table IV.1. - ITR solubility without CD (D0), ITR solubility at the PSD inter-
cept (Dint), slope of regression line, IC stability constant (K1:1) calculated with 
either D0 or Dint, complexation efficiency (CE), drug to CD ratio (D:CD) increase 
in formulation bulk (IFB) and formulation bulk (IFB · 100 mg single dose of 
ITR) given for all three PSM and rounded to three significant decimals. 
 βCD in dem. water βCD in 0.1 N HCl HPβCD in 0.1 N HCl 
D0, M 4.560 x 10
-7 ± 3.092 x 10-7 8.174 x 10-6 ± 5.286 x 10-7 
Dint, M 5.697 x 10 
-8 -4.243 x 10-5 -2.381 x 10-5 
Slope 0.000250       0.0413 0.0270 
K1:1 D0, M
-1 548.228 5265.113 3398.739 
K1:1 Dint,, M
-1 4388.601 -1014.409 -1166.864 
CE 0.000250 0.0430 0.0278 
D:CD 
0.000250 
 ~ 1 : 4001 
0.0413 
 ~ 1 : 24 
0.0270 
 ~ 1 : 37 
IFB 6435.320 38.981 73.345 
Formulation 
bulk*, mg 
643532 3898.1 7334.5 
*assuming a single dose of 100 mg ITR 
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As all PSD depicted the mean value of at least three experiments and all IC 
constants were derived from there, no sd could be enumerated for these terms. 
Clearly, the medium in which PSM had been conducted had a strong influence on 
the obtained characteristic parameters for the IC. Comparing the results of βCD 
in dem. water and in 0.1 N HCl, K1:1 calculated with D0 increased 9.60-fold when 
using 0.1 N HCl. This might have been related to the enhancement of D0 it-
self (17.93­fold increase) due to the ionisation of the drug in the acid milieu. An 
increase in solubilisation properties of the CD with improved solubility of the API 
itself has been reported before and is in good agreement with the litera-
ture [122,146,148]. The medium-dependency demonstrates a challenge when 
interpreting PSM results and using them for formulation development. After oral 
administration of a drug formulation with CDs, the medium (i.e. the gastric envi-
ronment) will always differ, even for the same person. Therefore, the capability 
of the CD to include the API may be different upon every administration. This in 
itself supports the idea of a drug formulation which already entails ICs.  
Dint gave negative values for both PSD in 0.1 N HCl which resulted in negative 
K1:1 values. This is genuinely impossible. Alanazi et al. investigated K1:1 in 
0.1 N HCl for βCD and HPβCD at different temperatures [145]. Since PSM in this 
project were conducted at room temperature, their reported values for 25 °C 
were regarded as most comparable. With K1:1 of 5923.2 M
-1 for βCD and 
2953.6 M-1 for HPβCD, those results came close to the ones attained in this 
study (5265.113 M-1 and 3398.739 M-1, respectively). Assuming 1:1 complexa-
tion, Peeters et al. calculated K1:1 for HPβCD at pH 2 of 5280 M
-1 after six days. 
This was higher than 3398.739 M-1 but probably merely caused by the different 
experimental design [146]. Kumari et al. analysed βCD in dem. water at 37 °C 
and obtained a K1:1 value of 177.0 M
-1 [144]. This was smaller than 548.228 M-1 
as obtained here, however expectable, as higher temperatures increase Brownian 
motion, causing the IC to become less stable.  
Generally, K1:1 strongly depends on the drug solubility and is therefore often 
very inaccurate and yields differing results. The more precise expression for IC 
interpretation is CE. The higher the efficiency of the CD to include the API, statis-
tically less CD molecules are necessary until an IC is formed [121]. Upon com-
paring CE of all three PSM, it seemed that βCD had shown the highest potential 
for ICF. Just by changing the experimental medium from dem. water to 
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0.1 N HCl, CE had increased 172-fold. The CE of βCD in 0.1 N HCl was also about 
1.55 times higher than for HPβCD. The K1:1 values obtained with D0 were in 
agreement with this as they followed the same order. It appeared that the stabil-
ity and likelihood of ICF between CD and ITR rose from βCD in dem. wa-
ter < HPβCD in 0.1 N HCl < βCD in 0.1 N HCl. The D:CD ratio (see Table IV.1.) 
also clearly showed the high influence of the medium, as in dem. water, only 
every 4001th molecule of CD resulted in a 1:1 IC. HPβCD in 0.1 N HCl statistically 
needed at least 37 CD molecules for the encapsulation of one ITR molecule and 
βCD in 0.1 N HCl still 24 molecules. Compared to 4001, this number appeared 
small but the formulation bulk would have still increased 38.981-fold which 
would have resulted in a single dose of nearly 4 g per administration. This was 
unacceptable for many reasons; mainly because the amount of orally taken βCD 
would have exceeded the proposed maximum of 20 mg/kg bw by far (see sec-
tion III.1.3.). 
The marketed oral solution Sporanox® which has a pH of approximately 2 con-
tains 400 mg/mL of HPβCD in contrast to 10 mg/mL of ITR. This results in a 
D:CD ratio of 0.014 M : 0.286 M or rather 1 molecule of ITR to around 20 mole-
cules of HPβCD. This is less than the determined 37 CD molecules but this is likely 
caused by the addition of other excipients such as propylene glycol [10] which 
might interfere with the CE or further enhance the API’s solubility. 
IV.1.2. Concluding Remarks about Phase Solubility Measurements 
As PSM results showed, ICF took place in both dem. water and 0.1 N HCl be-
tween βCD and ITR resulting in improved drug solubility. Complex stoichiometry 
of 1:1 could be assumed from the gained PSD. Resulting from this, all future PM 
and formulations were prepared striving this ratio to avoid excess use of CDs and 
evaluate the possibility of 100 % encapsulation. PSM results displayed that the 
determined CE was very low, clearly stating that for spontaneous ICF, the equi-
librium would call for an extreme overabundance of CD. This would subsequently 
result in an intolerable increase in formulation bulk when trying to acquire thera-
peutic ITR doses of 50 - 400 mg. Therefore, it was not possible to solely rely on 
voluntary ICF. PSM outcome also showed higher attraction between βCD and ITR 
compared to HPβCD which further supported βCD being the preferred choice as 
extrudate matrix. An oral liquid formulation containing HPβCD is on the market, 
but high dose therapy causes patients to take about 20 mL of the solution twice 
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daily which results in a HPβCD intake of 16 g. Even though this is considered in-
nocuous, it might be non-ideal for patient adherence due to the large amounts 
that have to be consumed, especially since it should be taken 10 mL at a time 
and swished extensively in the mouth before swallowing. Also, the oral solution 
of Sporanox® is marketed in 150 mL amber glass bottles. With a recommended 
dose, e.g. for oropharyngeal candidiasis, of 20 mL per day for up to two weeks, 
one unit would not be enough, causing higher expenses [10].  
Taking all these results into account, the development of a binary hot-melt pro-
cess for βCD and ITR could be the resolve to overcome the low CE by using the 
mTSE to force the API into the βCD cavity. This could successively lead to an in-
novative solid formulation containing preformulated ICs. The accompanying 
amorphisation of ITR might influence ICF favourably or further improve product 
characteristics such as ITR dissolution. 
IV.2. Development of Binary Hot-Melt Process  
As described in section I.2., the aim of this thesis was to develop a binary melt 
process for PM of βCD and ITR resulting in ICF within the mTSE and showing suf-
ficient product qualities. PSM results (see section IV.1.) showed that βCD indeed 
encapsulated ITR and improved its aqueous solubility which qualified it as matrix 
candidate for the hot-melt process. 
IV.2.1. Binary Hot-Melt Extrusion Process 
The most common application when utilising mTSE is HME (see section II.2.1.). 
The investigation of βCD as sole matrix during a hot-melt process has only been 
carried out marginally before. Subsequently, nearly no literature references were 
available for the planning of the HME process. For that reason, first approaches 
were taken to develop and optimise this procedure. The results are shown in the 
subsequent segments. To generate valuable information about the two compo-
nents of the desired melt-extrudate, they were physico-chemically characterised, 
both individually and as PM which was prepared according to section III.2.1.1.. 
IV.2.1.1. Physico-Chemical Characterisation of Raw Material and Pow-
der Blend  
To develop a hot-melt process, it is necessary to gain an understanding about 
the properties of the involved goods. Even though the absolute thermal stress on 
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the material is sometimes lower than expected due to the short residence time in 
the barrel, it is still important to investigate the degradation behaviour of the ap-
plied substances. Temperatures above the degradation point (Td) are not feasi-
ble. The determination of ITR Tm was also of importance, as, depending on the 
operating temperatures, amorphisation of the API remained a possibility. 
Figure IV.2. shows XRPD diffractograms of βCD, ITR and PM.  
 
Figure IV.2. - XRPD diffractograms of a) βCD, b) ITR and c) PM. 
Both mixture components were fully crystalline as they gave strong defined 
peaks. The PM diffractogram appeared to be the addition of the other two diffrac-
tograms. In some 2θ regions where both pure components presented signals, 
peaks now seemed to overlap, e.g. around 20° 2θ. With ITR being fully crystal-
line in PM, a distinct Tm peak had to be expected in the DSC trace. Results of 
DSC measurements of ITR, βCD and PM are shown in Figure IV.3.. The curve of 
pure ITR exhibited a melting signal at 166.73 °C which was in good agreement 
with the literature reference of 166.2 °C (see section III.1.1.). No sign of degra-
dation was detectable for ITR between Tm and 300 °C. The trace of βCD showed 
a broad peak at 119.09 °C which corresponded to the cavity water loss.  
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Figure IV.3. - DSC curves of a) ITR, b) βCD and c) PM; analysis conducted from 
25 - 300 °C; ITR and βCD heating rate 10 K/min; PM heating rate 20 K/min. 
No further signal could be observed, neither of melting (see section III.1.3., 
255 - 265 °C) nor deterioration. This was in compliance with βCD’s thermo-
analytical behaviour as described by Giordano et al. [149]. DSC results of PM 
seemed to be the sum of the components as seen in XRPD. Both events, βCD 
water loss and Tm of ITR, were observed. Heating up to 300 °C revealed no deg-
radation. Consequently, TGA experiments were carried out to further investigate 
this. In TGA, the maximum temperature can be higher than in DSC and it is 
more sensitive to weight loss corresponding with deterioration. The resulting TGA 
curve of PM is shown in Figure IV.4.. The stretch between 50 °C and 150 °C rep-
resented the water content of the sample. Following the water loss, the sample 
gave a weight plateau during which the temperature rose further until two turn-
ing points became detectable at 320.26 °C and 360.31 °C, serving as the Td of 
the two mixture components. TGA experiments of pure ITR and βCD (data not 
shown) led to the conclusion that the first event at 320.36 °C belonged to βCD 
and 360.31 °C to ITR.  
Taking all data from XRPD, DSC and TGA into account, it could be concluded 
that no degradation seemed to have occurred at the applicable temperatures of 
the mTSE (< 280 °C), at least if no mechanical stress was acting on the materi-
al. ITR Tm was detected around 167 °C. Process temperatures slightly below and 
above this limit may very well lead to amorphisation of the API. As amorphisation 
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can lead to additionally improved aqueous solubility of ITR, the first HME runs 
were carried out around Tm of ITR. 
 
Figure IV.4. - TGA results of PM; analysis conducted from 25 - 850 °C; heating 
rate 20 K/min. 
IV.2.1.2. Preliminary Hot-Melt Extrusion Trials and Optimisations 
Results from section IV.2.1.1. were taken to establish the basic framework of 
the HME process. Screw design was utilised according to section III.2.1.3. with-
out variations, while different die arrangements were investigated. The die is the 
part of the mTSE where most pressure builds up and where product shape is de-
termined. In common polymer HME, this typically results in an infinite homoge-
nous extrudate strand drooling from mTSE that can then be pulled with uniform 
velocity towards further downstream equipment. By doing so, die swelling (swell-
ing of the extrudate strand after exiting the die due to molecular relaxation of 
the polymer matrix) can be avoided and the molecular orientation of the polymer 
can be controlled [115]. Since βCD does not possess these thermoplastic proper-
ties, it was not expected to yield a potentially never-ending fully deformable ex-
trudate strand. Thus, it was important to not only investigate the suitable tem-
perature profile for the HME process combined with monitoring the throughput 
and torque, but also to evaluate the influence of different die structures on the 
product. Principally, due to lowering the mechanical stress on the extrudate as 
well as for safety reasons, the lowest applicable temperature should be chosen 
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for an HME process. Therefore, not only product qualities were taken into ac-
count for the preliminary HME runs but also the lowest feasible temperature for 
the different die arrangements. 
 Different Die Arrangements: 2 mm Standard Die IV.2.1.2.1.
PM was given into the hopper and average throughput of PM was determined as 
presented in section III.2.1.3.. The standard die of the Pharma 11 TSE has a 
2 mm diameter and allows separate heating up to 280 °C which is functionalised 
by a die heater. Due to the space-saving design and since uniform heating is 
crucial, no direct cooling aid is applied. It can only be air-cooled. A frontal image 
of the standard die is presented on the left in Figure IV.5.. In TSEs, the die usu-
ally connects to the barrel with an 8-O transition after which the material is led 
into the flow channel [115]. This can be seen in the cross section view of the 
standard die (see on the right in Figure IV.5.). 
    
Figure IV.5. - Left: frontal view of standard 2 mm die; a) die opening, 2 mm in 
diameter, b) adapter for die heater, c) adapter for temperature control, 
d) adapter for pressure control; Right: Cross section image of standard 2 mm 
die; a) 8-O transition, b) measuring point for pressure control, c) strict 
narrowing inner structure, d) flow channel 2 mm in diameter. 
Two different HME temperature profiles (see Table IV.2.) were investigated, 
both nearly reaching the maximum mTSE temperature of 280 °C. HME Trial 1 
was implemented with a screw speed (ScS) of 100 rpm whereas the higher tem-
perature in HME Trial 2 allowed a faster ScS of 225 rpm. Torque and die pressure 
varied during the HME run and are given as average values during stable sample 
collection. TExtrudate is the temperature that was measured directly at the die and 
was slightly above the set die temperature for both HME runs (+4 °C in Trial 1 
and +6 °C in Trial 2). This is a common phenomenon as the high energy input 
causes the extrudate to heat up. 
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Table IV.2. - mTSE parameters for HME Trials with 2 mm standard die, torque 
and die pressure are given as average values monitored during sampling. 
HME Trial Z1,°C Z2,°C Z3,°C Z4,°C Z5,°C Z6,°C Z7,°C Die,°C ScS, rpm 
1 95 120 160 170 190 210 250 270 100 
2 120 160 200 245 265 270 270 275 225 
HME Trial Throughput, % Torque, % Die Pressure, bar TExtrudate, °C 
1 15 25 9 274 
2 25 21 4 281 
The average pressure at the die when material was flowing out was quite low 
with 9 bar and 4 bar but this parameter strongly varied within both HME runs. In 
some cases, material got stuck in the die, causing the momentary pressure to 
rise above 100 bar which resulted in mTSE emergency shut-down. While apply-
ing the standard die, only very short partial extrudate strands could be acquired 
and most of the extrudate was strongly deteriorated (see Figure IV.6.). Extru-
date pieces exhibited the phenomenon of “shark skin” which is defined as a 
“rough, wavy appearance of the extrudate” [115].  
 
Figure IV.6. - Deteriorated extrudate strand coming out of the 2 mm standard 
die during an HME run. 
The average throughput is given in Table IV.2. as 15 % and 25 % for 
HME Trial 1 and 2, respectively. Even though the throughput capacity was corre-
lated to an amount of PM in g/h, this correlation did not longer hold true during 
the HME runs. This was caused by the instability of the operating pressure, the 
resulting process interruptions and the fact that the extrudate strands were not 
continuously leaving mTSE. Consequently, it was not possible to determine the 
exact material throughput for HME Trial 1 and 2. Nevertheless, it can be noted 
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that the lowest applicable temperature for applying the 2 mm die was around 
270 - 275 °C to acquire any kind of product. This temperature was considerably 
close to the possible maximum of the apparatus. After conducting experiments 
with the 2 mm standard die, a material sample was extracted out of it. The extri-
cated specimen is shown in Figure IV.7. in the position from where it was taken.  
 
Figure IV.7. - Cross section view of standard 2 mm die with extracted extrusion 
sample positioned inside; a) undegraded material right after barrel exit, 
b) origin of deteriorated product at steep narrowing within die. 
The extruded material appeared white-greyish intact after leaving the barrel 
and when entering the 8-O transition zone. At the stricture before penetrating 
the 2 mm flow channel, degradation was visible and seemed to originate from 
there. It appeared that product congestion had occurred before the flow channel. 
High shear and mechanical forces impacted on the partially molten mixture when 
arriving at this narrowing point. The material was rapidly conveyed towards the 
die and due to the missing thermoplastic behaviour of βCD, it could not follow 
the path down towards the flow channel but rather caused a blockage which then 
resulted in product deterioration.  
 Different Die Arrangements: 3 mm and 6 mm Variable Systems IV.2.1.2.2.
To overcome the problem of product congestion at the narrowing within the die, 
a variable die system was tested. Here, the general inner structure was similar to 
the 2 mm standard die but different insets could be used that presented wider flow 
channels. A 3 mm and a 6 mm inset were studied to evaluate differences to the 
standard die. Different temperature profiles with die temperatures between 
200 - 280 °C were examined without reaching a completely stable process for 
both die insets. On the left in Figure IV.8., a typical result if applying the 3 mm in-
set is shown, while on the right, a typical result of the 6 mm inset can be seen.  
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Figure IV.8. - Left: extrudate strand coming out of the variable die with 3 mm die 
inset; Right: extrudate strand coming out of the variable die with 6 mm die inset. 
Even though short extrudate strand-like pieces could leave the die due to the 
larger opening, product degradation still occurred. Again, “shark skin” was ob-
served. Pressure was unstable, causing the mTSE to shut down at some points 
and the lowest applicable die temperature was around 270 °C which was nearly 
as high as for the 2 mm standard die. This might have also been explained by 
the similar inner structure of the die. As the variable nozzle head is not severable 
in two parts as the standard die, it was not possible to retrieve a sample from 
within. To examine an even wider flow channel and subsequently, a less steep 
narrowing inside the die, a 6 mm inset was built and attached to the die head as 
can be seen on the right in Figure IV.8.. Short extrudate strands could leave 
mTSE in partially undegraded shape. Comparing the product to the extrudate 
from the variable 3 mm inset, it appeared distinguishably lighter in colour, espe-
cially in the extrudate core. The degraded surface of these strands might have 
been the cause of product deterioration or product residue that became previ-
ously stuck on the die caused by material from mTSE filling phase. The first 
specimen to enter always exhibits a longer residence time within the barrel. The 
extrudate surface occurred smoother than before. Upon using the 6 mm inset, 
the die pressure was considerably lower but yet unstable as material flow was 
not continuous. However, the mTSE did not shut down. The lowest applicable 
temperature was 200 °C which was a considerate decrease compared to the oth-
er investigated die arrangements. Nevertheless, degradation due to product con-
gestion could not be completely excluded and the extrudate strand was not 
drooling from the die without interruptions.  
To conclude, experiments with the described die arrangements showed that 
βCD as an oligosaccharide and lacking thermoplastic properties was only partially 
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susceptible to the appropriate deformation at the die, even when mixed with fully 
molten ITR. Even though partial extrudate strands could be obtained, this was 
not of importance as the instability of the process necessitated the need for a dif-
ferent die system without steep narrow inner structures. The development of this 
original die is presented subsequently. 
 Development of 6 mm Conical Die and Utilisation IV.2.1.2.3.
Because the 6 mm inset had yielded the only HME product that appeared rather 
intact than deteriorated, this diameter was also chosen for the new die arrange-
ment. Figure IV.9. presents a frontal image of the self-developed die. As the var-
iable 6 mm die had demonstrated irregular extrudate exit, the opening of the 
flow channel was slightly widened. Die heater and temperature control were in-
corporated in the die head. In regard to product congestion caused by the steep 
angle in the standard die head (see Figure IV.7.) the new die should not present 
any harsh stricture. Hence, a conical structure was selected.  
 
Figure IV.9. - Frontal view of self-built 6 mm conical die; a) die orifice with 
6 mm diameter and widened opening for easier extrudate exit, b) adapter for 
die heater, c) adapter for temperature control. 
Figure IV.10. displays the rear view of the built 6 mm die. Due to the large 
opening at the die entry, it was not possible to apply the usual 8-O transition. 
The opening was tapering concentrically towards the 6 mm orifice and the die 
head did not harbour a flow channel of measurable length as visible in 
Figure IV.5. (right). Since the inner cone took up most of the inner die space and 
due to enabling sufficient heating properties, it was not possible to enlarge the 
die in a way that the pressure control was applicable. Thus, no die pressure was 
measurable when applying this die arrangement. 
Results and Discussion 
 
 
70 
 
Figure IV.10. - Rear view image of 6 mm conical die; a) conical inner ring-
structure, b) attached die heater, c) adapter for temperature control. 
The first HME experiments utilising the 6 mm conical die showed the necessity 
to install the ventilation port into the system directly after the powder feed (see 
section III.2.1.3) because water evaporated continuously in the barrel, causing 
material to get stuck in the powder entry. This caused the torque to vary and the 
temperature in Zone 1 to destabilise as it became higher due to the water va-
pour. Upon attaching the die to mTSE and starting the HME process, the first 
material exiting during the filling phase came out degraded, but after the process 
was stabilised, longer white-greyish extrudate strands could be obtained than 
before. Table IV.3. exhibits the parameters chosen for Trial 3 and 4. The 
throughput of 40 % was correlated to 200.6 g/h and could not be increased fur-
ther because the ventilation port became blocked. Torques between 35 and 39 % 
were considerably higher than for the 2 mm standard die but not distressing for 
a stable HME process where 60 - 80 % is often common. A ScS of 250 rpm was 
examined but the screws started screeching. This is a sign for lack of lubrication 
within the barrel. Thus, 225 rpm was chosen as maximum ScS. 
Table IV.3. - Parameters of HME runs with 6 mm conical die attached to mTSE. 
HME Trial Z1,°C Z2,°C Z3,°C Z4,°C Z5,°C Z6,°C Z7,°C Die,°C ScS, rpm 
3 75 130 170 200 240 260 260 260 225 
4 98 130 170 200 200 220 220 225 225 
HME Trial Throughput, % Torque, % Die Pressure, bar TExtrudate, °C 
3 40 35 X X 
4 40 39 X X 
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The die pressure and TExtrudate which are monitored by the pressure sensor could 
not be measured with the conical 6 mm die. Because mostly black degraded 
product was acquired from Trial 3, operating temperatures were lowered. Even 
though it was possible to gain extrudate strands with die temperatures as low as 
200 °C, the parameters presented for Trial 4 yielded a more continuous process, 
probably due to a lower melt viscosity at the die temperature of 225 °C. As 
shown in Figure IV.11., the extrudate surface appeared smoother than for the 
6 mm variable inset though there was still minor roughness observable. The ex-
trudate strand could leave mTSE continuously but no infinite strand was created. 
This caused irregular fragments of the strand to break off due to the brittle un-
thermoplastic behaviour of βCD.  
 
Figure IV.11. - Intact extrudate strand coming out of the 6 mm conical die dur-
ing HME Trial 4. 
Through applying the self-developed 6 mm conical die, it was possible to 
achieve an applicable operating temperature as low as for the 6 mm variable in-
set, of about 200 °C. The procedure appeared to be stable at 225 °C die temper-
ature judging from torque monitoring, though this could not be fully confirmed 
due to the missing pressure data. Nevertheless, the conical die was the only die 
arrangement feasible for constant visually completely undegraded extrudate 
strand production and was therefore utilised for all following HME experiments.  
IV.2.1.3. Characterisation of Extrudates for Content Evaluation and 
Amorphousness  
Of all presented HME runs, Trial 4 was regarded as the most promising HME 
profile as it was the only one yielding fully white-greyish extrudates. It was not 
considered necessary to investigate degraded samples. Therefore, only samples 
Results and Discussion 
 
 
72 
from Trial 4 were examined for ITR and βCD content, as well as for ITR amor-
phisation by DSC analysis. Determined contents were 98.04 ± 0.10 % and 
102.85 ± 2.22 % for βCD and ITR, respectively. The analysis was carried out in 
triplicate. This supported the hypothesis after visual inspection of the extrudate 
strands that no product degradation had occurred.  
DSC results of HME Trial 4 are shown in Figure IV.12.. When evaluating the DSC 
trace as presented by the software (large DSC curve in Figure IV.12.), the sam-
ple appeared fully amorphous as no distinct Tm of ITR could be detected. Only 
upon further magnification of the DSC curve (see a and b in Figure IV.12.) small 
signals at 163.57 °C (0.1530 J/g) corresponding to the melting of crystalline ITR 
and Tg of aITR at approximately 60 °C were identified. Additionally, a very small 
broad exothermic signal slightly above 110 °C became visible in this magnifica-
tion. This exothermic broad peak had previously been reported in the literature as 
so-called “cold crystallisation” of ITR during DSC analysis [150]. This phenomenon 
describes the recrystallisation of ITR while being heated during the experiment.  
 
Figure IV.12. - Excerpt from DSC trace of HME Trial 4 sample; analysis conduct-
ed from 30 - 300 °C; heating rate 20 K/min, Δ Y: 50 mW; a) excerpt from 
50 - 120 °C , Δ Y = 1 mW, b) excerpt from 150 - 180 °C, Δ Y = 1 mW. 
For technical reasons, XRPD analysis of this sample was not possible. Thus, af-
ter the examination of DSC results, two possible hypotheses were set. Firstly, not 
all ITR was either amorphous after HME or recrystallised between manufacture 
and DSC measurement (approximately one day at ambient storage conditions), 
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resulting in the very small Tm signal of ITR. Secondly, ITR was fully amorphous in 
the sample but recrystallised upon heating during the DSC analysis. 
IV.2.1.4. Concluding Remarks about the Hot-Melt Extrusion Process 
Considering the results presented in the previous section, it can be concluded 
that it was possible to develop a stable HME procedure resulting in undegraded 
product that appeared at least partially amorphous. However, the production of 
extrudate strands was not continuous as for a typical HME process. During mTSE 
operating, no die pressure could be monitored with the self-developed conical 
6 mm die system. This aggravated the feasibility of the process. An alternative to 
the more common HME practice is the HMG procedure, where the mTSE is oper-
ated without a die. As particularly the die arrangement was identified as the cru-
cial parameter responsible for product deterioration, this was a promising ap-
proach for an alternative hot-melt procedure.  
Consequently, a binary HMG process was developed and results are given in 
the following section. Moreover, HME Trial 4 was further characterised regarding 
ITR solubility and dissolution as well as compared to the novel HMG operation. 
IV.2.2. Binary Hot-Melt-Granulation Process 
Deviating from HME where the material left mTSE through the die, in HMG pro-
cesses, the die was switched to the granulation heel slide, allowing the melt-
granulated material to gently slide out of the mTSE. HME Trial 4 was previously 
identified as the most stable HME procedure, yielding undegraded extrudate 
strands. Thus, parameters used for Trial 4 served as foundation for the develop-
ment of the HMG process as this would allow substantial statements regarding 
the comparison of the two hot-melt operations.  
IV.2.2.1. Hot-Melt Granulation Parameters 
The chosen parameters for the HMG process are presented in Table IV.4.. The 
throughput of 40 % correlated to 200.6 g/h as it was the case for HME Trial 4. 
The only difference apart from the removal of the die was the ScS of 150 rpm 
which could not be further enhanced as the screws started shrieking und the risk 
of barrel scratch marks became too high. Consequently, the presented parame-
ters are the closest possible towards HME Trial 4.  
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Table IV.4. - Parameters for the chosen HMG procedure. 
HMG Trial Z1,°C Z2,°C Z3,°C Z4,°C Z5,°C Z6,°C Z7,°C Die,°C ScS, rpm 
1 100 130 170 200 200 220 220 X 150 
HMG Trial Throughput, % Torque, % Die Pressure, bar TExtrudate, °C 
1 40 20 X X 
The average torque of 20 % was considerably lower than for HME Tri-
al 4 (39 %). The torque was more stable during HMG Trial 1. This was most likely 
attributed to the missing die as material could leave mTSE without hindrance and 
without any component causing constrictions. The final product appeared as white-
greyish pasty granules that seemed partially molten as is shown in Figure IV.13.. 
 
Figure IV.13. - Collection of HMG sample with the granulation heel slide. 
Since βCD does not melt at the applied temperatures but ITR does, it is most 
likely that the molten ITR caused the pasty appearance and granulation-like pro-
cedure within mTSE. Thus, the agglomerated granules appeared larger in size. 
However, the granules were not evenly distributed regarding their particle size, 
as this varied strongly during product collection which is why it was so important 
to crush and sieve all samples prior to further testing (see section III.2.1.3.). 
IV.2.2.2. Characterisation of Hot-Melt-Granules 
HMG Trial 1 was investigated for ITR and βCD content in triplicate. The deter-
mined amounts of 97.83 ± 0.31 % and 102.34 ± 3.51 % for βCD and ITR re-
spectively agreed well and showed that no product degradation had occurred as 
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the intact white-greyish appearance of the granules had suggested. DSC meas-
urements were also performed and results are shown in Figure IV.14.. 
 
Figure IV.14. - Excerpt of DSC trace of HMG Trial 1; analysis conducted from 
30 - 300 °C; heating rate 20 K/min, Δ Y: 50 mW; a) excerpt from 50 – 120 °C, 
Δ Y = 1 mW, b) excerpt from 150 - 180 °C, Δ Y = 1 mW. 
Upon first inspection of the DSC trace no melting peak of ITR was detectable 
and amorphousness of sample seemed likely but by magnifying the DSC 
curve (b in Figure IV.14.) a small endothermic signal correlatable to ITR melting 
became observable at 164.94 °C (0.1375 J/g). Moreover, Tg of ITR slightly above 
60 °C was observed, as well as the very small signal ascribed to “cold crystallisa-
tion” of ITR (a in Figure IV.14.). Accordingly, either ITR only partially melted dur-
ing HMG process, it recrystallised between manufacturing and DSC analysis (ap-
proximately one day at ambient conditions) or ITR was fully amorphous after HMG 
and recrystallised during DSC analysis. XRPD measurements of this sample could 
not be conducted due to technical reasons. 
IV.2.3. Closing Remarks about the Hot-Melt-Granulation Procedure 
Summarising the results presented in the previous section it can be stated that 
it was possible to create a stable HMG process by switching the die to the granu-
lation heel slide and maintaining the same temperature profile which was pre-
sented for the most successful HME run (HME Trial 4, see section IV.2.). Merely 
ScS had to be reduced from 225 rpm to 150 rpm to avoid damaging mTSE. 
Samples collected showed no product degradation whereas ITR appeared to be 
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at least partially amorphous in the DSC measurements. At this point, two differ-
ent hot-melt procedures were available for the processing of PM of βCD and ITR. 
Comparative approaches were necessary to choose the most sufficient operation 
for achieving improved ITR dissolution and possibly ICF. 
IV.3. Comparative Evaluation of Hot-Melt Extrusion and 
Hot-Melt Granulation Procedures  
A more detailed comparison between HME and HMG was carried out that uti-
lised further analysis tools and investigated the possibility of ICF within mTSE as 
this was defined as an important quality parameter. By this, it was attempted to 
examine the possible superiority of one process over the other. 
IV.3.1. Physico-Chemical Comparison of Melt Extrudate and Granules 
Comparing the physico-chemical results of HMG Trial 1 and HME Trial 4, no dif-
ferences stood out. Content evaluation studies disclosed no ITR degrada-
tion (102.85 ± 2.22 % for HME Trial 4, 102.34 ± 3.51 % for HMG Trial 1) and 
βCD (98.04 ± 0.10 % for HME Trial 4, 97.83 ± 0.31 % for HMG Trial 1). Both 
DSC traces gave small endothermic peaks at 163.57 °C and 164.94 °C for 
HME Trial 4 and HMG Trial 1, respectively, after magnification. By that, a broad 
signal ascribed to “cold crystallisation” of ITR was also observed. Generally, the 
Tm of ITR in PM occurred at approximately 166 - 167 °C which was higher than 
Tms presented for HME and HMG samples. It had yet to be determined whether 
the detected Tm was corresponding to partial crystallinity of the product or caused 
by recrystallisation during DSC analysis. Figure IV.15. shows SEM images of both 
HMG and HME surfaces prior to crushing. No visual differences were observed.  
 
Figure IV.15. - SEM visualisation of HMG (left side) and HME extrudate strand in 
cross section (right side); bar = 2 µm. 
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IV.3.2. Solubility Measurements and Itraconazole Dissolution  
Of utmost importance for the finished hot-melt product was the solubility or 
dissolution rate enhancement of ITR. For a first impression, an excess amount of 
HME Trial 4 and HMG Trial 1 was each weighed in brown glasses and 50 mL of 
dem. water was added. Samples were stirred at room temperature for 24 h be-
fore ITR and βCD contents were evaluated. These measurements were conducted 
in duplicate and results are shown in Figure IV.16.. PM served as control and was 
treated the same way. No enhancement of aqueous solubility of βCD was detect-
ed for any hot-melt treatment. Whereas PM reached βCD solution of 
6.80 ± 0.01 mg/mL, HMG Trial 1 and HME Trial 4 presented dissolved βCD in the 
amounts of 6.72 ± 0.08 mg/mL and 6.75 ± 0.02 mg/mL, respectively. One the 
one hand, this was expected as both hot-melt procedures were carried out below 
the reported melting range of βCD, so no amorphisation of the oligosaccharide 
should have taken place [80]. Additionally, as described in section III.1.3., the 
limited aqueous solubility of βCD is hypothesised to be caused by intramolecular 
hydrogen bonds due to the ring-structure. As no degradation was detected for 
the samples, the same solubility-limiting structural qualities should have been 
intact as reflected by similar solubility.  
 
Figure IV.16. - Results of solubility analysis of PM, HMG and HME after 24 h, 
n = 2, error bars = min/max. 
Substantial differences became observable in the amount of dissolved ITR. PM 
reached ITR solubility of 2.21 ± 0.05 µg/mL while HMG Trial 1 and HME Trial 4 
showed extended amounts of dissolved ITR of 7.83 ± 0.67 µg/mL and 
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7.73 ± 0.60 µg/mL. This constituted an increase of approximately 250 % for 
both hot-melt procedures. This solubility enhancement might have been attribut-
ed to ITR amorphousness or ICF during HME/HMG. Here, no substantial differ-
ence was found between HMG Trial 1 and HME Trial 4. 
ITR dissolution was also investigated. The same amount of dissolved ITR after 
24 h might have hinted at identical improvement in absolute solubility but it did 
not indicate which of the two hot-melt procedures gave the faster ITR dissolution 
rate. This is of importance for a novel formulation. The medium had to be 
switched to 0.1 N HCl as preliminary experiments failed to deliver quantifiable 
amounts in the beginning of the analysis, especially for PM. Thus, results were 
not comparable to the absolute amounts of dissolved ITR acquired by the solubil-
ity testing shown in Figure IV.16.. PM was chosen as negative control. Further-
more, aITR was investigated as well as PMaITR to evaluate the possibility of dis-
solution rate enhancement caused solely by ITR amorphisation. Dissolution test-
ing with pure crystalline ITR was carried out but yielded un-evaluable results 
possibly due to ITR particles passing the installed filter system and distorting 
content evaluation. Sample amount was the equivalent to 100 mg of ITR. Results 
of dissolution testing are given in Figure IV.17..  
 
Figure IV.17. - Dissolution results of PM*, PMaITR, aITR, HMG* and HME* in 
0.1 N HCl over 4 h; n = 3; error bars = sd; *)dissolution medium replaced. 
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PM reached ITR dissolution of 10.32 ± 0.76 % after 4 h. Upon inspecting the dis-
solution curve, a slight increase starting approximately at 30 min became appar-
ent. This rise could be attributed to ICF in aqueous medium. As results of PSM had 
shown (see section IV.1.), the presence of βCD increased ITR solubility in 
0.1 N HCl. This definitely occurred within the dissolution vessel as well. As longer 
experiment times were not evaluated, it remained a possibility that PM could have 
reached higher absolute ITR dissolution levels then. However, in regard to a later 
immediate release formulation, longer experimental times would not hold that 
much realistic value. Even though it was not possible to investigate pure crystalline 
ITR, it could be assumed that its dissolution profile would not have exceeded that 
of PM. Pure aITR showed an almost zero-order-like dissolution profile with a con-
stantly rising amount of dissolved API and reached dissolution of 61.71 ± 0.67 % 
after 4 h. This strongly underlined the effect of API amorphisation and proved to be 
a dissolution enhancement of 576.80 % compared to PM. This phenomenon was in 
general agreement with the literature [151]. Kumar et al. stated that dissolution of 
aITR prepared by melt quenching reached comparable results in 0.1 N HCl. After 
2 h, approximately 30 µg/mL were dissolved at only 50 rpm paddle rotation speed 
versus approximately 45 µg/mL with the faster 100 rpm rotating set-up used in 
this project. They also observed a similar zero-order-type curve [151]. 
Comparing PMaITR to PM, the ICF period between 30 - 120 min was observed as 
well. PMaITR reached dissolution of 63.76 ± 1.65 % after 4 h which was very simi-
lar to pure aITR. Although PMaITR and aITR reached nearly the same dissolution 
after 4 h, PMaITR clearly showed a faster dissolution rate which might have hinted 
at the fact that either small amounts of ICs were present in the mixture or that 
due to the generally better dissolving properties of aITR, it had experienced faster 
ICF in the dissolution medium. The dissolution curve of PMaITR was always above 
aITR. Both HME and HMG samples reached nearly complete dissolu-
tion (91.48 ± 2.16 % and 92.75 ± 7.15 %). Both dissolution curves were not sub-
stantially different, especially since the error bars overlapped for most of the sam-
pling time points. Nevertheless, upon inspecting the first 30 min, HMG seemed to 
have achieved faster dissolution. At 15 min of investigation, HMG and HME gave 
ITR dissolution levels of 40.68 ± 0.73 % and 30.26 ± 5.27 % respectively. After 
60 min, though, ITR dissolution of HME slightly outperformed HMG until both near-
ly delivered the same dissolution levels from 2 h on. Generally, variations were 
much higher for HME than HMG as sd for nine out of thirteen sampling points was 
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above 5 %, whereas this was only the case for three sampling points of HMG. This 
might have indicated less ICF during HME procedure or inhomogeneous dispersion 
thereof within the sample. Apart from this high variance, both hot-melt procedures 
had resulted in products that showed strongly improved ITR dissolution compared 
to PM (898.74 % increase for HMG after 4 h and 786.43 % increase for HME) and 
to PMaITR (45.46 % increase for HMG and 43.48 % for HME). Although dissolution 
medium was replaced for HMG and HME, results were still comparable as later dis-
solution analyses of hot-melt processed samples did not show tremendous chang-
es upon not replacing the dissolution medium. In regard to PM, dissolution was 
lower without replacing dissolution medium (see section IV.4.2.). As all later disso-
lution studies were carried out without media replacement, PM results obtained in 
section IV.4.2. were used as appropriate reference values. 
IV.3.3. Inclusion Complex Detection in Melt Extrudates and Granules 
As shown in previous sections, both HMG and HME were manageable processes 
that yielded products with similar physico-chemical properties and dissolution 
over 4 h. However, they additionally had to be evaluated for possible ICF. The 
subsequent section gives insights into the analysis thereof by ATR-FT-IR. By eval-
uating these results together with the dissolution results, it could be attempted to 
choose the optimal processing strategy between HME Trial 4 and HMG Trial 1. 
IV.3.3.1. ATR-FT-IR Results and Discussion  
In section III.2.2.6. it was explained that ATR-FT-IR measurements are an easy 
opportunity for evaluating ICF in solid samples. In Figure IV.18., exemplary 
ATR FT-IR spectra of aITR, crystalline ITR, PMaITR as well as HMG Trial 1 (HMG) 
and HME Trial 4 (HME) are presented. These samples were evaluated according 
to the identified marker wave numbers as given in section III.2.2.6.. During 
these first experiments, ITR, aITR, PM and PMaITR were investigated separately 
to determine the suitable negative control for the melt processed samples. Al-
ready by visual inspection it was obvious that aITR and ITR generated different 
spectra, as did their corresponding PMs. Accordingly, PMaITR was used as refer-
ence for HMG and HME samples and PM for crystalline material. On first macro-
scopic review of the ATR-FT-IR spectra, HME and HMG appeared almost the 
same. Detailed results of the detected peaks are given in Table IV.5.. After eval-
uating HMG and HME wave bands it could be concluded that they were nearly 
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identical. Of special importance was the comparison between PM and PMaITR as 
it became apparent that aITR interacted stronger with βCD after mere blending 
compared to the crystalline blend. 
 
Figure IV.18. - Archetypal ATR-FT-IR spectra of a) ITR, b) PM, c) aITR, 
d) PMaITR, e) HME and f) HMG. 
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Table IV.5. - ATR-FT-IR results of HME and HMG evaluated by comparison with 
reference wave numbers; sd = ±; n = 3;*n = 5; if wave number markers were 
not detected in every single analysis, the percentage of their occurrence is giv-
en in brackets below. 
 
ITR* 
aITR* 
PM* 
PMaITR* 
HME HMG 
W
a
v
e
 N
u
m
b
e
r
s
, 
c
m
-
1
  
1697.80 ± 0.23 
1698.87 ± 0.43 
1697.60 ± 0.15 
1698.89 ± 0.33 
1699.63 ± 0.95 1699.59 ± 0.27 
1584.34 ± 0.17 
1585.57 ± 0.07 
1584.60 ± 0.25 
(80 %) 
1585.76 ± 0 
(20 %) 
1585.94 ± 0.09 
1585.90 ± 0 
(33.33 %) 
1551.43 ± 0.15 
1552.49 ± 0.01 
1551.18 ± 0.13 
1552.74 ± 0.27 
1552.96 ± 0.25 1552.75 ± 0.30 
1509.64 ± 0.29 
1510.59 ± 0.10 
1509.80 ± 0.23 
1511.07 ± 0.34 
1511.28 ± 0.22 1511.11 ± 0.05 
1451.26 ± 0.12 
1450.87 ± 0.06 
1451.20 ± 0.16 
(80 %) 
1451.08 ± 0.21 
1451.89 ± 0.27 1451.72 ± 0.07 
1272.85 ± 0.45 
1271.56 ± 0.04 
1270.96 ± 0.98 
(80 %) 
X 
X X 
1227.32 ± 0.28 
1227.50 ± 0.14 
1227.41 ± 0.59 
1228.55 ± 0.62 
1228.76 ± 0.28 1228.52 ± 0.13 
1185.03 ± 0.13 
1182.59 ± 0.18 
1184.44 ± 0.52 
X 
X X 
1140.53 ± 0.11 
1137.71 ± 0.28 
1140.58 ± 0 
(20 %) 
X 
X X 
X 
1072.64 ± 0.06 
(40 %) 
1077.55 ± 0.36 
(40 %) 
1078.32 ± 0.11 1078.35 ± 0.03 
1043.88 ± 0.50 
1040.81 ± 0.66 
1043.15 ± 0.11 
1042.58 ± 0.95 
(40 %) 
X X 
X 
X 
1028.45 ± 1.81 
(60 %) 
1026.80 ± 0.09 1026.41 ± 0.24 
824.10 ± 0.15 
823.81 ± 0.49 
823.82 ± 0.09 
824.74 ± 0.72 
826.14 ± 0.26 826.68 ± 0.29 
Some spectral bands altogether disappeared for PMaITR (e.g. around 
1270 cm-1 and 1185 cm-1) whereas others were not detected in all measure-
ments (e.g. around 1042 cm-1). This suggested interactions between the two 
substances and was more pronounced than for PM where only occasional missing 
events (e.g. around 1270 cm-1 and 1140 cm-1) were observed. This made the 
analysis of HME and HMG samples more challenging as the disappearance of 
spectral bands around 1270 cm-1, 1185 cm-1 and 1140 cm-1 could not be ascribed 
to ICF completely. Only the peak around 1040 cm-1 was never detected for the 
melt processed samples whereas partially observed for PMaITR which indicated 
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further interactions. This was backed up by the event around 1078 cm-1. As this 
signal was attributed to βCD and had only been partially detected for PM and 
PMaITR, it suggested enhanced interactions, such as hydrogen bonds possibly 
caused by ICF. The same was hypothesised for the wave band around 1026 cm-1 
which also originated from βCD. It appeared sheltered from the laser beam in PM 
and only partially detectable for PMaITR. The peak around 824 cm-1 had shifted 
to slightly higher wave numbers (around 826 cm-1) for HME and HMG which pro-
posed interactions between the two substances in the formulations. This shift 
was less pronounced for PMaITR. Concerning the vanished wave bands, it ap-
peared likely that parts of ITR became sheltered from the laser beam. Many 
wave numbers had not changed substantially, especially above 1300 cm-1 which 
indicated not too many interactions in that spectral region.  
When correlating the detected events with the functional molecular groups as 
presented in Figure III.15., results suggested that most changes occurred in the 
region of the tri-1,2,4-benzene ring system with the two aryl-Cl groups, as the 
Cl peak at 1043 cm-1 had disappeared completely for HME and HMG. The slight-
est shifts were seen for the corresponding aromatic C=C bonding wave numbers 
around 1451 cm-1 and 1509 cm-1 but this might have been caused by overlapping 
results from the two di-para benzene rings or partial ICF in the samples. The two 
piperazine markers around 1273 cm-1 and 1185 cm-1 disappeared as well which 
advocated inclusion of that molecular part. No changes were detectable for 
1584 cm-1 and 1551 cm-1, wave bands correlated to C=N bonding. As these 
bonds exist multiple times in the ITR molecule, this could have also been caused 
by partial ICF and overlapping of both the triazole and the triazolone rings. As no 
considerable change was seen for the wave band around 1699 cm-1 for any sam-
ple, it was concluded that the ring system hosting the ketone group was not in-
volved in ICF. This backed up the suggestion of overlapping results for the C=N 
bonds. The wave bands associated with ether groups around 1140 cm-1 and 
1227 cm-1 also disappeared and slightly increased, respectively, for each HME, 
HMG and PMaITR. This underlined the theory that at least the right “tail part” of 
ITR (as shown in Figure III.15.) took part in ICF, most probably up to the pipera-
zine system. Concerning the di-para benzene rings, it was not possible to establish 
if both of them became included due to overlapping peaks. The inclusion of the tri-
azole function was in agreement with the literature as Peeters et al. reported. 
They investigated a theoretical molecular mechanics framework of the βCD/ITR IC 
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which showed that in a 1:1 stoichiometric ratio, an interaction with this functional 
group was energetically favourable and the most stable possibility. Only for higher 
order ICs, the other part of ITR, namely the 2-butyl group, the piperazine and the 
1,4-diaminophenyl ring next to the triazolone interacted as well in the IC [146]. 
Recapping these outcomes, ATR-FT-IR appeared suitable to give results about 
interactions and even ICF between ITR and βCD. This technique further allowed 
suggestions regarding the functional groups involved. However, some signals 
were not detected in every conducted measurement. As each sample analysed 
by ATR-FT-IR was newly prepared, it was possible that the amount of IC posi-
tioned on the measuring crystal had varied. Also, interactions were already seen 
for PMs, especially with aITR. That raised the question if mere blending would 
yield the same amount of IC as processing PM in the mTSE. Secondly, as intensi-
ty of ATR-FT-IR spectra varied and the limit of peak detection was set to 0.5 % 
transmission in the current experimental setup, the results had to be interpreted 
mostly in a relative manner. Consequently, it became apparent that solely trust-
ing ATR-FT-IR determinations might not always capture the whole picture of pos-
sible ICF. Therefore, for the final detection of ICs, the dissolution results were 
also taken into account. Only the connection between changes in the ATR-FT-IR 
spectrum together with enhanced dissolution compared to the respective refer-
ence (PM or PMaITR) could enable the assured conclusion of ICF. The improved 
ITR dissolution after 4 h of HMG and HME compared to PMaITR (increase of 
45.46 % and 43.48 %, respectively) clearly supported the theory that although 
interactions were observed in ATR-FT-IR spectra of the PMs, sufficient ICF need-
ed a manufacturing procedure that further forced the API into the CD cavity.  
IV.3.4. Concluding Remarks and Decision for Hot-Melt Procedure 
Gold Standard  
Both hot-melt processes were feasible and operateable. However, some differ-
ences were found regarding the simplicity of the process and the resulting prod-
uct. As presented in section IV.2.1., particularly the die utilisation proved to be 
the biggest challenge during process development. The 6 mm conical die did not 
allow pressure monitoring which could be a safety risk even during a stable pro-
cess. Figure IV.19. shows the photography of an extrudate strand from 
HME Trial 4. Although results of content evaluation proved that no deterioration 
had taken place, the surface of the extrudate strand exhibited darker, brown-ish 
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areas. During HME procedure, it was visible that this was caused by product resi-
due at the die from hot-melt extruded material of the filling phase of the mTSE. 
Nonetheless, this contamination would not be acceptable when thinking about a 
later formulation. 
 
Figure IV.19. - Image of extrudate strand acquired with 6 mm conical die. 
Keeping in mind the results presented from physico-chemical analysis as well 
as from dissolution and solubility testing, no difference was found that suggested 
superiority of the HME sample over the HMG sample. The maximum dissolved 
amount of ITR (see Figure IV.16.) was higher for HMG Trial 1, albeit only to a 
very low extent of 0.10 µg/mL. Additionally, ITR dissolution appeared generally 
more stable with smaller variations compared to HME Trial 4. These results after 
4 h did not propose dominance of one sample over the other. Moreover, the pre-
sented results for IC detection by ATR-FT-IR did not reveal representative differ-
ences between the samples. By evaluating ATR-FT-IR spectra in correspondence 
with the dissolution profiles against PMaITR, nearly the same increase in ITR dis-
solution was seen as well as nearly identical peak patterns at the same wave 
number markers. Lastly, taking into account that the mTSE process for HMG was 
easier stabilised and simpler to control due to the missing die, it had to be con-
cluded that the gold standard to be further used in this study was the HMG pro-
cedure. Thus, all following results of hot-melt processes were prepared by HMG.  
IV.4. Hot-Melt Granulation Process Optimisation 
HMG was chosen as the most suitable hot-melt process while simultaneously 
delivering ICF and sufficient product properties. However, the developed HMG 
procedure was chosen in regard to HME Trial 4. The optimal hot-melt process 
Results and Discussion 
 
 
86 
presents a compromise between the lowest applicable temperature while main-
taining desired product qualities. For this reason, a granulation concept was in-
vestigated wherein different temperature profiles were analysed for their pro-
cessability as well as product characteristics. 
IV.4.1. Experimental Set-Up and Processability  
Five different temperature profiles were tested. Parameters are shown in 
Table IV.6.. HMG Trial A corresponded with HMG Trial 1 described in previous 
sections and was processed at the highest temperatures with a maximum of 
220 °C. From HMG Trial B to D, temperatures were further lowered. HMG Trial B 
was melt-granulated slightly above Tm of ITR, HMG Trial C slightly below and 
HMG Trial D at a maximum of only 100 °C. Another temperature profile, 
HMG Trial E, was investigated at a temperature of 50 °C throughout the whole 
barrel but no sample could be drawn. The screws started screeching and damage 
to the barrel became likely which necessitated stopping the procedure. 
Table IV.6. - Different HMG temperature profiles and processing parameters. 
HMG 
Trial 
Z1,°C Z2,°C Z3,°C Z4,°C Z5,°C Z6,°C Z7,°C 
ScS, 
rpm 
Throughput, 
g/h 
Torque, 
% 
A 100 130 170 200 200 220 220 150 200.6 10 
B 100 130 170 180 180 180 180 150 184.6 14 
C 100 130 150 150 150 150 150 150 207.2 6 
D 50 80 100 100 100 100 100 150 200.0 16 
  E* 50 50 50 50 50 50 50 150 X X 
*process not feasible due to screeching of mTSE screws 
An average throughput of 200.6 g/h was aimed at, as this had been chosen 
during the development of the HMG procedure, but, due to the volumetric feed-
ing system (see section III.2.1.3.), this was not always possible. During product 
collection, the actual throughput was calculated every few minutes and the feed-
er adjusted accordingly. The throughput presented in Table IV.6. constitutes the 
average derived from these calculations. While HMG Trials A and B resulted in 
melt-granules of equal appearance, HMG Trials C and D yielded more powder-like 
products. These HMG runs were carried out below ITR Tm. Therefore no molten 
material was present in the barrel which induced pasty properties of the finished 
product. Nevertheless, both processes were stable during mTSE operating, only 
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nearing the end of sample collection for HMG Trial D, the screws began to 
screech.  
IV.4.2. Physico-Chemical Characterisation of HMG Trial A - D 
All samples derived from the different HMG temperature profiles and PM were 
analysed for their physico-chemical properties. Figure IV.20. shows SEM images 
of PM and the four HMG Trial runs. The granulated specimen were manually 
crushed and sieved through 425 µm prior to this visualisation.  
 
Figure IV.20. - SEM images of a) PM, b) HMG Trial A, c) HMG Trial B, 
d) HMG Trial C, e) HMG Trial D; bar = 100 µm. 
Observing PM (a in Figure IV.20.), smaller needle-like particles were visible as 
well as larger particles. Concluding from the particle size measurements reported 
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in the corresponding material sections, the smaller particles could be ascribed to 
ITR and the larger particles to βCD. Comparing HMG Trial A and B (b and c in 
Figure IV.20.), particles appeared almost identical. Although in the chosen im-
age, HMG Trial A seemed to show larger particle sizes, this did not hold true 
when examining the results of laser diffraction measurements as presented in 
Table IV.7..  
Table IV.7. - Results of particle size measurements for PM, HMG Trial A, B, C 
and D conducted directly after manufacturing; n = 3; ± = sd. 
 
PM HMG Trial A HMG Trial B HMG Trial C HMG Trial D 
x50, µm 15.1 ± 0.2 96.4 ± 10.7 116.3 ± 24.4 16.6 ± 0.4 41.9 ± 0.8 
HMG Trial B exhibited slightly larger particles with a x50 of 116.3 ± 24.4 µm as 
opposed to 96.4 ± 10.7 µm for HMG Trial A. Investigating the HMG runs below 
ITR Tm (d and e in Figure IV.20. for HMG Trial C and D) the particle surfaces ap-
peared somewhat rougher than for HMG Trial A and B. This might have been due 
to no melted component having been present during processing. For HMG Trial A 
and B, liquefied, molten ITR served as a kind of "binder" in the granulation pro-
cess and was kneaded into the βCD matrix. This could have caused the particle 
surfaces to appear slightly smoother. In the SEM image, HMG Trial D seemed to 
consist of larger particles than HMG Trial C. This held true when examining the 
laser diffraction results as x50 of 41.9 ± 0.8 µm was more than twice the size of 
16.6 ± 0.4 µm for HMG Trial C. Particles of HMG Trial D appeared similar to the 
particles of HMG Trial A and B. On first inspection, it seemed as if ITR was forced 
into the βCD cavity with less single ITR particles present. In contrast, HMG Tri-
al C looked more like PM (x50 of 15.1 ± 0.2 µm). Nevertheless, it has to be stated 
that HMG Trial C and D were more powder-like and although they were sieved 
through 425 µm, both samples passed the sieve mostly without any need for 
grinding. HMG Trial A and B presented larger particles than HMG Trial C and D, 
explained by the "binding" ability of the molten ITR.  
Figure IV.21. displays DSC traces of all four HMG Trials and PM. For PM, an en-
dothermic signal was visible slightly above 100 °C corresponding to the evapora-
tion of βCD cavity water. Moreover, Tm of ITR could be detected (see Ta-
ble IV.8.). The corresponding signal to cavity water loss was also detectable for 
HMG Trial C and D, however not as distinctively. 
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Figure IV.21. - Excerpts from DSC curves of a) PM, b) HMG Trial A, 
c) HMG Trial B, d) HMG Trial C, e) HMG Trial D, measured from 30 - 200 °C after 
2 min holding period at 30 °C; heating rate 3 K/min. 
This was in good agreement with the results of the TGA study which showed 
water contents of 4.887 % and 4.846 % for HMG Trial C and D, respectively. 
These values were only slightly smaller than for PM (5.717 %). Even though 
HMG Trial C was processed well above 100 °C, the rapid conveying of the mate-
rial through the barrel apparently hindered vaporisation of most of the present 
water. ITR Tm of HMG Trial C was approximately 1 °C higher than for PM, where-
as HMG Trial D showed a marginal shift to a lower temperature (164.96 °C) as 
well as broadening of the peak. This might have been indicative of an IC alt-
hough not in a substantial portion. HMG Trial A and B lacked any distinctive sig-
nal corresponding to water loss which was supported by evaluating their residual 
water contents of 1.893 % and 2.335 %. Due to processing at such high temper-
atures (≥ 180 °C), most water of PM had evaporated as had been observed dur-
ing HMG (vapour formation). 
Table IV.8. - Signals correlated to melting of ITR examined in the DSC traces of 
PM, HMG Trial A, B, C and D. 
 PM HMG Trial A HMG Trial B HMG Trial C HMG Trial D 
ITR signal, °C 
Onset 
Peak 
 
164.79 
166.08 
 
151.58 
156.51 
 
163.47 
165.48 
 
155.25 
157.39 
 
163.89 
165.70 
 
165.98 
167.45 
 
161.70 
164.96 
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Interestingly though, two endothermic signals were observed correlating to ITR 
melting (see results shown in Table IV.8.). Apart from the typical Tm of ITR at 
about 166 °C, another peak was detected at around 157 °C. This agreed with a 
polymorph described in the literature [150,152,153]. It seemed as if ITR had re-
crystallised after HMG procedure. Since Zhang et al. described this polymorph, 
also called Form II, as having the fastest crystallisation velocity of all recognised 
ITR crystal forms, this might have backed up this hypothesis. The second Tm 
might have been caused by either ITR changing from Form II to the more stable 
Form I, or by crystalline material left in the sample after melt processing. How-
ever, as previously mentioned, ITR can show a special behaviour during melting 
called "cold crystallisation". Moreover, ITR forms thermotropic mesophases. Fig-
ure IV.22. presents a magnification of the DSC traces of HMG Trial A and B in the 
range of 50 - 120 °C. Especially by carefully inspecting the trace of 
HMG Trial B (b in Figure IV.22.), two very small signals just above 70 °C and be-
tween 80 and 90 °C became visible. These have been described by Six et al. as 
monotropic mesophases [154]. 
 
Figure IV.22. - Magnified DSC traces of a) HMG Trial A and b) HMG Trial B; 
measured from 30 - 200 °C after 2 min holding period at 30 °C; heating rate 
3 K/min. 
In another publication, Six et al. investigated ITR extrudates in a polymer matrix 
and not only observed the two endothermic signals of the mesophases but also re-
ported "cold crystallisation" of ITR above 100 °C and two ITR melting endotherms 
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corresponding to the polymorph and the more stable form. They concluded that 
upon DSC analysis, recrystallisation had occurred and the recrystallised polymorph 
then further recrystallised into Form I during the measurement. This last recrystal-
lisation was not observed in the DSC trace due to overlapping with Tm. They also 
found this to be correlatable to high amounts of ITR in their solid dispersions [150]. 
These results agreed with the findings of Janssens et al. who investigated solid dis-
persions with ITR and Kollicoat IR®. Up from 40 % of ITR in the solid dispersions, 
they also observed “cold crystallisation” and two Tms of the polymorphic Form II as 
well as the stable Form I [155]. In Figure IV.22., at approximately 110 °C, an exo-
thermic broad signal could be detected that might have been correlating to "cold 
crystallisation". Since the endothermic signal of water loss was nearly at the same 
point, the exothermic and endothermic reactions might have overlapped, causing 
decreasing observabilities. Lastly, the polymorphic Tm was not previously detected 
for the first HMG and HME runs but as those had been investigated by higher DSC 
heating rates, this could have been ascribed to this. It had yet to be determined if 
ITR was fully amorphous in the samples after melt processing or if the changes re-
garding the crystallinity appeared during DSC analysis.  
Thus, XRPD measurements were conducted and results are given in 
Figure IV.23.. It appeared that both HMG Trial A and B were partially amorphous 
as the peak pattern was not as tidy and strict as for PM. However, some peaks 
could be detected. It was mentioned before that βCD did not melt upon heating. 
Subsequently, it stayed in its crystalline form. When evaluating the XRPD diffrac-
tograms of the pure substances, ITR and βCD, many peaks showed the same dif-
fraction angle and overlapped. Thus, for PM, it was not always possible to ascribe 
a peak to either substance. There is a patent available regarding the polymorphic 
Form II where a distinctive IR spectrum and XRPD diffractogram are pub-
lished [153]. When comparing the results obtained in this project to the identi-
fied marker diffraction angles of the polymorphic Form II as described 
there (7.3° 2θ, 19.9° 2θ, 21.9° 2θ, 26.1° 2θ and 32.2° 2θ), none of these sig-
nals could be detected. This was also in agreement with the results of ATR-FT-IR 
analysis (see Table IV. 9.). Specific wave numbers were identified for the poly-
morph and none of those were seen. Observed shifts regarding possible ICF were 
not in accordance with the defined polymorph. Many signals ascribed to the pol-
ymorph had already vanished in PMaITR and were also not observable in HMG 
Trial A and B (e.g. 1585 cm-1, 1275 cm-1, 1191 cm-1, 1137 cm-1 and 1043 cm-1). 
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Figure IV.23. - Excerpts from XRPD diffractograms of a) PM, b) HMG Trial A, 
c) HMG Trial B, d) HMG Trial C and e) HMG Trial D; measurement conducted 
from 5 - 50 °2θ. 
Taking all these results as well as the literature into account, it seemed appro-
priate to conclude that even though partial crystallinity of ITR could not be ex-
cluded with certainty (see XRPD results), the presence of the polymorphic 
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Form II was most likely only caused by recrystallisation during DSC analysis as 
no other analysis technique showed results that proved the existence of it in the 
solid form. Regarding the XRPD results of the two HMG samples processed below 
ITR Tm, HMG Trial C and D (d and e in Figure IV.23.), it seemed apparent that 
the distinctive peak pattern could still be observed for both of them, as they 
were fully crystalline. However, the intensity of the detected diffraction angles 
had decreased compared to PM which might have been indicative of ICF. In this 
regard, following the results of SEM imaging and particle size determination, it 
appeared that HMG Trial D seemed to stronger interact with βCD.  
Lastly, content analysis was carried out. Results are shown in Figure IV.24.. No 
degradation was detected for either ITR or βCD. No degradation products were 
observed. ITR and βCD contents of HMG Trial A, B, C, D and PM were 
97.59 ± 0.11 % and 105.21 ± 0.37 %, 93.00 ± 2.34 % and 93.70 ± 1.93 %, 
97.67 ± 1.18 % and 98.45 ± 0.94 %, 100.93 ± 2.53 % and 97.44 ± 4.22 % as 
well as 100.86 ± 2.69 % and 94.06 ± 5.14 %, respectively. As later results of 
HMG Trial B stability data (see section IV.10.) suggested, the determined ITR 
value of 93.00 % might have been too low.  
 
Figure IV.24. - Content evaluation of different HMG samples and PM; n = 3; er-
ror bars = sd. 
Reviewing the general physico-chemical characterisation, the HMG runs could 
be divided into two categories, the specimen prepared above ITR Tm and the 
samples prepared below. Evaluating HMG Trial A and B, no differences were de-
tected in the presented methods so far, whereas for the fully crystalline samples 
HMG Trial C and D, variabilities were found, regarding particle size, intensity in 
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XRPD and the broadened ITR Tm for HMG Trial D. All these results hinted at the 
possibility that HMG Trial D might show superior dissolution properties due to 
higher ICF compared to HMG Trial C. 
IV.4.3. Dissolution Testing and Inclusion Complex Formation Evalu-
ation of HMG Trial A - D 
To gain further insights into possible ICF during HMG, dissolution testing was car-
ried out and results for HMG Trial A, B, C and D and PM are shown in Figure IV.25.. 
 
Figure IV.25. - Dissolution results of HMG Trial A, B, C, D and PM; n = 2; error 
bars = min/max. 
After 4 h, HMG Trial A and B reached ITR dissolution of 92.49 ± 4.48 % and 
97.89 ± 2.39 %, respectively. HMG Trial C and D showed ITR dissolution of 
10.84 ± 0.07 % and 14.67 ± 0.12 %, whereas PM gave 7.89 ± 0.16 %. This was 
18.58 % less as seen for PM in section IV.3.2. (10.32 ± 0.76 %) and was caused 
by the fact that the dissolution medium was not replaced in this analysis. As re-
ported, HMG Trial A and B were produced above Tm of ITR which led to at least 
partially amorphous API in the samples. As described in section IV.3.2., PMaITR 
had already presented improved ITR dissolution of 63.76 ± 1.65 % after 4 h. 
Thus, it was plausible that ITR dissolution of HMG Trial A and B exceeded the ful-
ly crystalline samples by far. Consequently, it was most suitable to evaluate the 
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samples according to their processing regimen of either above ITR Tm or below. 
Only by this it was possible to distinguish if improved dissolution was caused by 
ICF. HMG Trial B reached highest and also fastest ITR dissolution. The average 
curve was always slightly above HMG Trial A. However, as deviations for both 
samples were quite high (e.g. after 15 min 6.56 % and 5.23 % for HMG Trial A 
and HMG Trial B, respectively), this could not be viewed as significant at this 
point. However, the maximum and minimum values varied far more for 
HMG Trial A. Compared to PMaITR, HMG Trial A reached improved dissolution of 
45.06 %, whereas HMG Trial B reached an enhancement of 53.53 % after 4 h. 
Both dissolution curves of HMG Trial A and B showed nearly the same kinetics 
with fast ITR dissolution during the beginning of the experiment, resulting in a 
plateau phase up from approximately 120 min. The fast dissolution at the outset 
of the experiment indicated ICF during HMG as the dissolution curve of pure aITR 
and PMaITR (see section IV.3.2.) did not give this steep beginning of the curves. 
Moreover, the dissolution profile of aITR appeared rather zero-order like 
throughout the analysis while PMaITR only showed this behaviour in the begin-
ning. Then, PMaITR started to reach a plateau after approximately 150 min.  
These results proved that HMG procedure above ITR Tm had definitely altered 
HMG Trial A and B in a way that further improved ITR dissolution rate which 
could most likely be ascribed to ICF. Nonetheless, ICF during dissolution testing 
also occurred simultaneously, as generally, 100 % ICF after processing the ma-
terial is improbable. Although HMG Trial B was processed at colder temperatures, 
the dissolution and dissolution rate appeared higher than for HMG Trial A. 
Table IV.7. showed that HMG Trial B presented a larger x50 value than HMGTri-
al A which constituted that improved dissolution velocity was not caused by larg-
er surface area of the material. As presented in Table IV.6., the average torque 
during processing was slightly higher with 14 % compared to 10 %. This might have 
been an explanation for greater ICF in this sample as a higher torque correlates with 
higher energy input in the sample due to rising shear forces. Apart from that, in 
general the melt viscosity is higher with lowered temperatures. Consequently, more 
shear forces might have generated improved kneading and mixing abilities within 
mTSE, forcing a larger amount of ITR into the βCD cavities for HMG Trial B. Albeit 
the differences in dissolution between HMG Trial A and HMG Trial B were not exten-
sive, the high absolute dissolution in general as well as the lower temperature pro-
file for HMG Trial B deemed it the favourable HMG process.  
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For a more comprehensive understanding, the dissolution results of HMG Trial C 
and D and PM are shown in Figure IV.26. in magnification. Upon first inspection 
of the three curves, it became obvious that PM showed a different dissolution 
profile than the two processed samples. PM dissolution started slowly and expe-
rienced a rise between 30 - 120 min (1.45 ± 0.02 % - 6.74 ± 0.67 %). This 
hinted at ICF within the dissolution vessel. After 120 min, the ITR content nearly 
stayed on a plateau and reached 7.89 ± 0.16 % after 4 h. 
 
Figure IV.26. - Close up view of the dissolution results of HMG Trial C, D and PM; 
n = 2; error bars = min/max. 
HMG Trial C and HMG Trial D exhibited different dissolution profiles. From the 
beginning onwards, for HMG Trial C, the dissolved amount of ITR was always 
above PM. Although there was a similar rise between 15 - 120 min which was 
most likely attributed to ICF in the liquid media, surely, mTSE processing had in-
creased ITR dissolution. With 10.84 ± 0.07 % after 4 h, the final dissolution was 
enhanced by 37.39 %. Examining the dissolution profile of HMG Trial D, the 
curve presented even further improved dissolution and dissolution rate. It started 
above the other samples. Kinetic-wise the dissolution profile appeared more as 
shown for HMG Trial A and B, only on a smaller scale. The slow rise shown for 
HMG Trial C and PM was not certainly detected for HMG Trial D. Nonetheless, at 
30 - 120 min, small dissolution increase (11.43 ± 0.12 % - 13.71 ± 0.19 %) was 
seen. After 4 h, HMG Trial D reached ITR dissolution of 14.67 ± 0.12 % which 
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was an increase of 85.93 % compared to PM. Thus, the outcome suspected in 
the previous section held true for the fully crystalline samples. As also shown for 
HMG Trial A and B, although HMG Trial D was processed at lower temperatures, 
the torque during HMG had been higher (16 % in respect to 6 % for 
HMG Trial C). This might have caused higher shear forces resulting in improved 
mixing and kneading during HMG. Again, particle size measurements excluded 
faster dissolution due to larger surface are (see Table IV.7.). Despite the fact that 
the absolute ITR dissolution was not largely improved by processing crystalline 
material, the highest relative enhancement of all samples was seen for 
HMG Trial D. To completely evaluate possible ICF, ATR-FT-IR results were also 
taken into account (see Table IV.9.).  
Particularly for HMG Trial C, no substantial changes became apparent in the ATR-
FT-IR spectrum compared to PM. Partial ICF was most likely, as it appeared that 
non-included ITR was overlapping IC signals. The detected wave numbers for 
HMG Trial C were very similar to PM throughout the whole spectrum. Evaluating 
HMG Trial A and B, the previously detected changes for partial amorphous content 
also became apparent. The peak at 1042.58 cm-1 detected for PMaITR had com-
pletely disappeared. As HMG Trial D had shown the highest relative improvement in 
dissolution most likely caused by ICF, the largest spectral changes were suspected 
for this sample. This suspicion held true upon inspecting ATR-FT-IR results, espe-
cially by comparing the detected wave numbers to PM or HMG Trial C. Overall, the 
results of HMG Trial D appeared more distinct and less challenging to interpret as 
shown for the partially amorphous samples. Some peaks (around 1585 cm-1, 
1271 cm-1, and 1184 cm-1) had disappeared altogether and the signal around 
1027 cm-1 had previously only been reported for at least partially amorphous sam-
ples. The signal at 1077.45 cm-1 had shifted to a higher wave number compared to 
the other crystalline samples that gave a wave band at approximately 1073 cm-1. 
The signal at 1462.05 cm-1 presented a shift of over 10 cm-1 in contrast to all other 
samples. As HMG Trial D showed the largest relative dissolution enhancement, it 
might have been possible that this sample exhibited lowest amount of remaining, 
non-included ITR, causing overlapping signals. Thus, in the other samples, this shift 
in wave number might have been masked.  
It was shown again that the sole examination of ATR-FT-IR spectra did not give 
sufficient results for proving ICF. Even though for HMG Trial D, changes were de-
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tected that could not be explained by amorphisation, it has to be acknowledged 
that these changes largely appeared in regions that became affected by amor-
phisation. Therefore, these results stressed the limited informative value for melt 
processed samples with amorphous content. IC detection for HMG Trial A and B 
only by ATR-FT-IR was not possible. However, the determination of spectral 
changes could help to further explain dissolution results. 
Table IV.9. - ATR-FT-IR results of HMG Trial A, B, C and D; evaluated by compar-
ison with reference wave numbers; sd = ±; n = 3; *n = 5; if wave number 
markers were not detected in every single analysis, the percentage of their oc-
currence is given in brackets below. 
 
PM* 
PMaITR* 
HMG Trial A HMG Trial B HMG Trial C HMG Trial D 
W
a
v
e
 N
u
m
b
e
r
s
, 
c
m
-
1
  
1697.60 ± 0.15 
1698.89 ± 0.33 
1698.40 ± 0.08 1698.63 ± 0.23 1697.93 ± 0.02 1698.26 ± 0.04 
1584.60 ± 0.25 
(80 %) 
1585.76 ± 0 
(20 %) 
X X 
1584.72 ± 0 
(66.67 %) 
X 
1551.18 ± 0.13 
1552.74 ± 0.27 
1552.73 ± 0.10 
1552.69 ± 0.21 
(66.67 %) 
1551.38 ± 0.05 1551.57 ± 0.08 
1509.80 ± 0.23 
1511.07 ± 0.34 
1510.50 ± 0.20 1510.75 ± 0.25 1510.16 ± 0.06 1510.50 ± 0.04 
1451.20 ± 0.16 
(80 %) 
1451.08 ± 0.21 
1451.44 ± 0.22 
1451.51 ± 0.21 
(66.67 %) 
1451.44 ± 0.01 1462.05 ± 0.10 
1270.96 ± 0.98 
(80 %) 
X 
X X 
1270.34 ± 0.07 
(66.67 %) 
X 
1227.41 ± 0.59 
1228.55 ± 0.62 
1228.35 ± 0.41 1229.45 ± 0.55 1227.98 ± 0.27 1229.38 ± 0.14 
1184.44 ± 0.52 
X 
X X 1184.53 ± 0.29 X 
1140.58 ± 0 
(20 %) 
X 
X X X X 
1072.64 ± 0.06 
(40 %) 
1077.55 ± 0.36 
(40 %) 
1078.43 ± 0.06 1078.32 ± 0.29 
1072.92 ± 0.18 
(66.67 %) 
1077.45 ± 0.11 
1043.15 ± 0.11 
1042.58 ± 0.95 
(40 %) 
X X 1043.13 ± 0.09 
1042.05 ± 0 
(66.67 %) 
X 
1028.45 ± 1.81 
(60 %) 
1026.06 ± 0.58 1025.93 ± 0.63 X 
1027.84 ± 0.25 
(66.67 %) 
823.82 ± 0.09 
824.74 ± 0.72 
824.93 ± 0.45 825.01 ± 0.69 824.00 ± 0.03 824.11 ± 0.02 
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IV.4.4. Concluding Remarks about HMG Trial A - D 
The previous section showed the physico-chemical analyses of different HMG 
runs as well as evaluations of possible ICF and ITR dissolution. As stated, the 
most suitable HMG temperature profile was supposed to be chosen. Although the 
largest relative improvement in dissolution was gained for a fully crystalline 
sample (HMG Trial D), it was shown that the combination of amorphisation and 
ICF during HMG resulted in the highest absolute ITR dissolution (see Figure 
IV.25.). Both at least partially amorphous samples yielded ITR dissolution above 
90 %. Since the lowest applicable temperatures should always be chosen during 
melt processes, it was concluded that the most promising temperature profile for 
HMG was HMG Trial B, where PM was processed above Tm of ITR. Consequently, 
all alternative formulation approaches from here on that were processed with the 
mTSE were operated at this temperature profile. The scientific value of the 
greatest relative improved dissolution (HMG Trial D) will be taken up again in 
section V. for the overall discussion and scientific perspective of this work. 
IV.5. Investigating Hot-Melt-Granulation against Physi-
cal Inclusion Complex Formation Methods 
For comparative reasons, the developed HMG procedures were evaluated 
against a kneading process (KN) as well as a melt processed wet granula-
tion (WG). KN was chosen as it is the traditional method of creating ICs. Since 
HMG with temperatures above ITR Tm had shown to enhance ITR dissolution after 
4 h but yet had reached maximum dissolution after 2 h, it was hypothesised that 
a combination of WG and HMG might further improve the dissolution rate. Even 
though KN and the melt processed WG were different regarding their fabrication, 
they were evaluated together in the following subchapter as they shared manu-
facturing steps that utilised physical modification to improve ICF.  
IV.5.1. Kneading Process and Wet Granulation Processability 
KN and WG were produced according to section III.2.1.2.. KN was further char-
acterised without alterations, whereas WG was dried to residual moisture of 
13.30 % and then given into the hopper. As reported, HMG Trial B had shown 
favourable characteristics coinciding with the lowest processing temperatures. 
Thus, WG was hot-melt granulated using these parameters. Processing features 
of HMG Trial WG are given in Table IV.10..  
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Table IV.10. - HMG processing details for HMG Trial WG. 
HMG 
Trial 
Z1,°C Z2,°C Z3,°C Z4,°C Z5,°C Z6,°C Z7,°C 
ScS, 
rpm 
Throughput, 
g/h 
Torque, 
% 
WG 100 130 170 180 180 180 180 150 187.1 13 
WG exhibited best flowability of all samples processed by mTSE with a calibrated 
maximum throughput of 1268.7 g/h. During the mTSE filling phase, it became ap-
parent that the residence time was much shorter than for the other HMG runs, alt-
hough the later average throughput was kept below the desired value of 200.6 g/h 
and ScS constant at 150 rpm. A large part of WG was lost as reject during this 
starting period. Whereas the process itself was stable, the yielded product ap-
peared different from the reference HMG Trial B which had emerged as partially 
molten granules. However, for HMG Trial WG, next to no molten ITR was visible. 
The difference in appearance between the raw WG and the melt-granulated prod-
uct was less pronounced compared to the reference. Moreover, the observed wa-
ter loss by vaporisation through the ventilation port was also to a lesser extent. 
The torque was well in range with the HMG runs presented in the previous chapter 
with 13 %. The general processability of WG could be regarded as acceptable. No 
deteriorated material was observed during the process, not even in the mTSE fill-
ing phase, most probably caused by the shorter residence time. Both, KN and 
HMG Trial WG, were manually crushed and sieved through 425 µm. But, for both 
of the samples crushing was mostly not necessary for passing the sieve. 
IV.5.2. Physico-Chemical Characterisation of KN and HMG Trial WG 
Both samples were characterised regarding their physico-chemical properties. 
SEM images of KN and HMG Trial WG are shown in Figure IV.27..  
 
Figure IV.27. - SEM images of a) KN and b) HMG Trial WG; bar = 10 µm. 
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Upon this magnification, the samples appeared very similar. For both portrayed 
granules, it was clearly visible that they were composed of different materials. 
Some of the larger βCD particles were visually observable in the agglomerates. 
Also, ITR particles could be visibly identified. Especially for HMG Trial WG, some 
needle-shaped ITR crystals were seen which hinted at partial crystallinity of the 
sample. However, areas that seemed to consist of molten ITR were also detect-
ed. With lesser magnification, KN and HMG Trial WG particles appeared identical, 
only differing in particle size as KN particles were smaller. These results were 
backed up by laser diffraction analyses which resulted in x50 values of 
12.5 ± 0.2 µm and 48.5 ± 3.2 µm for KN and HMG Trial WG, respectively. 
DSC traces of KN and HMG Trial WG are presented in Figure IV.28.. DSC events 
correlating to ITR are given in Table IV.11.. KN displayed an endothermic signal 
slightly above 100 °C corresponding to water loss, and ITR Tm at 164.93 °C. This 
result was slightly below that of PM (see Table IV.8.), indicating ICF during knead-
ing. The DSC curve of HMG Trial WG seemed to show only one Tm corresponding 
to ITR but when magnified (data not shown), a very small melting endotherm be-
came detectable at 157.06 °C. This signal most likely belonged to the polymorph 
Form II. Due to the diminutiveness of the melting signal, no exothermic signal of 
the previously described “cold crystallisation” could be detected around 110 °C.  
 
Figure IV.28. – Excerpts of DSC traces of a) KN and b) HMG Trial WG; analysis 
conducted from 30 - 200 °C after 2 min holding period at 30 °C; heating rate 
3 K/min. 
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Table IV.11. - DSC signals correlating to ITR melting for KN and HMG Trial WG. 
 KN HMG Trial WG 
ITR signal, °C 
Onset 
Peak 
 
163.46 
164.93 
 
155.85 
157.06 
 
164.35 
166.65 
Due to lack of polymorphic signals in XRPD or ATR-FT-IR analyses, it was con-
cluded that material within HMG Trial WG was most likely negligibly amorphous 
and mostly crystalline. This hypothesis was based on the Tm at 166.65 °C. The 
exhibited ITR Tm was slightly higher compared to KN which indicated less ICF. 
The observation that HMG Trial WG showed shorter HMG residence time and ap-
peared different from other HMG runs was reflected in this DSC result and the 
subsequent crystallinity. Succeeding production, a water content of 2.133 % was 
determined for HMG Trial WG. This was only inconsiderably below the value de-
termined for HMG Trial B (2.335 %), so the observation that less water had 
evaporated during HMG did not hold true. Nonetheless, it might have been pos-
sible that the energy during HMG was sufficient for water removal but, due to the 
fast conveying within the barrel, was not enough to completely melt the API. 
XRPD results of KN and HMG Trial WG are presented in Figure IV.29.. KN ap-
peared completely crystalline with distinct peaks that could mostly be correlated 
to either ITR or βCD. 
 
Figure IV.29. - Excerpts of XRPD diffractograms of a) KN and b) HMG Trial WG. 
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This had been somewhat expected as no processing steps had been conducted 
that would have changed ITR crystallinity. It has been reported that ICF in crystal-
line samples can cause changes in peak intensity, disappearance or shift of XRPD 
signals or in some cases, results in new peaks. Very often, studied samples have 
been exposed to techniques that could have altered API crystallinity. Then, XRPD 
results are without value in making distinct conclusions (see Figure IV.23. and 
XRPD evaluation of HMG Trial A and B) [133,156]. In the here presented case, 
XRPD diffractogram of KN gave the same diffraction pattern as PM. As ICF during 
kneading most probably did not take place quantitatively, there was the possibil-
ity that un-included ITR signals overlapped possible changes caused by the IC. 
Otherwise, XRPD results did not support ICF in KN. The XRPD pattern of 
HMG Trial WG supported the DSC results. Though most peaks had dropped in 
their absolute intensity, there still was a pattern observable that hinted at partial 
ITR crystallinity. Especially the peaks at 8.69° 2θ, 12.29° 2θ, 17.54° 2θ, 
17.99° 2θ and 20.36° 2θ could be correlated to crystalline ITR.  
ITR and βCD content were evaluated. Results are given in Figure IV.30.. No 
product degradation was visible during HMG. These results were backed up by 
the content analyses. KN exhibited respective ITR and βCD contents of 
98.78 ± 0.38 % and 97.13 ± 1.25 %. ITR content in HMG Trial WG was 
97.48 ± 1.51 % and βCD 102.91 ± 0.63 %. Deviating from all other samples, 
longer ultrasonification times had been necessary for HMG Trial WG samples to 
dissolve.  
 
Figure IV.30. - Content evaluation of KN and HMG Trial WG; n = 3; error bars = sd. 
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Comparing these two samples with the melt processed specimen presented 
previously, it seemed as if HMG Trial WG lacked amorphousness compared to 
reference HMG Trial B. This would most likely decrease ITR dissolution. Solely by 
investigating physico-chemical characteristics of KN, the only detectable change 
compared to PM was that ITR Tm had shifted to a slightly lower temperature.  
IV.5.3. Dissolution Testing and Inclusion Complex Formation Evalu-
ation of KN and HMG Trial WG 
To further examine possible ICF, dissolution experiments of KN and 
HMG Trial WG were carried out. Dissolution curves are shown in Figure IV.31.. 
Although HMG Trial WG had been melt processed above ITR Tm, partial crystallin-
ity of ITR was detected in DSC.  
 
Figure IV.31. - Dissolution results of KN and HMG Trial WG; n = 2; error 
bars = min/max. 
The assumption of a decrease in dissolution caused by this held true. After 4 h, 
HMG Trial WG reached 20.47 ± 0.08 % ITR dissolution which was only 20.91 % 
of the reference sample’s result (97.89 % for HMG Trial B). No relative difference 
in absolute dissolution could be calculated as none of the two chosen references 
was appropriate. PM could not be used due to a ITR in the sample, PMaITR could 
not be used since most ITR appeared crystalline. KN showed dissolution of 
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10.99 ± 0.08 % after 4 h. With this, it was nearly on the same level as 
HMG Trial C (10.84 %). Compared to PM, this was an increase in ITR dissolution 
of 39.29 %. This was most likely caused by ICF. The curvature of KN also hinted 
at ICF, as the previously described slow rise between 30 - 120 min for PM was 
not as pronounced for this sample. The plateau phase of KN was already reached 
after approximately 75 min. The dissolution profile of HMG Trial WG partially re-
sembled the dissolution curve of HMG Trial D (see Figure IV.25.), but presented 
a higher absolute amount of dissolved ITR as well as the complete lack of rising 
caused by ICF in the liquid medium. The plateau phase was reached after 
30 min. Taking into account the observation during content analysis and the fact 
that after dissolution testing, large fragments of white sample were swirling in 
the dissolution medium, it was possible that the dissolution result of 
HMG Trial WG was solely built on aITR dissolving whereas the crystalline gran-
ules did not dissolve at all. Without sufficient solvation of βCD, ICF within the 
dissolution vessel was hindered.  
To further characterise possible ICF, ATR-FT-IR experiments were carried out. 
The detected marker wave numbers for KN and HMG Trial WG are given in 
Table IV.12.. For KN, only one marker wave number directly hinted at ICF, the 
signal at 1075.09 cm-1. This meant a shift from 1072.64 cm-1 as seen for PM. 
However, this wave number was only detected during one experiment run. As 
opposed to HMG Trial D (see Table IV.9.) where numerous signals had disap-
peared without ITR amorphisation, these peaks were still observed for KN (e.g. 
1584.79 cm-1 and 1185.07 cm-1). It appeared that only partial ICF had occurred 
during kneading and caused overlapping ATR-FT-IR results. The detected wave 
numbers for HMG Trial WG also differed strongly from the reference 
HMG Trial B (see Table IV.9.). The disappeared signals around 1140 cm-1 and 
1043 cm-1 might have been connected to ITR amorphisation, however, those two 
signals had also not been observed in every analysis run of PM and PMaITR. Oth-
er markers, e.g. at 1585.30 cm-1 and 1185.11 cm-1 were detected in every 
measurement of HMG Trial WG. The shift of the peak around 1072 cm-1 to 
1078.04 cm-1 might have either indicated amorphisation or ICs in the sample. 
Generally, the results of HMG Trial WG strongly suggested that most ITR was 
crystalline. Otherwise the spectral signals were inconclusive and did not allow 
any distinct conclusion or support of dissolution results. Combining dissolution 
and ATR-FT-IR results, it seemed fairly certain that ICF had occurred for KN, 
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however only partially. The existence of ICs within HMG Trial WG could not be 
proven or concluded as the dissolution stayed well below the reference range of 
aITR. Therefore, it was not possible to ascribe the change in dissolution to either 
amorphous content or ICF. 
Table IV.12. - ATR-FT-IR results of KN and HMG Trial WG, evaluated by compar-
ison with reference wave numbers; sd is given as ±, n = 3,*n = 5; if wave num-
ber markers were not detected in every single analysis, the percentage of their 
occurrence is given in brackets below. 
 
PM* 
PMaITR* 
KN 
HMG Trial 
WG 
W
a
v
e
 N
u
m
b
e
r
s
, 
c
m
-
1
  
1697.60 ± 0.15 
1698.89 ± 0.33 
1698.12 ± 0.14 1698.11 ± 0.14 
1584.60 ± 0.25 
(80 %) 
1585.76 ± 0 
(20 %) 
1584.79 ± 0.10 1585.30 ± 0.11 
1551.18 ± 0.13 
1552.74 ± 0.27 
1551.51 ± 0.14 1551.65 ± 0.08 
1509.80 ± 0.23 
1511.07 ± 0.34 
1510.31 ± 0.13 1510.55 ± 0.21 
1451.20 ± 0.16 
(80 %) 
1451.08 ± 0.21 
1451.34 ± 0.12 1451.19 ± 0.09 
1270.96 ± 0.98 
(80 %) 
X 
1272.61 ± 0.16 1272.51 ± 0.14 
1227.41 ± 0.59 
1228.55 ± 0.62 
1227.48 ± 0.09 1227.77 ± 0.12 
1184.44 ± 0.52 
X 
1185.07 ± 0.05 1185.11 ± 0.06 
1140.58 ± 0 
(20 %) 
X 
1141.16 ± 0 
(33.33 %) 
X 
1072.64 ± 0.06 
(40 %) 
1077.55 ± 0.36 
(40 %) 
1075.09 ± 0 
(33.33 %) 
1078.04 ± 0.17 
1043.15 ± 0.11 
1042.58 ± 0.95 
(40 %) 
1042.81 ± 0.10 X 
X 
1028.45 ± 1.81 
(60 %) 
X 1026.38 ± 0.21 
823.82 ± 0.09 
824.74 ± 0.72 
824.04 ± 0.04 824.12 ± 0.11 
 
IV.5.4. Concluding Remarks about KN and HMG Trial WG 
This chapter presented two approaches of physically creating ICs and the com-
parison against reference samples. For KN, it was concluded that manual knead-
ing had resulted in only partial ICF. Dissolution after 4 h was increased by 
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39.29 %. Comparing this with HMG Trial C, nearly the same dissolution results 
were achievable without the addition of water during the continuous HMG pro-
cess. This was an advantage over KN, particularly when taking into account that 
HMG Trial D (see previous chapter) had reached even higher final ITR dissolution 
after being processed at lower temperatures. The crystalline HMG samples ap-
peared superior to the traditional ICF method.  
The hypothesis that a combination of WG and HMG processed above Tm of ITR 
might further enhance dissolution rate or product properties had to be rejected. 
The tremendously improved flowability properties of WG had negatively influ-
enced HMG procedure. Even though a short residence time is favourable for melt 
processes as the material is only exposed to high temperatures for a very short 
time, it needs to be long enough to allow complete melting and mixing within the 
barrel. This had apparently not been the case for HMG Trial WG. The obtained 
results of physico-chemical and dissolution analyses were difficult to evaluate as 
the degree of ICF could not be determined and thus, the degree of aITR’s influ-
ence. Overall, it was concluded that both physical methods, KN and 
HMG Trial WG were inferior to the reference sample HMG Trial B. Furthermore, 
KN was also inferior to HMG Trial C and D. The combination of WG and HMG was 
discarded as ineffective.  
IV.6. Examination of the Influence of Hydroxypropyl-
β-Cyclodextrin on Product Quality 
As described in section IV.1., PSM showed improved ITR solubility with HPβCD. 
Apart from this, HPβCD is used in the marketed oral solution Sporanox® (see sec-
tion III.1.3.). Thus, HPβCD was investigated as matrix in HMG to evaluate possi-
ble advantages and disadvantages over βCD. For comparative reasons, the stoi-
chiometry of 1:1 was kept which meant a smaller mass fraction of ITR in the 
blend compared to βCD. 
IV.6.1. Hot-Melt Granulation Process 
Since operating parameters of HMG Trial B were selected as favourable (see sec-
tion IV.4.), these parameters were used for PM of HPβCD and ITR. They are given 
in Table IV.13.. The procedure was stable as had been seen for PMs with βCD. 
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Table IV.13. - HMG processing parameters for HMG Trial HP. 
HMG 
Trial 
Z1,°C Z2,°C Z3,°C Z4,°C Z5,°C Z6,°C Z7,°C 
ScS, 
rpm 
Throughput, 
g/h 
Torque, 
% 
HP 100 130 170 180 180 180 180 150 214.6 23 
However, this PM appeared dustier during handling which was not a desired 
quality. The average throughput was kept at 214.6 g/h with a torque of about 
23 % which was substantially higher as for the reference sample 
HMG Trial B (14 %). The yielded product looked the same as the other HMG 
samples processed above ITR Tm. Seemingly intact CD particles were agglomer-
ated by molten ITR that had solidified. The material passing mTSE during the fill-
ing phase exited degraded. After a stable process was reached, the product ap-
peared completely intact without visible deterioration. Even though the torque 
was considerably higher than observed before, the screws did not screech and 
the whole operation could be described as successful. No differences were seen 
compared to using βCD as matrix regarding the behaviour within mTSE. 
IV.6.2. Physico-Chemical Characterisation of HMG Trial HP 
HMG Trial HP was analysed in view of its physico-chemical properties. Fig-
ure IV.32. shows a magnified SEM image of the sample. Differently sized ag-
glomerates were present, but commonly appeared like the one displayed in the 
picture. The molten surface was plainly visible. Still, not all particles of one ag-
glomerate were covered by molten material. The solidified melt seemed 
“bumpy”. This might have been explained by the fact that HPβCD did not melt 
during HMG and thus, these particles did not change regarding roughness or 
general composure during processing.  
 
Figure IV.32. - SEM image of HMG Trial HP shortly after production; bar = 10 µm. 
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The x50 value of the sample after manual crushing was determined to be 
66.8 ± 2.1 µm. This was only 57.44 % of the reference sample 
HMG Trial B (116.3 ± 24.4 µm) and could indicate a faster dissolution rate due to 
a larger surface area. 
Figure IV.33. and Table IV.14. display the DSC results of HMG Trial HP. Com-
paring the curve with the DSC trace of the reference sample HMG Trial B (see 
Figure IV.21.), they appeared similar. Again, there was a second, colder Tm of 
ITR, in this case at 158.41 °C, corresponding to the previously reported poly-
morph. The second melting endotherm of ITR occurred at 166.97 °C. 
 
Figure IV.33. – Excerpt from DSC curve of HMG Trial HP; analysis conducted 
from 30 - 200 °C after 2 min holding period at 30 °C; heating rate 3 K/min. 
Upon magnifying the DSC trace as shown for HMG Trial A and B (see Fig-
ure IV.22.; data for HMG Trial HP not shown), the “cold crystallisation” of ITR as 
well as the endothermic signals correlating to ITR mesophases became detectable. 
This characteristic was a property that all samples processed above Tm of ITR had 
in common except the previously presented HMG Trial WG. Same as for the other 
HMG samples, no further sign of the polymorph was detected for HMG Trial HP in 
any further analysis which is why it was concluded that the polymorph had formed 
during the DSC experiment and was not present in the solid sample. 
Table IV.14. - DSC signals correlating to melting of ITR for HMG Trial HP. 
 HMG Trial HP 
ITR signal, °C 
Onset 
Peak 
 
156.70 
158.41 
 
164.79 
166.97 
The second Tm at 166.97 °C might have been caused by partially crystalline ITR 
within the sample or by recrystallisation during the DSC measurement. To further 
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study these possibilities, XRPD diffractograms of the sample and pure HPβCD were 
obtained. They are given in Figure IV.34.. The diffractogram of HPβCD did not 
show any peak pattern in contrast to βCD. This was probably caused by the ir-
regular substitution of the glucose units with the hydroxylpropyl groups and corre-
sponded to literature results [157]. The XRPD diffractogram of HMG Trial HP sug-
gested the sample to be amorphous. No peaks of ITR were visible for the sample. 
This supported the theory regarding “cold crystallisation” of the polymorph during 
DSC analysis. Moreover, it suggested that both detected Tms of ITR in the DSC 
were caused by recrystallisation processes during the analysis. 
 
Figure IV.34. - Excerpts from XRPD diffractograms; a) pure HPβCD and 
b) HMG Trial HP. 
Nevertheless, as XRPD has a limit in detecting crystallinity, the possibility of at 
least minimal ITR crystallinity could not be excluded. Anyhow, the XRPD analysis 
of HMG Trial HP showed the least traces of crystalline ITR of all investigated 
samples. It seemed that HPβCD was better suited as matrix in keeping ITR 
amorphous, also during the analysis. This might again have been caused by the 
substitutional pattern, as this might have hindered ITR from redefining its long-
range crystal order. Content evaluation was carried out in triplicate for each ITR 
and HPβCD. No product degradation was visible. This was mirrored in the analy-
sis results with an ITR content of 100.20 ± 1.39 % and HPβCD content of 
102.49 ± 2.62 %.  
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The physico-chemical examination of the sample showed parallels to the refer-
ence sample HMG Trial B but also highlighted one possibly important difference, 
the ability of HPβCD to maintain aITR and prevent recrystallisation directly after 
production. These results hinted at the possibility of improved dissolution com-
pared to the reference. However, as was presented in section IV.1., unmodified 
βCD had shown a higher CE with ITR compared to HPβCD. Thus, any changes in 
dissolution of the CD derivative might solely be caused by higher aITR content 
and not due to more extensive ICF within mTSE. 
IV.6.3. Dissolution Testing and Inclusion Complex Formation Evalu-
ation of HMG Trial HP 
The dissolution of HMG Trial HP was investigated over 4 h and results are 
shown in Figure IV.35.. As the physico-chemical examination had shown, the 
sample appeared fully amorphous which is why the negative control for dissolu-
tion testing had to be PMaITR (63.76 % after 4 h; see section IV.3.2.).  
 
Figure IV.35. - Dissolution results of HMG Trial HP; n = 2; error bars = min/max. 
HMG Trial HP reached ITR dissolution of 79.50 ± 0.42 % after 4 h. This was an 
enhancement of 24.69 % compared to PMaITR but a reduction of 18.79 % com-
pared to HMG Trial B (97.89 ± 2.39 % after 4 h; see section IV.4.3.). The disso-
lution profile started higher than for HMG Trial B (37.19 ± 1.48 % after 5 min for 
HMG Trial HP compared to 22.15 ± 3.22 % after 5 min for HMG Trial B). This 
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could have been related to a burst effect of aITR on the granules’ surface (see 
Figure IV.32.) or to the fast dissolution rate of formed ICs. Another possibility 
could be the larger surface area of the smaller particles as shown in the x50 de-
termination. After 45 min, HMG Trial B dissolution exceeded HMG Trial HP. Same 
as for the reference sample, there was a long rise between 30 - 120 min that 
most probably was caused by ICF in the dissolution vessel. After that, compara-
ble to HMG Trial B as well, a plateau was reached. Dissolution of HMG Trial B 
rose 61.33 % between 30 - 120 min. Dissolution of HMG Trial HP on the other 
hand, only 35.52 %. As it was shown that βCD gave a higher CE for ITR, this dis-
crepancy could possibly at least in part be ascribed to more extensive ICF during 
analysis. However, the investigation of PMaITR had shown an increase of only 
38.23 % in the same time period which was well below 61.33 % of HMG Trial B. 
This overrode the theory that most of the aforementioned discrepancy was caused 
by ICF during the dissolution testing. Therefore, the higher result of HMG Trial B 
must have been either caused by more aITR or more ICs in the sample compared 
to HMG Trial HP. As DSC and XRPD analyses had shown, more aITR was most 
probably not the case. Thus, higher ICF during HMG of HMG Trial B was the most 
presumable explanation. Consequently, it could be stated that contradicting the 
assumption based on the results of the physico-chemical analysis, HMG Trial HP 
did not show superior dissolution compared to the reference sample in view of the 
full experiment. Its dissolution rate was faster during the first 30 min, but it was 
not possible to ascribe this to ICF due to the smaller particle size. 
As the dissolution results allowed speculations regarding ICF in HMG Trial HP, 
ATR-FT-IR results were evaluated. Marker wave numbers of the samples com-
pared to PMaITR and pure HPβCD are given in Table IV.15.. Nothing really stood 
out. As already seen for the other samples containing aITR, some signals of ITR 
had disappeared (e.g. around 1585 cm-1 and 1043 cm-1). Still, it is noteworthy 
that PM of HPβCD and ITR was not evaluated and the chosen reference PMaITR 
only contained βCD. In Table IV.15., it can be seen that HPβCD only presented 
two wave bands in the regions of the marker wave numbers. Most of the selected 
markers were attributed to ITR anyway. Still, it was possible that detected chang-
es for HMG Trial HP might have only been typical results for a PM of ITR and 
HPβCD. However, the general results of HMG Trial HP were very compliant with 
PMaITR. Since the presence of aITR in the samples generally interfered with a 
clear evaluation of possible ICs, using PMaITR as reference was considered ac-
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ceptable. Accordingly, the only strong indicator that there were in fact ICs within 
HMG Trial HP was the improved dissolution compared to pure aITR.  
Table IV.15. - ATR-FT-IR results of HMG Trial HP, evaluated by comparison with 
reference wave numbers; sd = ±; n = 3; *n = 5; if wave number markers were 
not detected in every single analysis, the percentage of their occurrence is giv-
en in brackets below. 
 
PM* 
PMaITR* 
HPβCD HMG Trial HP 
W
a
v
e
 N
u
m
b
e
r
s
, 
c
m
-
1
  
1697.60 ± 0.15 
1698.89 ± 0.33 
X 1700.24 ± 0.72 
1584.60 ± 0.25 
(80 %) 
1585.76 ± 0 
(20 %) 
X X 
1551.18 ± 0.13 
1552.74 ± 0.27 
X 
1552.78 ± 0.08 
(66.67 %) 
1509.80 ± 0.23 
1511.07 ± 0.34 
X 1511.03 ± 0.06 
1451.20 ± 0.16 
(80 %) 
1451.08 ± 0.21 
X 
1450.96 ± 0 
(33.33 %) 
1270.96 ± 0.98 
(80 %) 
X 
X X 
1227.41 ± 0.59 
1228.55 ± 0.62 
X 1228.55 ± 0.22 
1184.44 ± 0.52 
X 
X X 
1140.58 ± 0 
(20 %) 
X 
X 1152.14 ± 0.63 
1072.64 ± 0.06 
(40 %) 
1077.55 ± 0.36 
(40 %) 
1080.27 ± 0 
(33.33 %) 
1079.87 ± 0.01 
(66.67 %) 
1043.15 ± 0.11 
1042.58 ± 0.95 
(40 %) 
X X 
X 
1028.45 ± 1.81 
(60 %) 
1025.27 ± 0.10 1028.20 ± 0.77 
 823.82 ± 0.09 
 824.74 ± 0.72 
X   826.26 ± 1.11 
 
IV.6.4. Concluding Remarks about HMG Trial HP 
The present chapter showed the investigation and interpretation of the melt 
processed sample HMG Trial HP. By these experiments, the suitability of a modi-
fied CD matrix was investigated compared to unmodified βCD. To reach a distinct 
conclusion from the presented data was challenging as HMG Trial HP did show 
positive properties. The ability to keep ITR amorphous after production had not 
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been as distinctively shown for βCD. The HMG procedure was stable. However, 
dissolution results were somewhat surprising with average ITR dissolution after 
4 h of 18.79 % less than for the reference HMG Trial B. It was not distinguisha-
ble to what extent aITR and ICs influenced dissolution. But, when comparing the 
data to pure aITR or PMaITR, it seemed apparent that ICF had occurred during 
HMG for HMG Trial HP, however, not to the extent as for HMG Trial B. Within the 
first 30 min, HMG Trial HP showed superior dissolution, but it was also possible 
that this had been caused by a larger surface area. Nonetheless, the sample was 
subjected to stability experiments. Even so, at this point, a definite superiority of 
the CD derivative over the unmodified CD could not be ascertained. 
IV.7. Influence of a Polymer Matrix in Hot-Melt Granu-
lation 
Usually, hot-melt procedures are operated using a polymer matrix due to ther-
moplastic properties of these substances (see section II.2.2.). Thus, HMG with a 
polymer was carried out for comparative reasons. SOLU (see section III.1.4.) 
was chosen as matrix. Since ICF could not occur during HMG with ITR and this 
substance, ATR-FT-IR results were used to examine the amorphous character of 
ITR and possible interactions with SOLU. Thus, in the present chapter, these re-
sults were integrated in the physico-chemical characterisation. 
IV.7.1. Hot-Melt-Granulation Process Parameters and Processability 
SOLU was especially developed for HME procedures. It shows excellent thermo-
plastic behaviour and is known to result in stable extrudate strands with a variety 
of different die structures. However, in this project, it served as an alternative 
matrix for the developed HMG process and was supposed to be processed as 
similar as possible to the reference sample HMG Trial B. That is why the utilisa-
tion of a die was waived. To keep the ratio of the PM comparable to the reference 
HMG Trial, a drug load of an approximate mass fraction of 38 % was chosen for 
the PM with SOLU and ITR. The investigated HMG process parameters are given 
in Table IV.16.. The flowability of PM with SOLU and ITR was very low with a 
maximum of 178.8 g/h in the hopper. This made it impossible to calibrate the 
desired feeding capacity of 200.6 g/h. During HMG, the feeder was set to 100 % 
throughout the whole procedure. 
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Table IV.16. - HMG processing parameters for HMG Trial SOLU. 
HMG 
Trial 
Z1,°C Z2,°C Z3,°C Z4,°C Z5,°C Z6,°C Z7,°C 
ScS, 
rpm 
Throughput, 
g/h 
Torque, 
% 
SOLU 100 130 170 180 180 180 180 150 max. 178.8 33 
Figure IV.36. shows a picture of the product sampling of HMG Trial SOLU. Since 
no die was present to force material into a specific form, the pasty yield trooped 
up at the die position and could not pass the granulation heel slide. It was neces-
sary to manually pull the product from the mTSE. Upon this, thin strands result-
ed. The thickness of these strands was dependent on the dragging force. During 
HME, it is important to obtain an extrudate strand with defined diameter and in 
regular shape. In the present HMG procedure, however, it was not feasible to 
deem this a priority. Even though the shown process did not really qualify as 
HMG, it was labelled accordingly as HMG Trial SOLU since the processing param-
eters were those of the previous HMGs. As it was impractical to keep the strand-
pulling 100 % accurate during HMG, it was not possible to calculate the average 
throughput by measuring the yielded product over a defined time period. The 
process itself was stable with a torque of 33 %. This was a higher value than for 
the partially molten HMG runs, yet an anticipated result. The polymeric elasticity 
necessitates the higher shear energy not only for mixing and kneading but also 
for conveying the material along the barrel.  
 
Figure IV.36. - Product sampling during HMG process of HMG Trial SOLU. 
The obtained strands were greyish-brown in colour which raised the question of 
possible ITR degradation. Since SOLU is theoretically stable at the applied tem-
peratures (see section III.1.4.) and particularly designed for mTSE operation and 
forming translucent extrudate strands, it was excluded that the change in colour 
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was caused by this component. The amorphisation of ITR had previously shown 
that the white-greyish powder morphed into a brown-greyish liquid and then af-
ter solidification and grinding, appeared in this colour-range without showing any 
signs of degradation in the HPLC. Therefore, it was most likely that this was 
causing the appearance of the strands. This was further elaborated in regard to 
the content analysis. More force was necessary for the manual grinding of this 
polymer sample as the obtained strands were quite stable. 
IV.7.2. Physico-Chemical Characterisation of HMG Trial SOLU 
Same as for all other HMG runs, HMG Trial SOLU was investigated for its physi-
co-chemical properties. Figure IV.37. shows a SEM image of the sample. Smooth 
areas were visible as well as agglomerates. However, it could not be determined 
whether ITR was only dispersed in SOLU or if it was at least partially or fully dis-
solved in the polymer.  
 
Figure IV.37. - SEM image of HMG Trial SOLU; bar = 100 µm. 
The manual grinding yielded particles of different sizes. The determined x50 val-
ue was 190.1 ± 18.2 µm. This was the highest of all samples with an increase of 
63.46 % compared to the largest sample so far (HMG Trial B). Furthermore, sd 
was quite high, undermining the fact that manual grinding of the material result-
ed in an uneven particle size distribution. To investigate the amorphousness of 
ITR, DSC and XRPD analysis were carried out. The DSC trace is shown in 
Figure IV.38.. No Tm of crystalline ITR was visible. Upon magnifying the DSC 
curve (data not shown), a very small, broad signal corresponding to the Tg be-
came visible around 60 - 70 °C. This one signal might have hinted at the pres-
ence of a solid solution where ITR was completely dissolved in SOLU.  
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Figure IV.38. - Excerpt from DSC trace of HMG Trial SOLU; analysis conducted 
from 30 - 200 °C after 2 min holding period at 30 °C; heating rate of 3 K/min. 
However, it was also a possibility that separate Tgs of ITR and SOLU had over-
lapped in the broad signal. This has previously been reported in the literature. 
Singh et al. found that the compression of a ITR/SOLU extrudate could cause 
phase separation which resulted in broadened Tg signals that appeared bimodal 
and overlapping when evaluating the derivative reversing heat flow [158]. In 
contrast to the DSC results shown for all other samples processed above ITR 
Tm (HMG Trial, A, B, WG and HP), no melting endotherm of ITR was detected for 
HMG Trial SOLU. The phenomenon of “cold crystallisation” was also not visible 
here, regardless of the DSC trace magnification. It was probable that the poly-
mer matrix inhibited recrystallisation of ITR altogether and kept it stable in its 
amorphous state. The very low water content of the sample (0.395 %) might 
have been a supporting factor in this, since the presence of water often promotes 
recrystallisation. 
The drug load of this sample was approximately 38 %. It is known that SO-
LU/ITR systems with high drug load can behave differently from systems with 
less ITR. Singh et al. studied extrudates with a 50 : 50 ratio of drug : polymer. 
They observed a melting endotherm of ITR at approximately 159 °C which they 
attributed to small crystalline regions in their sample. However, when investigat-
ing a DSC signal at approximately 110 °C which is in this thesis described as 
“cold crystallisation”, they experienced the same challenges as presented previ-
ously in section IV.4.2.. The very small signal was hard to regard as either endo- 
or exothermic depending on the baseline slope. Yet, they conducted high tem-
perature XRPD measurements and proved the peak to be an exothermic crystalli-
sation signal [158]. These results further supported the previously described ITR 
behaviour during DSC. Zhang et al. also observed a small ITR Tm in ITR/SOLU 
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extrudates which only appeared for the sample with 60 % drug load although no 
diffraction pattern was detectable in XRPD. However, they did not further charac-
terise this occurrence in relation to “cold crystallisation” and concluded that ITR 
was partially crystalline in the extrudate but below the XRPD detection limit. For 
extrudates with a 40 % drug load, they did not observe any melting endotherms 
in DSC [62]. Taking all these literature results into account and comparing them 
to the results obtained in this work, it was concluded that given the drug load of 
38 %, the SOLU matrix kept ITR immobile and hindered its recrystallisation. 
Nonetheless, it could not be determined if HMG Trial SOLU was in fact, a solid so-
lution or a dispersion, whereby generally, the latter would have been much more 
likely. DSC results were also in agreement with the XRPD diffractogram (see Fig-
ure IV.39.). No diffraction pattern could be seen throughout the whole measure-
ment range, only a halo was visible for both, pure SOLU (data not shown) and 
HMG Trial SOLU. 
 
Figure IV.39. - Excerpt from XRPD diffractogram of HMG Trial SOLU. 
For further characterisation of the interactions between SOLU and ITR, ATR-FT-
IR measurements were conducted. Exemplary ATR-FT-IR spectra of pure SOLU, 
PM of SOLU and ITR as well as HMG Trial SOLU are presented in Figure IV.40.. 
Interactions between the polymer and the API were clearly visible. The signals 
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belonging to pure SOLU seemed more dominant in the melt processed sample in 
contrast to PM. This was strongly pronounced for the peak around 1634 cm-1.  
 
Figure IV.40. - Excerpts from ATR-FT-IR spectra of a) pure SOLU, b) PM of SOLU 
and ITR, c) HMG Trial SOLU. 
The signal around 1705 cm-1, corresponding to the ketone group of ITR, was 
shown as a strong peak for PM with the SOLU peak around 1735 cm-1 presenting 
only as a shoulder. This was reversed for HMG Trial SOLU with the peak around 
1705 cm-1 being the shoulder of the more intense peak around 1735 cm-1. Rea-
sons for this behaviour could be found in the organised structure of the melt pro-
cessed sample where there was a stable matrix surrounding and immobilising 
ITR or by the fact that aITR was present after HMG. Yet, the possibility that the 
analysed sample of HMG Trial SOLU consisted of a SOLU-rich phase could not be 
discarded. Singh et al. observed similar SOLU-rich regions during their anal-
yses [158]. To exclude the possibility of ITR degradation being the cause for the 
colour change in the HMG product, content analysis was carried out in triplicate. 
The content of HMG Trial SOLU was 96.04 ± 2.02 %. The fed mixture showed an 
average ITR content of 97.51 ± 5.58 % for ten samples drawn during the HMG 
procedure. This large sd could be ascribed to the poor flowability of the mixture 
which had supported segregation. Especially during the beginning of HMG proce-
dure, the feedstock content was the lowest (87.92 %) and then rose over time. 
Taking these feeder results into account, it was concluded that no product deg-
radation seemed to have occurred for HMG Trial SOLU.  
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IV.7.3. Dissolution Results of HMG Trial SOLU 
The solubilising property of SOLU is often exploited when applying SOLU as ma-
trix in hot-melt processes. Figure IV.41. shows the results of the dissolution test-
ing of HMG Trial SOLU which obviously showed the highest dissolution rate of all 
samples presented so far.  
 
Figure IV.41. - Dissolution results of HMG Trial SOLU; n = 6; error bars = sd. 
After 10 min, ITR dissolution had already reached 96.92 ± 0.38 %. After that 
point, the amount of ITR stayed on the same level until the end of the experi-
ment (100.44 ± 0.41 %). In contrast to all other dissolution analyses, the disso-
lution medium became cloudy quite fast and stayed that way throughout testing. 
This was ascribed to SOLU forming solubilising micelles. The high sd for the first 
sampling point after 2 min (7.99 %) could be explained by the fact that prior to 
the analysis, all samples were manually given into the appropriate dissolution 
vessels as fast as possible before the autosampler was started. That way, there 
was a time inaccuracy of about 15 s between the investigated samples. Appar-
ently, this short time frame had a large impact on the solubilisation velocity of 
SOLU. The absolute amount of dissolved ITR after 4 h was only 2.60 % higher 
compared to the reference sample HMG Trial B (97.89 %). Nevertheless, the dis-
solution rate of HMG Trial SOLU exceeded any other sample by far. These ob-
tained dissolution results were well in line with other reports of SOLU and ITR. 
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Zhong et al. reported 98 % of dissolution for their ITR/SOLU tablet system in HCl 
pH 1.2, whereas Zhang et al. observed dissolution between 80 - 90 % for their 
ITR/SOLU extrudate with 40 % drug load in simulated gastric fluid without pep-
sin. It is noteworthy that the paddle rotation speed was 75 rpm in both of these 
references in contrast to 100 rpm used here [62,86]. 
IV.7.4. Concluding Remarks about HMG Trial SOLU 
This chapter gave insights into the HMG production of a polymer-based sample 
and its characterisation. As section IV.7.1. highlighted, SOLU is not explicitly an 
excipient usable in HMG but rather appropriate for HME where the elastic materi-
al is forced through a die. The process itself was stable, yet it was constantly 
necessary to pull the product strands from the mTSE. Even though this could in-
dustrially be managed by employing a conveyor belt, the collecting of material 
directly at the end of the screws would hardly be manageable in a reproducible 
manner. The need for a die when working with SOLU became apparent.  
Compared to all other samples described so far, the flowability of the SOLU PM 
was by far the worst, making it impossible to reach the desired throughput. The 
variability in feeding was resembled in the content of the produced sample. It is 
advisable to use separate feeding stations when processing ITR and SOLU. Thus, 
only speaking for the process itself, HMG Trial SOLU was inferior to the reference 
sample HMG Trial B. However, when interpreting the results of the physico-
chemical analysis and especially from dissolution testing, it was clearly shown 
that the polymer managed to keep amorphous ITR stable at this given drug load. 
Additionally, it reached nearly quantitative dissolution only after 10 min. This was 
a definite acceleration compared to HMG Trial B (beginning of the plateau phase 
approximately at 120 min). In this regard, there was a very strong superiority of 
HMG Trial SOLU. The sample underwent stability testing to examine this effect 
over time. The scientific relevance of these results will be evaluated in the overall 
conclusion of this project (see section V.), not only because there are many liter-
ature references available for ITR/SOLU formulations but also regarding the like-
lihood of a SOLU-based formulation being used in a marketed product as this - to 
the best of the author’s knowledge - has not been accessible up to date.  
 
Results and Discussion 
 
 
122 
IV.8. Comparison of Hot-Melt Granulation Procedure 
against the Marketed Formulation 
The marketed formulation, Sempera® capsules (see section III.1.2) (SEMP), 
was investigated as comparison against the reference sample HMG Trial B. Due 
to the nature of the marketed product (coated sugar spheres) only chosen tech-
nologies were carried out for sample characterisation. The most vital experiment 
for the comparison with HMG Trial B was the dissolution analysis. 
IV.8.1. Physico-Chemical Characterisation of SEMP and Pellet Disso-
lution 
Since SEMP consists of sugar beads filled in hard gelatin capsules, the pellets 
were emptied from the capsule container for all analyses to increase comparabil-
ity to the reference. That way, the gelatin capsule could not interfere, especially 
during dissolution testing. Weighing of the capsule content gave an average fill-
ing mass of 464 mg per capsule, corresponding to the declared ITR content of 
100 mg. This was a drug load of 21.55 %. Figure IV.42. shows a SEM picture of 
a SEMP pellet. The PEG seal coating was visible on the pellet surface. Most of the 
coating appeared intact. Upon strong magnification, very small ruptures became 
visible. Generally, the surface of the pellet appeared smooth. Based on this im-
age, the analysed pellet had a diameter of about 968 µm which was in the range 
described in the corresponding patents (see section III.1.2.). 
 
Figure IV.42. - SEM image of SEMP pellet; bar = 100 µm. 
The small tears in the seal coating should not have influenced product quality 
as it had to be assumed that the ITR/HPMC coating of the spheres should have 
been intact. This had to be suspected because SEMP is a marketed formulation 
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with a validated shelf life and the investigated sample shown in Figure IV.42. was 
emptied from a recently obtained hard gelatin capsule. Results of DSC analysis of 
SEMP are given in Figure IV.43. and Table IV.17..  
 
Figure IV.43. - Excerpt from DSC trace of SEMP; analysis conducted from 
30 - 200 °C after 2 min holding period at 30 °C; heating rate 3K/min. 
Two endothermic signals were visible at 62.97 °C and 185.62 °C. The first peak 
corresponded to Tm of the PEG seal coating. Unfortunately, this signal would 
most likely have concealed Tg of aITR. The signal at 185.62 °C was ascribed by 
Kapsi et al. to Tm of crystalline ITR dispersed in the HPMC coating [159]. Howev-
er, it seemed more likely that this endothermic event corresponded to Tm of the 
sucrose spheres. The defined Tm of sucrose is given in the literature as 
185.5 °C [160]. This fit the DSC results perfectly and was more probable than a 
shift in Tm for ITR of about 20 °C which – to the best of the author’s knowledge – 
has not been reported regardless of the excipients used. The width of the su-
crose melting peak was obtained by manual integration which caused an inaccu-
racy. It could not be excluded that the sucrose peak might have masked an ear-
lier melting of ITR around its usual Tm, but again, it seemed unlikely due to the 
large difference in temperature.  
Table IV.17. - DSC signals detected for SEMP. 
 SEMP 
Signal, °C 
Onset 
Peak 
 
60.75 
62.97 
 
179.07 
185.62 
Concluding these findings, no Tm distinctively corresponding to ITR was ob-
served regardless of the magnification of the DSC trace. No sign of “cold crystal-
lisation” was visible. It seemed that the HPMC film matrix kept immobilised ITR 
in its amorphous state and hindered recrystallisation. 
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Figure IV.44. presents the results of the dissolution testing of SEMP. The disso-
lution profile obtained showed dissolution of 98.49 ± 4.29 % after 4 h which cor-
responded to the full ITR amount in the sample. The curve progression during 
the first 30 min could be explained by the SEMP formulation.  
 
Figure IV.44. - Dissolution profile of SEM; n = 6; error bars = sd. 
In the beginning, there was a lag time of about 5 min at which point the de-
tected ITR content was 5.90 ± 0.72 %, corresponding to the dissolving of the 
PEG seal coating. After 10 min, 17.01 ± 3.13 % of ITR were dissolved, indicating 
that the HPMC/ITR coating began to dissolve. The curve now showed a steep rise 
and reached dissolution of 94.63 ± 4.74 % after 60 min. Here, the rest of the 
wetted ITR in the HPMC film matrix dissolved. From 60 min on, the dissolution 
profile reached a plateau and fluctuated around 97 - 99 % for the rest of the ex-
periment. This was in excellent agreement with the literature. Kapsi et al. inves-
tigated Sporanox® dissolution in 900 mL simulated gastric fluid at pH 1.4 with 
the paddle apparatus at 100 rpm and observed about 15 % of dissolution after 
10 min and about 70 % after 30 min (compared to 66.00 ± 6.42 % for SEMP). 
After 60 min, about 90 % of ITR was dissolved in their analysis [159]. Sarnes et 
al. investigated Sporanox® dissolution over 60 min under the same conditions as 
shown in this work. They also experienced a lag time which they explained with 
the time necessary for the PEG seal coating to dissolve [161]. The curvature of 
their investigated sample was similar to SEMP. However, they reached 100 % of 
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dissolution at 30 min and 120 % after 60 min which raised questions about 
quantification method or if their investigated sample might have contained more 
than 100 mg of ITR. Comparing SEMP dissolution with the reference sample 
HMG Trial B, it could be stated that the cumulative amount of dissolved ITR after 
4 h was on the same level (98.49 ± 4.29 % vs. 97.89 ± 2.39 %). The beginning 
of the dissolution differed. The dissolved amounts of ITR for HMG Trial B against 
SEMP during the first 60 min of the experiment are shown in Table IV.18..  
Table IV.18. - Amount of dissolved ITR during dissolution testing for 
HMG Trial B (n = 2; error bars = min/max) and SEMP (n = 6; error bars = sd). 
Sampling 
point, min 
Dissolved ITR of 
HMG Trial B, % 
Dissolved ITR of 
SEMP, % 
2  9.72 ± 2.85 2.83 ± 0.44 
5  22.15 ± 3.22 5.90 ± 0.72 
10  34.78 ± 2.90 17.01 ± 3.13 
15  45.96 ± 5.23 25.39 ± 2.03 
30 65.55 ± 2.01 66.00 ± 6.42 
45 76.75 ± 1.67 87.85 ± 7.88 
60 91.90 ± 2.24 94.63 ± 4.74 
HMG Trial B showed faster dissolution until 30 min. At this time, both formula-
tions showed average dissolution of about 65 %. Relatively seen, HMG Trial B 
exhibited 81.02 % more dissolution than SEMP after 15 min which could be of 
therapeutic value. SEMP reached the plateau phase faster than HMG Trial B. 
IV.8.2. Concluding Remarks about SEMP 
This chapter presented the evaluation of the marketed formulation SEMP and 
the comparison against reference sample HMG Trial B. The dissolution results of 
SEMP were as anticipated and showed quantitative ITR dissolution within 60 min. 
This was expected from a marketed formulation. The dissolution profile could be 
explained by the specially formulated sugar spheres. HMG Trial B showed superi-
or dissolution during the first 15 min of the experiment. Remembering the pro-
claimed rapid absorption of ITR from the GIT this could be of therapeutic inter-
est. Apart from this, it can be said that SEMP is a complex pharmaceutical prod-
uct which is produced in various manufacturing steps that include the use of or-
ganic solvents (see section III.1.2.). This was not the case for HMG Trial B that 
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combined the mixing of the excipients with the continuous HMG process plus 
crushing and sieving. All of these processes could be combined with the right 
equipment. Additionally, the drug load of SEMP was approximately 22 % com-
pared to HMG Trial B with about 38 % which was 73 % higher. Nevertheless, dis-
solution properties of SEMP were satisfactory and the DSC analyses did not show 
signs of crystalline ITR. Therefore, SEMP was subjected to testing of storage sta-
bility and will be taken up again in section V. for the overall discussion and de-
nouement of this work. 
IV.9. Ternary Additives as Possible Dissolution Enhancers 
CDs do not show good thermoplastic behaviour which complicates their pro-
cessing within mTSE. Thus, most research conducted in the field of hot-melt pro-
cesses with CDs utilises ternary additives in the formulations such as polymers to 
increase the operability and to potentially further increase drug bioavailability 
and/or dissolution [63,87]. Section IV.7. clearly showed the fastest dissolution 
rate for HMG Trial SOLU, judging from the beginning of the plateau phase in the 
dissolution profile. Although HMG Trial B, the HMG sample with the most suffi-
cient product properties, showed nearly quantitative ITR dissolution after 4 h, it 
was still to be determined if a ternary additive could further enhance the dissolu-
tion rate within the first 30 min to a level comparable to SEMP and 
HMG Trial SOLU.  
The subsequent chapter highlights the influence of ternary additives on HMG 
samples. In that regard, the sugar alcohol xylitol was employed to investigate 
the phenomenon of API displacement from the CD cavity. HMG formulations con-
taining different ratios of xylitol were investigated. Secondly, two typical 
HME/HMG polymers, PEG 6000 and HPMC 4000 were used and evaluated in bina-
ry and ternary form. Due to technical issues as well as time constraints, not all of 
the samples of the following case studies could be evaluated by XRPD, SEM and 
for their βCD content. Thus, these experimental results were omitted in the fol-
lowing chapter, even if they were carried out. By this, the same argumentative 
basis could be applied to all investigated specimen. Foundation of the HMG pro-
cess were the parameters of the reference sample HMG Trial B.  
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IV.9.1. Case Study Polyethylene Glycol 6000 
Due to its frequency of occurrence in research about hot-melt processes with 
ITR, PEG 6000 was chosen to be investigated in one binary and two ternary for-
mulations with ITR and βCD.  
IV.9.1.1. Preparation and Behaviour During Hot-Melt-Granulation of 
Polyethylene Glycol 6000 Blends 
Three different PMs were prepared. Firstly, a binary mixture of ITR and 
PEG 6000 with a drug content of about 38 % in mass corresponding to the binary 
formulations with βCD and ITR (HMG Trial PEG), and secondly, two ternary mix-
tures. These contained mass fractions of 10 % and 20 % 
PEG 6000 (HMG Trial PEG10 and PEG20), referring to the overall mixture, e.g. 
PM in the stoichiometric ratio of 1:1 of ITR and βCD was prepared, resembling 
mass fractions of 80 % or 90 % and was then added up to 100 % with 
PEG 6000. That way, HMG Trial PEG10 and PEG20 showed ideal drug content of 
33.54 % and 30.52 %, respectively. HMG parameters of all three HMG runs of this 
case study are shown in Table IV.19.. 
Table IV.19. - HMG parameters of the case study with PEG 6000. 
HMG 
Trial 
Z1,°C Z2,°C Z3,°C Z4,°C Z5,°C Z6,°C Z7,°C 
ScS, 
rpm 
Throughput, 
g/h 
Torque, 
% 
PEG 100 130 170 180 180 180 180 150 169.9 3 
PEG
10 
100 130 170 180 180 180 180 150 90.0 8.5 
PEG
20 
100 130 170 180 180 180 180 150 213.3 13 
The PMs did not show similar flowability compared to the binary ITR/βCD mix-
ture. The maximum average throughput during calibration of PEG was 299 g/h, 
for PEG10 311 g/h and 324 g/h for PEG20. Interestingly, HMG Trial PEG10 
showed the lowest actual HMG throughput by far with only 90 g/h. Only 
HMG Trial PEG20 could be produced with a throughput above 200.6 g/h which 
was the target (see section IV.4.). PEG 6000 melts at about 60 °C, so during the 
production of HMG Trial PEG, the whole mixture was liquefied, dripped from 
mTSE and hardened in the steel bowl where samples were collected. This did not 
meet the general definition of HMG. However the sample was referred to as 
HMG Trial PEG. The low melt viscosity explained the very low torque of 3 %. Up-
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on leaving mTSE, the product was bubbling as if water vaporisation had not been 
possible through the ventilation port. Otherwise, the process was stable. 
HMG Trial PEG10 and PEG20 exhibited higher torques due to βCD in the mixture 
which increased the formulation’s viscosity. Both of these HMG runs appeared 
slightly inhomogeneous upon leaving mTSE with product that appeared either as 
binary ITR/βCD granules or seemed liquefied due to higher percentage of 
PEG 6000. The ventilation port got stuck a few times during the procedure which 
forced the water to exit the barrel at the granulation heel slide. Nevertheless, the 
general processes of the ternary mixtures were stable. 
IV.9.1.2. Physico-Chemical Characterisation of HMG Trial PEG, PEG10 
and PEG20 
The samples in this case study were evaluated for ITR crystallinity by DSC 
analysis. Moreover, particle size distribution and ITR content were examined. x50 
values of the three different HMG runs after crushing and sieving are given in 
Table IV.20..  
Table IV.20. - Results of particle size measurements for the case study PEG; 
n = 3; ± represents sd. 
 HMG Trial PEG HMG Trial PEG10 HMG Trial PEG20 
x50, µm 161.8 ± 28.6 175.4 ± 13.0 176.1 ± 23.1 
Compared to all other previous HMG runs, the PEG 6000 samples showed high-
er x50 values. This could influence ITR dissolution by decreasing the dissolution 
rate. Additionally, sd was quite high for all three HMG runs. Manual crushing and 
sieving did not yield particles of a precise size. However, comparing 
HMG Trial PEG, PEG10 and PEG20 amongst each other, no substantial difference 
was detected. Thus, differences in dissolution between these three could not be 
ascribed to differences in particle size. 
Results of the DSC analysis are shown in Figure IV.45. and Table IV.21.. 
PEG 6000 has a defined Tm of approximately 60 °C. This endothermic signal was 
visible for all three samples. The most pronounced peak was shown for the bina-
ry HMG run due to the high PEG 6000 content. All melting signals of PEG 6000 
did not appear like one distinctive peak. HMG Trial PEG10 seemed to present two 
overlapping signals and HMG Trial PEG and PEG20 exhibited shoulders to the 
peaks. There were two different explanations for this. Firstly, it is known that 
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PEG 6000 crystallises by forming lamellae that either have their chains folded 
once or twice or are fully extended.  
 
Figure IV.45. - Excerpts from DSC traces of a) HMG Trial PEG, b) HMG Trial PEG10, 
c) HMG Trial PEG20; analysis conducted from 30 - 200 °C after 2 min holding pe-
riod at 30 °C; heating rate 3 K/min. 
Consequently, when melting semi-crystalline PEG 6000, the different folding 
modifications can exhibit different Tms. Wang et al. reported endothermic peaks 
at 56 °C, 59 °C and 63 °C corresponding to that [162]. This hypothesis might 
explain why HMG Trial PEG10 showed the most unpronounced Tm. Having the 
lowest PEG 6000 content, it could have been possible that the least amount of 
PEG 6000 had recrystallised after HMG, giving way to higher amounts of semi-
crystalline lamellae in the system. This explanation also accounted for the results 
of HMG Trial PEG. Due to the large PEG 6000 content and the lack of a third 
component that might have hindered recrystallisation, Tm around 60 °C seemed 
the most distinct. 
Table IV.21. - DSC signals corresponding to ITR melting for the case study PEG. 
 HMG Trial PEG HMG Trial PEG10 HMG Trial PEG20 
ITR signal, °C 
Onset 
Peak 
 
151.85 
155.71 
 
154.41 
160.13 
 
150.64 
157.92 
Nevertheless, the second possibility could have been that ITR Tg which also lies 
around 60 °C overlapped with PEG 6000 melting and caused the peak shoulders. 
Wang et al. found that at drug loads of 40 % ITR in solid dispersions with 
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PEG 6000, only one melting peak for PEG 6000 was detectable. This was ex-
plained by ITR’s ability to influence the folding properties of PEG 6000 [162]. All 
three PEG 6000 samples exhibited broad melting endotherms corresponding to 
ITR. From the detected temperatures, this should have been the earlier men-
tioned polymorph. Upon magnifying the DSC traces, no signals corresponding to 
“cold crystallisation” or liquid mesophases of ITR were observed. Despite that, it 
has been reported that ITR shows this phenomenon in PEG 6000 at higher con-
centrations [162]. Probably it was the case that the “cold crystallisation” signals 
were too small to be detected by the utilised DSC method. No ITR Tm around 
164 - 167 °C was detected which would have suggested stable crystalline ITR in 
Form I. Unfortunately, XRPD analysis could not be conducted to further investi-
gate the possible ITR crystallinity in the HMG samples with PEG 6000.  
When working with ternary PMs, segregation of the components is always an 
important issue. That is why Figure IV.46. not only shows the determined ITR 
contents of HMG Trial PEG, PEG10 and PEG20, but also the average ITR contents 
during mTSE feeding. That way, variations in final content may be explained.  
 
Figure IV.46. - ITR content of HMG Trial PEG, PEG10 and PEG20 during feed-
ing (n = 10) and of the HMG yield (n = 3); error bars = sd. 
For all three samples no ITR degradation was detectable. ITR content of 
HMG Trial PEG, PEG10 and PEG20 was 104.56 ± 1.02 %, 109.69 ± 0.85 % and 
108.83 ± 0.83 %, respectively. ITR content was implausibly high for all three 
samples. At this point, ITR contents during feeding had to be evaluated. For 
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HMG Trial PEG, the average content of fed ITR was 103.12 ± 3.48 %. For HMG 
Trial PEG10 and PEG20 it was 101.77 ± 3.93 % and 106.07 ± 4.83 %. All three 
HMG runs showed high variations during feeding, especially considering that this 
value was derived from ten samples throughout the whole HMG process. For all 
PMs, the average ITR content was above 100 %. It seemed that particularly dur-
ing the filling phase, PEG 6000 had segregated from the mixtures and had been 
hot-melt granulated predominantly. That way, upon product collecting, too much 
of PEG 6000 had already been processed. This was in agreement with the obser-
vations described in section IV.9.1.1.. The lowest variation was shown for the bi-
nary formulation which could be expected. Nonetheless, obviously, it is advised 
to use separate feeding stations for co-processing these two substances. 
IV.9.1.3. Dissolution Results and Inclusion Complex Formation Evalu-
ation of HMG Trial PEG, PEG10 and PEG20 
Dissolution results of HMG Trial PEG, PEG10 and PEG20 are given in 
Figure IV.47.. Interestingly, even though all of these samples were processed 
above Tm of ITR, the reached dissolution was well beyond the level of aITR. The 
only sample to reach dissolution this low after the same heat treatment had been 
HMG Trial WG (see section IV.5.).  
 
Figure IV.47. - Dissolution results of the case study PEG; n = 3; error bars = sd. 
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In the previous subsection, it was not possible to determine whether ITR was 
completely amorphous in these PEG 6000 systems. The dissolution results now 
indicated that this was not the case (maximum dissolution of 18.82 ± 0.63 % af-
ter 4 h for HMG Trial PEG10). This was only 19.23 % of the reference amount by 
sample HMG Trial B. It appeared as if PEG 6000 had not improved ITR dissolution 
at all, but rather supported the production of inhomogeneous melt-granules. 
During the beginning of dissolution, HMG Trial PEG gave the lowest amount of 
dissolved ITR (10.00 ± 0.34 % after 15 min). This could be explained by the fact 
that the other two samples contained βCD which most likely had resulted in 
some ICF during HMG. From 30 min on, the binary formulation HMG Trial PEG 
showed a higher dissolution rate than HMG Trial PEG20 which had already 
reached a plateau. HMG Trial PEG exhibited a slow rise between 30 - 120 min 
from where on its ITR dissolution fluctuated around 15.50 % before finishing at 
15.86 ± 0.58 % after 4 h. This low rise in curvature could have been caused by 
ITR diffusion out of the crystalline PEG 6000 matrix.  
Interestingly, the highest dissolution and dissolution rate were shown by 
HMG Trial PEG10 that had combined βCD and the lowest amount of PEG 6000. 
Compared to HMG Trial PEG (13.66 ± 0.59 % after 4 h), HMG Trial PEG10 
showed 37.78 % enhanced ITR dissolution. Nevertheless, the presence of 
PEG 6000 during HMG did not present the desired effects. Janssens et al. made 
similar experiences for polymeric mixtures of PVPVA 64 and PEG 6000. They 
found that the addition of PEG 6000 to mixtures with 20 % ITR did not show any 
enhancing effect during dissolution testing. They only detected dissolution im-
provement for solid dispersions containing at least 40 % of ITR [163].  
The presented dissolution results showed that PEG 6000 was not helpful in 
keeping ITR amorphous as well as in improving the dissolution and solubility 
rate. Still, the absolute dissolution and the fast dissolution rates for both samples 
containing βCD showed the likelihood of ICF during HMG. Thus, ATR-FT-IR re-
sults were evaluated for further indications of this. It has to be stated however, 
that the addition of a third component to the mixture aggravated the interpreta-
tion of these data even further. Results of the ATR-FT-IR investigation are given 
in Table IV.22.. 
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Table IV.22. - ATR-FT-IR results of the case study PEG 6000, evaluated by com-
parison with reference wave numbers; sd = as ±; n = 3; *n = 5; if wave number 
markers were not detected in every single analysis, the percentage of their oc-
currence is given in brackets below. 
 
PM* 
PMaITR* 
Pure 
PEG 6000 
HMG Trial 
PEG 
HMG Trial 
PEG10 
HMG Trial 
PEG20 
W
a
v
e
 N
u
m
b
e
r
s
, 
c
m
-
1
  
1697.60 ± 0.15 
1698.89 ± 0.33 
X 1698.03 ± 0.20 
1698.78 ± 0.13 
(66.67 %) 
1698.72 ± 0.03 
(66.67 %) 
1584.60 ± 0.25 
(80 %) 
1585.76 ± 0 
(20 %) 
X X X X 
1551.18 ± 0.13 
1552.74 ± 0.27 
X 1551.99 ± 0.11 X X 
1509.80 ± 0.23 
1511.07 ± 0.34 
X 1510.73 ± 0.20 1511.37 ± 0.01 
1511.11 ± 0.05 
(66.67 %) 
1451.20 ± 0.16 
(80 %) 
1451.08 ± 0.21 
1466.71 ± 0.03 1466.60 ± 0.06 
1466.20 ± 0 
(33.33 %) 
X 
1270.96 ± 0.98 
(80 %) 
X 
1279.53 ± 0.11 1278.89 ± 0.11 
1277.94 ± 0 
(33.33 %) 
X 
1227.41 ± 0.59 
1228.55 ± 0.62 
1241.31 ± 0.10 1240.71 ± 0.08 
1230.91 ± 2.14 
(66.67 %) 
1229.21 ± 0.03 
1184.44 ± 0.52 
X 
X 
1184.84 ± 0 
(33.33 %) 
X X 
1140.58 ± 0 
(20 %) 
X 
1147.40 ± 0.14 1147.90 ± 0.06 
1149.28 ± 0.39 
(66.67 %) 
1149.97 ± 0 
(33.33 %) 
1072.64 ± 0.06 
(40 %) 
1077.55 ± 0.36 
(40 %) 
1060.21 ± 0.04 1060.69 ± 0.07 X 1073.66 ± 6.47 
1043.15 ± 0.11 
1042.58 ± 0.95 
(40 %) 
X X X 
1043.19 ± 0 
(33.33 %) 
X 
1028.45 ± 1.81 
(60 %) 
X X 1025.50 ± 0.50 
1027.82 ± 0 
(33.33 %) 
823.82 ± 0.09 
824.74 ± 0.72 
X 
825.44 ± 0.06 
(66.67 %) 
X X 
Pure PEG 6000 showed wave bands in regions that overlapped with chosen 
marker wave bands, such as around 1466 cm-1, 1279 cm-1, 1241 cm-1 or 
1060 cm-1. Comparing the results of pure PEG 6000 with HMG Trial PEG, no sub-
stantial shifts in the given wave numbers were seen. This hinted at low interac-
tions between the polymer and ITR. As the DSC analyses had already shown, 
PEG 6000 and ITR did not form a solid solution. Consequently, this was ex-
pected. This lack of interaction with APIs has been reported for PEG 6000 with 
other drugs as well, such as indomethacin or zolpidem [91,164]. 
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It was hard to determine if ITR was amorphous in the samples due to marker 
wave numbers such as 1270 cm-1 and 1140 cm-1 overlapping with pure PEG 6000 
signals. Taking a look at HMG Trial PEG10 and PEG20, it was interesting that the 
signal around 1698 cm-1 was not detected in all single measurements. This hinted 
at PEG 6000 chains shielding the ketone group. Apart from this, it was intriguing 
that there were differences observed between these two samples. No peak was 
observed for HMG Trial PEG10 around 1072 cm-1 in contrast to HMG Trial PEG20. 
Still, the high sd (1073.66 ± 6.47 cm-1) showed that no distinct wave band had 
been detected. Rather, either a peak around 1060 cm-1 originating from PEG 6000 
or the ITR peak around 1077 cm-1 were observed. Both samples lacked the signal 
around 825 cm-1. This had not been seen for any previously studied sample. 
Probably, PEG 6000 chains shielded this functional group from the laser beam as 
well. Generally, ATR-FT-IR results failed to determine ICF because of the various 
possible interferences that prevented a profound statement. 
IV.9.1.4. Outcome of Case Study Polyethylene Glycol 6000 
After close investigation of the samples it can be stated that PEG 6000 did not 
positively influence the developed HMG formulation. The solubility rate and abso-
lute ITR dissolution were not substantially enhanced, neither by the binary nor 
the ternary formulations. PEG 6000 failed to keep ITR amorphous. Processing 
with the mTSE was mostly stable, however, it was shown that the PMs had seg-
regated in the feeder. 
IV.9.2. Case Study Hydroxypropyl Methylcellulose 
As reported in section III.1.2., Sporanox® capsules are coated with a 
HPMC 2910/ITR solution. Therefore, much research has been conducted examin-
ing ITR together with HPMC 2910 [60,108,109,165]. In this project, another 
common quality of HPMC, HPMC 4000, was investigated as possible ternary addi-
tive during HMG. HPMC 4000 can be used as matrix component e.g. in tablets for 
sustained release due to its swelling in water. Furthermore, it can be utilised as 
seal coating for IR tablets. Thus, the addition of mass fractions of 10 % and 
20 % of HPMC 4000 (HMG Trial HPMC10 and HPMC20) to the ITR/βCD blend was 
examined. For comparative purposes, a binary formulation of HPMC 4000 and 
ITR was also hot-melt granulated (HMG Trial HPMC). Foundation of the HMG pro-
cess was again the reference sample HMG Trial B. 
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IV.9.2.1. Preparation and Behaviour During Hot-Melt Granulation of 
Hydroxypropyl Methylcellulose Blends 
Same as for the case study with PEG 6000, three different powder blends were 
prepared. Firstly, a binary formulation of HPMC 4000 and ITR with a drug load of 
approximately 38 %. Secondly, mass fractions of 10 % and 20 % of HPMC 4000 
were added to a binary blend of ITR and βCD, resulting in theoretical drug loads 
of 34.47% and 30.55 %. HMG parameters of all three HMG runs of this case 
study are given in Table IV.23.. 
Table IV.23. - HMG parameters of the case study with HPMC. 
HMG 
Trial 
Z1,°C Z2,°C Z3,°C Z4,°C Z5,°C Z6,°C Z7,°C 
ScS, 
rpm 
Throughput, 
g/h 
Torque, 
% 
HPMC 100 130 170 180 180 180 180 150 200.7 9 
HPMC
10 
100 130 170 180 180 180 180 150 165.2 6 
HPMC
20 
100 130 170 180 180 180 180 150 234.7 13 
Flowability of all three blends was sufficient compared to PM of ITR and βCD. 
This resulted in generally satisfactory throughputs. However, HMG Trial HPMC10 
showed the lowest average of the three mixtures with 165.2 g/h. During HMG of 
the binary formulation, the screws were screeching. HPMC 4000 was neither 
melted nor had become more elastic at the operating temperatures. The yielded 
product appeared similar to binary ITR/βCD granules. HMG Trial HPMC10 seemed 
inhomogeneous during HMG. While in the beginning, the product was powder-
like, in the end it looked more like the binary product, partially molten granules. 
This was in agreement with the lower throughput that could have also indicated 
segregation of PM. Screw screeching was not as pronounced for this sample. This 
was also the case for HMG Trial HPMC20 which exhibited the highest torque dur-
ing HMG. During this HMG run, the ventilation port got stuck a few times during 
operating. Otherwise the process was stable. Generally, it was possible to melt-
granulate the binary and ternary formulations with HPMC 4000. Nevertheless, 
screeching of the screws indicated that the molten ITR’s lubricating effect was 
not as sufficient as had been observed for the binary reference formulation, 
HMG Trial B. 
Results and Discussion 
 
 
136 
IV.9.2.2. Physico-Chemical Characterisation of HMG Trial HPMC, 
HPMC10 and HPMC20 
The three HPMC formulations were investigated for their physico-chemical 
properties. Table IV.24. presents the mean x50 values for HMG Trial HPMC, 
HPMC10 and HPMC20. The binary HPMC 4000 formulation showed the largest x50 
with 162.2 ± 1.1 µm. This could potentially slow down ITR dissolution rate. The 
x50 value of HMG Trial HPMC10 showed quite high sd of 8.00 µm. This could have 
indicated inhomogeneities in the product. 
Table IV.24. - Results of particle size analysis for case study HPMC 4000; n = 3; 
± = sd. 
 HMG Trial HPMC HMG Trial HPMC10 HMG Trial HPMC20 
x50, µm 162.2 ± 1.1 137.0 ± 8.00 91.1 ± 4.3 
To investigate the possible amorphousness of ITR, DSC measurements were 
carried out. The DSC traces of the three samples are given in Figure IV.48., the 
DSC signals corresponding to melting of ITR in Table IV.25.. All three HPMC sam-
ples showed two Tm of ITR, corresponding to the most stable crystalline form and 
the defined polymorph. Upon magnifying the DSC traces (data not shown), signs 
of “cold crystallisation” became visible slightly above 100 °C as well as endother-
mic signs of the liquid mesophases of ITR around 70 °C and between 80 - 90 °C.  
 
Figure IV.48. - Excerpts from DSC traces of a) HMG Trial HPMC, 
b) HMG Trial HPMC10, c) HMG Trial HPMC20, analysis conducted from 
30 - 200 °C after 2 min holding period at 30 °C; heating rate 3 K/min. 
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Table IV.25. - DSC signals corresponding to ITR melting of case study HPMC. 
 HMG Trial HPMC HMG Trial HPMC10 HMG Trial HPMC20 
ITR signal, °C 
Onset 
Peak 
 
155.02 
156.49 
 
161.75 
164.54 
 
155.31 
156.50 
 
162.74 
164.10 
 
154.61 
156.13 
 
161.21 
164.23 
Interestingly, right before the first ITR Tm, there was a very small third event in 
the DSC trace. For the binary formulation this third event happened at 
150.74 °C. However, the distinction was hard if this event really was endo- or 
exothermic as the signal grew out of the rising slope of the DSC trace and then 
fell slightly down again before giving rise to Tm around 155 °C. It seemed to be 
the same difficulty as was previously reported for the characterisation of “cold 
crystallisation”. The detected liquid mesophases proved the presence of glassy 
ITR in the samples. Otherwise, the presence of crystalline ITR could not be ex-
cluded completely. This had to be suspected especially for HMG Trial HPMC10, 
since the peak area at 164.10 °C was distinctively larger than for the other two 
samples. Figure IV.49. shows the analysed ITR content of all three HPMC 4000 
samples after HMG and also during mTSE feeding to investigate possible segre-
gation of the PMs. No ITR degradation was observed.  
 
Figure IV.49. - ITR content of HMG Trial HPMC, HPMC10 and HPMC20 during 
mTSE feeding (n = 10) and of the melt-granulated yield (n = 3); error bars = sd. 
ITR content of HMG Trial HPMC, HPMC10 and HPMC20 was 94.44 ± 2.53 %, 
92.64 ± 2.33 % and 102.57 ± 2.51 %, respectively. Taking into account the ITR 
content during feeding, the reason for these values became obvious. All three 
0
10
20
30
40
50
60
70
80
90
100
110
HMG Trial
HPMC
HMG Trial
HPMC10
HMG Trial
HPMC20
I
tr
a
c
o
n
a
z
o
le
 C
o
n
te
n
t,
 %
 
Feeding HMG Run
Results and Discussion 
 
 
138 
HPMC samples exhibited sd above 4.8 % during feeding (95.35 ± 4.88 % for 
HMG Trial HPMC, 95.46 ± 7.19 % for HMG Trial HPMC10 and 102.68 ± 5.16 % 
for HMG Trial HPMC20). This again stressed the need for utilising at least a sec-
ond feeding station. HMG Trial HPMC10 which had appeared most inhomogene-
ous during HMG exhibited the largest sd during feeding. These results agreed 
with each other. The too high content of HMG Trial HPMC20 could also be ex-
plained by investigating the feeding content. Segregation of HPMC 4000 or βCD 
seemed to have occurred during the filling phase. 
IV.9.2.3. Dissolution Results and Inclusion Complex Formation Evalu-
ation of HMG Trial HPMC, HPMC10 and HPMC20 
Of utmost interest were the dissolution results of all three HPMC samples which 
are given in Figure IV.50.. All three HPMC samples reached quantitative ITR disso-
lution after 4 h. 97.83 ± 6.37 % ITR dissolution was shown for HMG Trial HPMC. 
HMG Trial HPMC10 and HPMC20 achieved 104.87 ± 0.60 % and 97.92 ± 4.74 %, 
respectively. 
 
Figure IV.50. - Dissolution results of case study HPMC 4000; n = 3; error bars = sd. 
The fact that HMG Trial HPMC10 showed ITR dissolution above 100 % up from 
60 min could be explained by the high sd in the content analysis. It might have 
been that the studied samples were not completely homogenous. This most likely 
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also explained the high variations for the binary system. When it came to the 
amount of dissolved ITR of all samples, it seemed that ITR was mostly amor-
phous in all systems. Interestingly, different curve progressions were observed 
for the three samples. HMG Trial HPMC showed a near zero-order like dissolution 
profile. The amount of dissolved ITR rose slowly. This was in agreement with 
HPMC 4000 being a swelling matrix and sustaining ITR dissolution. ITR had to 
diffuse through the swollen layer before dissolving in the dissolution medium. 
HPMC 4000 might have also slightly increased the viscosity of the dissolution 
medium. Of further importance were the dissolution profiles of the ternary sys-
tems as both of them showed substantially faster ITR dissolution rates. 
HMG Trial HPMC20 reached a plateau after 90 min with ITR dissolution of 
97.37 ± 3.06 %. HMG Trial HPMC10 showed the fastest ITR dissolution rate. 
Here, the plateau phase already began at 45 min (100.96 ± 0.82 %). This could 
be explained by the facts that HMG Trial HPMC20 with the higher HPMC 4000 
content formed a larger diffusion layer and/or further increased viscosity. The 
latter, however, was less likely, as Loftsson et al. reported only a negligible in-
crease in viscosity for an aqueous solution of 0.05 wt/v % HPMC 4000 at room 
temperature [166]. The HPMC 4000 concentration of HMG Trial HPMC20 in the 
dissolution vessel was 0.0074 wt/v % at maximum. HMG Trial HPMC20 present-
ed a slow rise in the dissolution curve between 30 - 90 min (from 
66.14 ± 7.33 % to 97.37 ± 3.06 %). During this time period, ICs were forming 
in the dissolution vessel. This slow rise was not observed for HMG Trial HPMC10. 
Here, the increase of the dissolution curve was steeper.  
Comparing all these dissolution results to the reference sample HMG Trial B, it 
became obvious that all dissolution curves gave nearly the same endpoint after 
4 h (97.89 ± 2.39 % for HMG Trial B). The curve progressions, however, were 
different. The binary HPMC 4000 formulation showed the slowest dissolution rate. 
During the first 15 min, HMG Trial HPMC10 and HPMC20 stayed on the same lev-
el as HMG Trial B but after that, they both showed superior dissolution rates. 
HMG Trial B had reached the dissolution plateau of 96.11 ± 2.14 % after 
120 min. This time was reduced by 62.5 % and 25 % by HMG Trial HPMC10 and 
HPMC20, respectively. This might hold therapeutic value and showed that the 
addition of HPMC 4000 to a binary mixture of βCD and ITR increased the in-vitro 
dissolution rate. Nevertheless, these results also indicated that the addition of 
too much HPMC 4000 delayed the dissolution. Rambali et al. also found that the 
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addition of a low viscosity HPMC to a mixture of ITR and HPβCD significantly in-
creased ITR solubility after HME. They reported the highest solubility for a 
HPMC:HPβCD:ITR system in the ratio of 17:60:23 [110]. 
ATR-FT-IR analysis was used to determine ICF in the case study samples. Re-
sults are shown in Table IV.26.. Regarding the marker wave numbers, pure 
HPMC 4000 only presented one wave band interfering around 1054 cm-1.  
Table IV.26. - ATR-FT-IR results of the case study HPMC, evaluated by compari-
son with reference wave numbers; sd = ±, n = 3, *n = 5; if wave number mark-
ers were not detected in every single analysis, the percentage of their occur-
rence is given in brackets below. 
 
PM* 
PMaITR* 
Pure 
HPMC 4000 
HMG Trial 
HPMC 
HMG Trial 
HPMC10 
HMG Trial 
HPMC20 
W
a
v
e
 N
u
m
b
e
r
s
, 
c
m
-
1
  
1697.60 ± 0.15 
1698.89 ± 0.33 
X 1699.72 ± 0.22 1699.37 ± 0.37 1699.52 ± 0.38 
1584.60 ± 0.25 
(80 %) 
1585.76 ± 0 
(20 %) 
X 1585.70 ± 0.05 
1585.43 ± 0.03 
(66.67 %) 
1585.50 ± 0.18 
1551.18 ± 0.13 
1552.74 ± 0.27 
X 1552.57 ± 0.06 1552.41 ± 0.06 1552.40 ± 0.05 
1509.80 ± 0.23 
1511.07 ± 0.34 
X 1510.86 ± 0.02 1510.88 ± 0.13 1510.93 ± 0.16 
1451.20 ± 0.16 
(80 %) 
1451.08 ± 0.21 
X 1451.13 ± 0.07 1450.85 ± 0.25 1451.04 ± 0.07 
1270.96 ± 0.98 
(80 %) 
X 
X 
1271.80 ± 0.02 
(66.67 %) 
1271.73 ± 0.10 
(66.67 %) 
X 
1227.41 ± 0.59 
1228.55 ± 0.62 
X 1228.23 ± 0.09 1228.44 ± 0.17 1228.74 ± 0.04 
1184.44 ± 0.52 
X 
X 1183.68 ± 0.11 
1184.58 ± 0 
(33.33 %) 
X 
1140.58 ± 0 
(20 %) 
X 
X 
1137.79 ± 0.25 
(66.67 %) 
1152.44 ± 0.22 1152.44 ± 0.12 
1072.64 ± 0.06 
(40 %) 
1077.55 ± 0.36 
(40 %) 
X X 1077.53 ± 0.16 1077.19 ± 0.06 
1043.15 ± 0.11 
1042.58 ± 0.95 
(40 %) 
1054.23 ± 0.72 1042.10 ± 0.54 X X 
X 
1028.45 ± 1.81 
(60 %) 
X X 1026.35 ± 0.70 1027.40 ± 0.16 
823.82 ± 0.09 
824.74 ± 0.72 
X 825.03 ± 0.17 825.18 ± 0.22 825.48 ± 0.17 
However, interpretation of the melt processed specimen was challenging as 
many signals that had previously disappeared after HMG above ITR Tm were de-
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tected, such as around 1585 cm-1 or 1184 cm-1. The peak around 1699 cm-1 was 
observed in every sample containing ITR. The results indicated that ITR was pre-
sent in both, crystalline and amorphous form. A shift from around 1072 cm-1 to 
1077 cm-1 was observed for HMG Trial HPMC10 and HPMC20. The wave band 
around 1271 cm-1 was not observed in every ATR-FT-IR run of HMG Trial HPMC 
and HPMC10 and not at all for HPMC20. Both samples containing βCD exhibited 
the wave band around 1027 cm-1 which showed interactions between ITR and 
βCD. Nevertheless, due to the partial presence of aITR and the addition of a third 
component, these results could not be utilised for clearly detecting ICs. The fast 
dissolution rates, however, strongly supported ICF during HMG. Still, it was not 
possible to determine if the faster dissolution rates were caused by improved ICF 
due to the HPMC 4000 presence, more stabilised glassy ITR in the samples or by 
additional mechanisms of the polymer. 
IV.9.2.4. Outcome of Case Study Hydroxypropyl Methylcellulose  
The second case study clearly showed that the dissolution rate of ITR could be 
increased by adding HPMC 4000. The binary HPMC 4000 formulation showed sus-
tained dissolution as had been expected. The addition of 10 % HPMC 4000 in 
mass showed more satisfactory results than a mass fraction of 20 % of 
HPMC 4000. The processing of the PMs was not ideal at the chosen temperature 
range. Additionally, feeding of the three-component systems should rather be con-
ducted with separate hoppers. 
IV.9.3. Case Study Xylitol 
Lastly, xylitol was investigated as ternary additive. It is known that different 
substances in the intestinal fluids can theoretically displace APIs from the CD 
cavity by becoming guest molecules themselves. This has e.g. been investigated 
in-vitro for ICs of ITR and HPβCD by Stappaerts et al. [167]. As a small, hydro-
philic molecule, it should be theoretically possible for xylitol to get included in the 
βCD cavity. Apart from this, xylitol has previously been investigated regarding its 
potential for improving dissolution rates. These two circumstances made it an in-
teresting third component in this case study. Again, basis for the HMG procedure 
was the temperature profile of the reference sample HMG Trial B. 
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IV.9.3.1. Preparation and Behaviour During Hot-Melt Granulation of 
Xylitol Blends 
Same as for the other two case studies, PMs were prepared. The binary formu-
lation of xylitol and ITR showed a drug load of approximately 38 % , the blend 
with 10 % in mass of xylitol 35.11 % and the blend with 20 % in mass of xylitol 
30.82 %. HMG parameters for the three samples are given in Table IV.27.. 
Table IV.27. - HMG parameters of the case study with xylitol. 
HMG 
Trial 
Z1,°C Z2,°C Z3,°C Z4,°C Z5,°C Z6,°C Z7,°C 
ScS, 
rpm 
Throughput, 
g/h 
Torque, 
% 
XYL 100 130 170 180 180 180 180 150 214.1 4 
XYL10 100 130 170 180 180 180 180 150 178.6 18 
XYL20 100 130 170 180 180 180 180 150 191.6 11.5 
All three mixtures showed sufficient flowability in the feeder. However, tenden-
cy to segregate was already visually observed. HMG of the binary formulation 
was generally stable with a very low torque of 4 %. As xylitol melts slightly 
above 90 °C, both components should have been completely molten. Still, the 
product appeared inhomogeneous as it was partially liquid and partially pasty. 
This could have related to possible segregation of PM and to very short residence 
time of the material in the barrel so that the substances could not fully melt.  
HMG of the two ternary systems was very similar. Both products seemed seg-
regated. Especially for HMG Trial XYL20, colour changes were observed during 
HMG. As previously reported, aITR was slightly brown-greyish in colour. During 
sample collection of HMG Trial XYL20, the product at the beginning appeared 
whiter. After a while, the melt-granules seemed to contain more aITR judged by 
a slight darkening in colour. Water vaporisation through the ventilation port was 
not working sufficiently for HMG Trial XYL10 where steam evaporated through 
the mTSE exit. The products of the ternary formulations appeared almost chew-
ing-gum like at some points (see Figure IV.51.). This elastic property could be 
ascribed to xylitol and most likely presented itself in inhomogeneous granule 
parts consisting of too much xylitol. 
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Figure IV.51. - Image of the HMG procedure of HMG Trial XYL20; granulation 
heel slide was removed for better visualisation. 
 
IV.9.3.2. Physico-Chemical Characterisation of HMG Trial XYL, XYL10 
and XYL20 
All samples of the xylitol case study were physico-chemically analysed. Particle 
size measurements were carried out to exclude possible changes in the dissolution 
rate being caused by larger surface areas. Results are shown in Table IV.28.. 
Table IV.28. - Results of the particle size measurements of the case study with 
xylitol; n = 3; ± = sd. 
 HMG Trial XYL HMG Trial XYL10 HMG Trial XYL20 
x50, µm 154.7 ± 16.3 164.1 ± 2.4 149.8 ± 4.0 
No substantial difference could be observed for the three samples as all showed 
x50 values well above 100 µm. HMG Trial XYL10 exhibited the largest particles. 
The binary formulation showed the largest sd with 16.3 µm. This could be related 
to the suspected inhomogeneity. No large differences in dissolution rate should 
have been expected judging from these results. To determine the possible crys-
tallinity of the samples, DSC measurements were conducted. Results are given in 
Figure IV.52. and Table IV.29.. Upon inspecting the DSC traces, a clear differ-
ence was detectable between the binary formulation and the two ternary sys-
tems. There was a distinct peak at 91.53 °C corresponding to Tm of xylitol. The 
sugar alcohol had recrystallised after HMG. The ternary systems did not show 
this signal which indicated that xylitol had stayed amorphous. The incorporation 
in the βCD matrix seemed to have hindered recrystallisation. Two Tms corresponding 
to ITR were observed for all samples. Upon magnifying the DSC traces (data not 
shown), two endothermic signals correlating to the ITR mesophases became visi-
ble between 70 - 80 °C and between 80 - 90 °C for HMG Trial XYL10 and XYL20. 
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HMG Trial XYL only showed one endothermic event between 70 - 80 °C. The sec-
ond endothermic event was most likely overlapping with Tm of xylitol. 
 
Figure IV.52. - Excerpts from DSC curves of a) HMG Trial XYL, 
b) HMG Trial XYL10, c) HMG Trial XYL20; analyses conducted from 30 - 200 °C 
after 2 min holding period at 30 °C; heating rate 3 K/min. 
DSC curves of HMG Trial XYL10 and XYL20 showed signs of “cold crystallisa-
tion” around 110 °C. This was not observed for the binary system. For 
HMG Trial XYL10 and XYL20, the second ITR Tm was 25.20-fold and 2.95-fold 
larger area-wise than the first peak around 155 °C. In contrast, for the binary 
system, the peak at 153.24 °C was 2.44-fold larger than the second event. Even 
though it was previously reported that different recrystallisation events could 
possibly happen during heating of glassy ITR, it still seemed unlikely that most of 
the polymorphic ITR had directly recrystallised. Rather, it had to be assumed that 
ITR was partially crystalline in the ternary systems. As xylitol in these formula-
tions was kept amorphous, it was possible that βCD could not hinder further re-
crystallisation of the API. 
Table IV.29. - DSC signals corresponding to ITR melting for case study xylitol. 
 HMG Trial XYL HMG Trial XYL10 HMG Trial XYL20 
ITR signal, °C 
Onset 
Peak 
 
151.36 
153.24 
 
158.75 
161.59 
 
152.16 
154.73 
 
159.95 
164.07 
 
155.29 
156.41 
 
162.68 
164.92 
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Since PMs appeared segregated during HMG, ITR content evaluation of the fin-
ished products as well as of the fed PM was carried out. Results are presented in 
Figure IV.53.. As already seen in DSC results, the binary formulation stood out 
again. Segregation of the PM was clearly proven with an average fed ITR content 
of 79.60 ± 14.91 %. It has to be added that during blending of the binary PM, it 
was already visually observable that ITR was strongly attached to the blending 
vessel which corresponded well with the fact that apparently, a large amount of 
ITR had been lost before PM had been filled into the hopper. 
 
Figure IV.53. - ITR content of HMG Trial XYL, XYL10 and XYL20 during mTSE 
feeding (n = 10) and of the yielded products (n = 3); error bars = sd. 
Inspecting the individual results, a trend became visible. At HMG beginning, the 
lowest ITR amounts were fed. The highest ITR content was determined for the 
last inspected sample. Xylitol segregated from PM and was melt-granulated pre-
dominantly. This varying feeding led to ITR content of 65.40 ± 3.15 % for the 
finished product. This might explain the DSC results of the binary formulation. If 
less ITR was present, the amount of crystalline ITR would be smaller. Additional-
ly, xylitol might have been able to keep ITR amorphous at this low content. The 
average ITR content during feeding was 104.08 ± 2.78 % and 97.46 ± 3.00 % 
for HMG Trial XYL10 and HMG Trial XYL20, respectively. This resulted in contents 
of 100.72 ± 5.11 % and 100.56 ± 0.92 % for the respective products. The same 
observation already made for the other two case studies applied again, it defi-
nitely had to be advised to use separate feeders. 
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IV.9.3.3. Dissolution Results and Inclusion Complex Formation Evalu-
ation of HMG Trial XYL, XYL10, XYL20 
Dissolution testing was carried out for the three xylitol formulations. Results are 
given in Figure IV.54.. The content analysis of HMG Trial XYL had shown high 
variations coupled with a very low ITR content. This resulted in high deviations 
determined for the ITR dissolution experiments.  
 
Figure IV.54. - Dissolution results for the case study xylitol; n = 3; error bars = sd. 
HMG Trial XYL reached about 46.33 ± 7.35 % ITR dissolution after 4 h. The 
curve progression showed a long rise. It appeared as if ITR was amorphous. 
However, xylitol did not influence the dissolution rate positively. Comparing 
HMG Trial XYL10 and XYL20, the suspected results of the DSC analysis were con-
firmed. HMG Trial XYL10 reached ITR dissolution of 39.18 ± 3.43 % after 4 h. 
This plateau was already reached after 30 min. ICF in the dissolution vessel did 
not seem to occur. The high variations of HMG Trial XYL10 could be correlated to 
the high determined variation in the content analysis (5.11 %; see Fig-
ure IV.53.). This low dissolution and fast reached plateau supported the presence 
of at least partially crystalline ITR. Three individual samples of HMG Trial XYL10 
were investigated. By inspecting these dissolution curves closely, it became ap-
parent that the determined ITR content at the end of the experiment was always 
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lower than the detected maximum (49.06 %  40.44 %, 48.37 %  41.81 %, 
38.33 %  35.30 %). This upheld the theory of competition for the βCD cavity. 
ITR could precipitate when dissolved xylitol displaced it from the cavity. Interest-
ingly, this phenomenon was not seen for HMG Trial XYL20. This sample showed 
highest ITR dissolution. After 4 h, 77.26 ± 1.68 % of ITR had dissolved. This was 
more than was experienced for aITR (61.71 ± 0.67 %, see section IV.3.) and 
strongly indicated ICF during HMG. The plateau phase of the dissolution was 
reached after 45 min which was faster than for the reference sample 
HMG Trial B. However, the final ITR dissolution was 21.07 % less than for the 
reference. An explanation for this might have been partially crystalline ITR or in-
sufficient ICF in the sample due to the presence of xylitol. 
To gain deeper understanding in possible ICF, ATR-FT-IR measurements were 
conducted. The obtained results are given in Table IV.30.. Pure xylitol did show 
wave bands interfering with the marker peaks, such as around 1279 cm-1. Judg-
ing from the ATR-FT-IR results, it seemed as if HMG Trial XYL10 would have con-
tained more aITR than crystalline. Most of the previously defined wave bands 
that disappeared upon amorphisation were not observed for HMG Trial XYL10, 
but in contrast, detected for HMG Trial XYL20. However, it could not be deter-
mined how much of this was influenced by the presence of xylitol. Xylitol in the 
βCD cavity could e.g. have negated the shielding ability for the functional groups 
of ITR. HMG Trial XYL20 showed the highest wave number around 1077.68 cm-1. 
This signal had previously been put in connection with ICF. HMG Trial XYL20 also 
presented a signal at 1153.80 cm-1 which had not been reported before. The sig-
nal around 825 cm-1 was not observed for HMG Trial XYL10, probably due to 
shielding by the xylitol molecules. Moreover, the signal around 1700 cm-1 was 
only detected once. This also supported xylitol lowering the interactions between 
ITR and βCD. Generally, the ATR-FT-IR results pointed out differences between 
the samples, but a distinct determination of ICF was not possible with the inter-
fering third component. 
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Table IV.30. - ATR-FT-IR results of the case study xylitol, evaluated by compari-
son with reference wave numbers; sd = ±, n = 3, *n = 5; if wave number mark-
ers were not detected in every single analysis, the percentage of their occur-
rence is given in brackets below. 
 
PM* 
PM aITR* 
Pure 
Xylitol 
HMG Trial 
XYL 
HMG Trial 
XYL10 
HMG Trial 
XYL20 
W
a
v
e
 N
u
m
b
e
r
s
, 
c
m
-
1
  
1697.60 ± 0.15 
1698.89 ± 0.33 
X 1700.00 ± 1.50 
1700.48 ± 0 
(33.33 %) 
1699.35 ± 0.31 
1584.60 ± 0.25 
(80 %) 
1585.76 ± 0 
(20 %) 
X 
1585.58 ± 0.10 
(66.67 %) 
X 1585.76 ± 0.09 
1551.18 ± 0.13 
1552.74 ± 0.27 
X 1552.34 ± 0.11 X 1552.53 ± 0.08 
1509.80 ± 0.23 
1511.07 ± 0.34 
X 1510.79 ± 0.11 
1511.53 ± 0 
(33.33 %) 
1511.08 ± 0.11 
1451.20 ± 0.16 
(80 %) 
1451.08 ± 0.21 
X 1450.63 ± 0.06 X 1450.90 ± 0.01 
1270.96 ± 0.98 
(80 %) 
X 
1279.27 ± 0.32 
1276.91 ± 0 
(33.33 %) 
X 1271.64 ± 0.09 
1227.41 ± 0.59 
1228.55 ± 0.62 
1230.13 ± 0 
(33.33 %) 
1229.16 ± 0.19 1229.46 ± 0.16 1228.34 ± 0.17 
1184.44 ± 0.52 
X 
X X X 1183.01 ± 0.32 
1140.58 ± 0 
(20 %) 
X 
1124.37 ± 0.88 1123.84 ± 0.11 X 1153.80 ± 0.06 
1072.64 ± 0.06 
(40 %) 
1077.55 ± 0.36 
(40 %) 
1087.15 ± 1.03 
1065.32 ± 1.07 
1065.90 ± 0.09 
1075.77 ± 0.19 
1066.10 ± 0.04 
1077.68 ± 0.12 
1043.15 ± 0.11 
1042.58 ± 0.95 
(40 %) 
X 
1057.64 ± 0 
(33.33 %) 
1055.07 ± 3.07 X 
X 
1028.45 ± 1.81 
(60 %) 
1027.64 ± 0 
(33.33 %) 
1027.93 ± 0.01 1027.88 ±0.03 1025.25 ± 0.09 
823.82 ± 0.09 
824.74 ± 0.72 
X 825.33 ± 0.27 X 825.19 ± 0.05  
 
IV.9.3.4. Outcome of Case Study Xylitol 
This third case study again showed that segregation was a valid problem, not 
only when operating with ternary PMs. Xylitol failed to further enhance ITR disso-
lution or solubility rate compared to the reference sample HMG Trial B. Addition-
ally, for the addition of 10 % xylitol in mass, indications for cavity competition 
and displacement as well as ITR precipitation were observed.  
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IV.9.4. Concluding Remarks About the Addition of Ternary Additives 
Three different case studies were presented that dealt with the addition of hy-
drophilic polymers and a sugar alcohol to the binary ITR/βCD formulation. Gen-
erally, it could be concluded that the detection of ICs in these ternary samples 
was more challenging, if not impossible. Due to interferences, ATR-FT-IR results 
were not useful in determining ICF. Solely the dissolution results could be inter-
preted for this. Furthermore, here it was questionable which amount of dissolved 
ITR could be ascribed to ICs, aITR and then, the addition of the third substance. 
The satisfactory dissolution results for the addition of 10 % and 20 % in mass of 
HPMC 4000 could also be explained by HPMC 4000 improving the wettability of 
ITR or maintaining more stable aITR.  
Apart from this, it is also reported that water-soluble polymers tend to form 
complexes with drugs themselves in aqueous solution [168]. Savolainen et al. 
found that the addition of HPMC to an oral glibenclamide formulation made it 
possible to reduce the necessary amount of CD due to synergistic effects. They 
further reported that the addition of HPMC did not change the PSM results re-
garding the proposed complex stoichiometry [169]. Nevertheless, the addition of 
polymers can positively influence the IC stability constant and CE [166]. All the 
polymeric mechanisms of interaction such as electrostatic bonds, Van-der-Waals 
forces or hydrogen bonds work together with the mechanisms influencing the in-
clusion complexation of the API. The determined drug solubility then shows the 
outcome of these synergistic couplings. As the results of the HPMC 4000 case 
study clearly showed, this synergism had occurred and optimised ITR dissolution 
and dissolution rate. It may be fair to say that the exact determination of ICs 
was not of that much interest when discussing these ternary formulations and 
their properties as a whole.  
To conclude, two of the presented case studies failed to yield sufficient results, 
namely the case study PEG 6000 and the case study xylitol. Apart from the seg-
regation of the PMs, the produced samples presented high amounts of crystalline 
ITR. The case study HPMC 4000, however, showed positive results. The dissolu-
tion rates of the two ternary formulations were superior compared to the refer-
ence sample HMG Trial B. Thus, this formulation approach will be taken up again 
in the overall discussion in section V.. 
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IV.10. Storage Stability 
All results presented so far were gained shortly after production of the corre-
sponding samples. For a complete interpretation of the different formulation ap-
proaches, it was also important to investigate their stability over a longer time 
period. Thus, a stability study was conducted at 25 °C/ambient humidity and 
40 °C/75 % RH over the course of six months. 
IV.10.1. Chosen Samples  
All presented formulations in sections IV.4., IV.5., IV.6., IV.7. and IV.8. were 
investigated for their storage stability. However, the main objective of this work 
was to determine the most favourable formulation approach which of course in-
cluded sufficient ITR dissolution. Therefore, only the results of the following cho-
sen samples will be presented in this chapter: 
1. HMG Trial A 2. HMG Trial B  3. HMG Trial HP 
4. HMG Trial SOLU 5. SEMP 
IV.10.2. Stability over Six Months 
The samples first exposed to the different conditions of the stability 
study (HMG Trial A and HMG Trial B) for six months did not show any substantial 
changes at 25 °C/ ambient humidity, regardless if they had been stored in closed 
or open containers (data not shown). Consequently, samples produced and 
stored at a later time were only analysed for their behaviour under the elevated 
conditions 40 °C/75 % RH. The corresponding results are presented in the fol-
lowing subsections. All shown results were conducted for samples stored at 
40 °C/75 % RH and thus, are only divided into “open” and “closed”, correspond-
ing to the used PE container, either with cap or without. 
IV.10.2.1. Changes in Physico-Chemical Properties 
The samples undergoing the stability study were investigated for their visual 
appearance by SEM. No differences were observed for HMG Trial A, HMG Trial B, 
HMG Trial HP and HMG Trial SOLU (data not shown). Figure IV.55. shows SEM 
images of SEMP. a and b show a SEMP pellet at the beginning of the stability 
study and a close-up of its surface, respectively. c and d were taken after 
six months of storage in the open container.  
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Figure IV.55. - SEM images of SEMP; a) pellet at the start of stability study, 
b) close up of pellet surface at start of stability study, c) pellet stored in open 
container at end of stability study, d) close up of pellet surface stored in open 
container at the end of stability study; left bars = 100 µm; right bars = 2 µm. 
In c, there was a circular area visible where the seal coating seemed to be torn 
whereas d showed a close-up of the seal coating surface. These results indicated 
that the PEG coating had become disrupted during storage and became more po-
rous. This could have been due to more molecular mobility in the polymer chains 
at 40 °C. The images suggested alterations during storage of SEMP, however, 
they could not display if the ITR coating had also become damaged. It has to be 
added that not all pellets under the microscope showed the same lacerations as 
shown in image c. Still, the torn surface was exhibited by more pellets than ob-
served at the beginning of the stability study. Additionally, it was visually possi-
ble to detect colour changes of the pellets. After six months of storage, a sub-
stantial amount of them had turned slightly yellow.  
Also of interest was the water content of the samples. Although formulations 
are usually packaged in a way that protects them from a humid environment as 
much as necessary, a less hygroscopic product might reduce costs for packaging 
material. Additionally, the formulation might still be efficacious even after wrong 
storage by the patient, e.g. after being kept out in the open in the bathroom. Re-
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sults of the water content analysis of all investigated samples over the whole 
storage time are given in Figure IV.56.. The investigated four samples exhibited 
two different behaviours.  
 
Figure IV.56. - Results of water content analyses during the stability study. 
HMG Trial HP and HMG Trial SOLU adsorbed water during storage. As could be 
expected, this adsorption was more pronounced for the samples in open contain-
ers. The water content of HMG Trial SOLU rose by 254.18 % and 90.89 % in the 
open and closed container over six months, respectively. The highest water con-
tent was observed for HMG Trial HP. Here, the increase in adsorbed water was 
200.48 % and 111.73 %, respectively. This might have induced further recrystal-
lisation of ITR. HMG Trial A and B, however, showed only a slow rise up to 
one month of storage and then, the water content decreased again. In the case 
of the two samples in closed containers, the water content even fell below the 
value at the beginning of the stability study (-17.99 % for HMG Trial A and 
-18.07 % for HMG Trial B). This was interesting for a few reasons. First of all, 
CDs are postulated to be non-hygroscopic in general, the parent βCD more so 
than the derivative HBβCD [170]. These results agreed well with that. Also, it 
had to be taken into account that usually in CDs, water is situated in the cavity. 
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These water molecules are exchanged with the API during ICF. Usually cavity 
water is not volatile. The fact that HMG Trial A and B exhibited water loss after 
three months indicated that the rest of the previous cavity water left in the sam-
ples after HMG was not situated within the cavity. This further supported the 
presence of ICs. At the maximum of the respective curves for HMG Trial A and B, 
they showed increases of 34.61 % and 22.28 % in open containers and 25.82 % 
and 14.60 % in closed containers.  
As the results of the water content have shown, indicators were present regard-
ing recrystallisation of ITR. Therefore, DSC measurements were conducted at all 
time points of the stability study. For reasons of clarity, the following figures pre-
senting these results only show the respective DSC trace at the beginning of the 
stability study (a) as well as the DSC curves after six months of storage in open 
(b) and closed (c) PE bottles. Figure IV.57. gives the DSC results of HMG Trial A. 
Regarding the melting of ITR and the presence of a signal corresponding to “cold 
crystallisation”, the sample appeared stable over the whole six months. 
 
Figure IV.57. - Excerpts from DSC traces of HMG Trial A during the stability 
study; a) start, b) 6 months in open container, c) 6 months in closed container, 
analyses conducted from 30 - 200 °C after 2 min holding period at 30 °C; heat-
ing rate 3 K/min. 
Only one observation was made concerning Tg of ITR around 60 °C. This signal 
was more pronounced after six months of storage both in open and closed con-
tainers. This was not surprising, as it is known that amorphous substances often 
exhibit enthalpy relaxation peaks in the region of Tg when stored at temperatures 
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close to Tg due to higher molecular mobility [171]. The same was observed for 
HMG Trial B. These results are given in Figure IV.58.. There were always two dis-
tinct peaks corresponding to ITR melting, as well as “cold crystallisation” visible in 
the DSC traces. The only difference to the beginning of the stability study was the 
more pronounced endothermic signal around Tg of ITR due to enthalpy relaxation.  
 
Figure IV.58. - Excerpts from DSC traces of HMG Trial B during the stability 
study; a) start, b) 6 months in open container, c) 6 months in closed container, 
analyses conducted from 30 - 200 °C after 2 min holding period at 30 °C; heat-
ing rate 3 K/min. 
HMG Trial HP showed the same behaviour in the DSC over storage as can be 
seen in Figure IV.59.. Upon magnification, the Tg of ITR became more pronounced 
as explained above. “Cold crystallisation” was also detectable. The fact that the 
detected Tg signal was smaller than for HMG Trial A and B might have been related 
to more crystalline ITR being present, as also indicated by the higher second Tm 
around 165 °C compared to the polymorph around 155 °C (see section IV.6.). The 
previously presented results of the water content had indicated further recrystalli-
sation of ITR during storage in HMG Trial HP. At the beginning of the stability 
study, the ratio between Tm one (polymorph) and two was 1:1.45. After six 
months of storage, this ratio rose to 1:1:85 and 1:2.15 for the open and closed PE 
bottle, respectively. This generally supported further recrystallisation. However, it 
also assumed total homogeneity of the samples after six months. Adding the fact 
that DSC measurements could only be conducted as single experiments, a sub-
stantial conclusion could not be drawn from the increase in the second endotherm. 
Results and Discussion 
 
 
155 
 
Figure IV.59. - Excerpts from DSC traces of HMG Trial HP during the stability 
study; a) start, b) 6 months in open container, c) 6 months in closed container, 
analyses conducted from 30 - 200 °C after 2 min holding period at 30 °C; heat-
ing rate 3 K/min. 
DSC results of HMG Trial SOLU are shown in Figure IV.60.. Here, no ITR melting 
signal could be observed which clearly showed that SOLU as a matrix hindered the 
API’s mobility and subsequently, recrystallisation.  
 
Figure IV.60. - Excerpts from DSC traces of HMG Trial SOLU during the stability 
study; a) start, b) 6 months in open container, c) 6 months in closed container, 
analyses conducted from 30 - 200 °C after 2 min holding period at 30 °C; heat-
ing rate 3 K/min. 
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With this used DSC technique, no Tg of ITR was detected, not even after 
six months of storage. On the one hand, this showed just how immobile SOLU kept 
ITR, suggesting the formation of a solid solution. But on the other hand, it might 
have indicated that the chosen DSC procedure for the stability study might not 
have been as specific as necessary for this sample. Lastly, SEMP was investigated 
by DSC analysis (Figure IV.61.). As was outlined in the corresponding section (sec-
tion IV.8.), the DSC trace of SEMP had shown Tm corresponding to the PEG seal 
coating around 60 °C and an endothermic peak at 185.5 °C which was correlated 
to sucrose melting. Comparing the DSC trace at the beginning of the stability study 
with the DSC curve after six months of storage in closed containers, no difference 
was visible. The DSC trace of the open container showed a new event around 
130 °C. One may suspect this to be an artefact in the DSC, however, this event 
was also observed in the SEMP sample stored at 25 °C/ambient humidity (data not 
shown) in the open container, only at a lower temperature, around 110 °C. 
 
Figure IV.61. - Excerpts from DSC traces of SEMP during the stability study; 
a) start, b) 6 months in open container, c) 6 months in closed contain-
er, analyses conducted from 30 - 200 °C after 2 min holding period at 30 °C; 
heating rate 3 K/min. 
This event might have been related to ITR recrystallising due to water adsorp-
tion during storage. The broad sucrose peak at 185.5 °C might have masked Tm 
of ITR. Also it had to be taken into account when comparing SEMP results to the 
melt-produced samples that this formulation is composed of many excipients 
that could all potentially influence the DSC curve. Therefore, it was not complete-
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ly possible to ascribe this signal specifically to one formulation component. En-
thalpy relaxation around the Tg of ITR could not be evaluated as this signal would 
have overlapped with Tm of PEG. Consequently, it could be concluded for the DSC 
measurements that all samples appeared generally stable after six months of 
storage. Possibly for HMG Trial HP, ITR had recrystallised further.  
All self-produced samples were investigated for their ITR, βCD or (if appropri-
ate) HPβCD content. SEMP, being an authorised marketed formulation was not 
examined for ITR content. The content was expected to stay in the acceptable 
range during the six months. Figure IV.62. to Figure IV.65 show the results of 
these analyses for HMG Trial A, B, HP and SOLU. Additionally, the ITR and CD 
contents at the beginning as well as at the end of the stability study are given in 
Table IV.31.. No substantial decrease in content of any component could be ob-
served throughout the storage over six months, regardless if the used container 
was closed or not.  
Table IV.31. - Summary of ITR and CD contents for the beginning and the end of 
the stability study for HMG Trial A, B, HP and SOLU. 
 HMG Trial A HMG Trial B HMG Trial HP HMG Trial SOLU 
Contents, % ITR βCD ITR βCD ITR HPβCD ITR 
Beginning of 
stability study 
    
 
97.59 
± 0.11 
105.21 
± 0.37 
93.00 
± 2.35 
93.70 
± 1.93 
100.20 
± 1.39 
102.49 
± 2.62 
96.04 ± 2.02 
Ending of sta-
bility study 
    
Open container 
100.69 
± 2.96 
102.78 
± 0.52 
98.36 
± 4.73 
102.51 
± 0.56 
96.18 
± 1.54 
97.84 
± 6.45 
93.54 ± 0.78 
Closed container 
97.18 
± 1.41 
103.13 
± 0.87 
100.32 
± 3.19 
101.90 
± 2.47 
98.74 
± 1.06 
96.82 
± 2.06 
95.17 ± 0.89 
Some experimental values appeared too high, possibly due to inhomogeneous 
samples or by analytical error. This applied e.g. to ITR content of HMG Trial SO-
LU at two weeks (open), HMG Trial A at one month (closed), HMG Trial B at two 
weeks (open) and one month (open and closed) (see Figure IV.62., Fig-
ure IV.63., and Figure IV.65.). The results of HMG Trial B (see Figure IV.63.) also 
indicated that the initially detected ITR and βCD contents might have been outli-
ers, revealing values too low. Additionally, it had to be taken into account that 
the crushed melt-granules were kept as a bulk in PE bottles. This might have 
negatively influence segregation of the components over storage time.  
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Figure IV.62. - Results of ITR and βCD content analyses of HMG Trial A during 
the stability study; n = 3; error bars = sd. 
 
 
Figure IV.63. - Results of ITR and βCD content analyses of HMG Trial B during 
the stability study; n = 3; error bars = sd; βCD closed 1 mo n = 1 due to experi-
mental issues. 
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Figure IV.64. - Results of ITR and HPβCD content analyses of HMG Trial HP dur-
ing the stability study; n = 3; error bars = sd. 
 
 
Figure IV.65. - Results of ITR content analyses for HMG Trial SOLU during the 
stability study; n = 3; error bars = sd. 
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To generally conclude the content analyses of the four self-produced samples, it 
could be stated that no degradation of either the API or the CD in question was 
observed and based on the attained content values, it seemed unlikely that dete-
rioration had taken place during storage. Yet, as the sometimes very high sd in-
dicated, content determination in triplicate might have been not ideal. 
IV.10.2.2. Variations in Dissolution and ATR-FT-IR Spectroscopic 
Changes 
The previous subsection revealed no substantial changes in all investigated 
samples’ physico-chemical properties. In addition, all samples undergoing the 
stability study were investigated regarding their ITR dissolution rate. Further-
more, the self-produced specimen were examined by ATR-FT-IR spectroscopy to 
detect changes in the interactions of functional groups. Figure IV.66. shows ex-
emplary ATR-FT-IR spectra of these measurements. The ATR-FT-IR spectra were 
evaluated for changes regarding the structure of the wave bands. Variabilities in 
intensity might have been ascribed to the unique sample and position in every 
single ATR-FT-IR run and thus, were not taken into account as indicators for 
changes in interaction.  
HMG Trial A (1 and 2 in Figure IV.66.) did not indicate any transformation over 
the storage time. Both samples stored in open and closed containers exhibited 
the same spectra at all investigated sampling time points. For technical reasons, 
it was not possible to obtain an ATR-FT-IR spectrum of HMG Trial A and B after 
three months, but the results after six months of storage also showed no differ-
ence compared to earlier analyses for HMG Trial A. This was not always the case 
for HMG Trial B. Mostly, no differences were observed between the spectra as 
well, particularly comparing the start of the stability study with the six months 
results. But, when taking a closer look at the wave bands around 1030 cm-1, the 
one month-measurements in 3 and 4 of Figure IV.66. presented not only one 
broadened signal with a shoulder on the right side but rather two small peak-like 
structures. This might have been ascribed to a higher amount of crystalline ITR 
in the sample or inhomogeneity of the investigated specimen. Despite differences 
in intensity, no distinct changes were detected for HMG Trial HP (5 and 6 in Fig-
ure IV.66.). Merely for the one month-measurement, the broad wave band 
around 1030 cm-1 presented two very small tips instead of one. Explanation for 
this might have also been a larger amount of crystalline ITR or inhomogeneity. 
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Figure IV.66. - Results of ATR-FT-IR spectroscopy during the stability study of 
1) HMG Trial A open containers, 2) HMG Trial A closed containers, 3) HMG Trial 
B open containers, 4) HMG Trial B closed containers, 5) HMG Trial HP open con-
tainers, 6) HMG Trial HP closed containers, 7) HMG Trial SOLU open containers, 
8) HMG Trial SOLU closed containers; from a) to e): start, 2 weeks, 1 month, 3 
months, 6 months; n = 3; due to technical issues, no 3 months-measurement 
could be conducted for HMG Trial A and B. 
The same held true for the results of HMG Trial SOLU. Here as well, no clear 
variabilities could be observed apart from slight changes in the region around 
1050 cm-1 after one month of storage both in open and closed containers.  
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Generally, the ATR-FT-IR results could be viewed as partially inconclusive. Only 
small alterations could be seen but nothing that would have justified the assump-
tion that any of the samples aged in an outstanding way.  
Importantly, all five samples were investigated for their dissolution perfor-
mance. On a general note, the following dissolution results were always calculat-
ed with the corresponding ITR content determined at that time point of the sta-
bility study.  
Figure IV.67. and Figure IV.68. give the results of HMG Trial A in open and 
closed containers, respectively. Regarding the dissolution profiles of the samples 
stored in the open, only minor differences could be detected. The achieved disso-
lution after 4 h ranged from 86.50 ± 1.46 % (three months) to 
93.55 ± 1.57 % (two weeks). During the first 30 min, all dissolution curves were 
nearly identical except the result of six months which presented a faster dissolu-
tion rate up until 45 min. All samples had reached 85 % of ITR dissolution after 
120 min. The seen variabilities were in an expected range, due to inhomogenei-
ties in the samples as well as natural fluctuations, especially when remembering 
that only duplicate experiments could be carried out.  
The samples stored in closed containers showed related results. After 4 h, ITR 
dissolution differed between 84.58 ± 0.91 % (two weeks) and 
98.73 ± 0.85 % (six months). The dissolution curve of the six months sample 
exhibited a faster dissolution rate than the other samples. It had to be kept in 
mind, however, that this sample was calculated with the lowest ITR con-
tent (97.18 ± 1.41 %). It might have well been that the derived ITR content was 
too low which would have subsequently meant that the calculated dissolution 
values in per cent were too high. The same had to be suspected for the 
one month-result, as the very high ITR content (106.87 ± 5.06 %) mathemati-
cally forced the dissolution curve down. For the calculated amount of ITR in the 
dissolution vessel, high variations during content analyses were not taken into 
account. This however, could also explain strong fluctuations of the dissolution 
curves.  
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Figure IV.67. - Dissolution results of HMG Trial A stored in open containers dur-
ing the stability study; n = 2; error bars = min/max. 
 
 
Figure IV.68. - Dissolution results of HMG Trial A stored in closed containers 
during the stability study; n = 2; error bars = min/max. 
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Figure IV.69. and Figure IV.70. present the dissolution results of HMG Trial B in 
open and closed containers. The detected variations here were stronger than for 
HMG Trial A. After storage in open PE bottles, the ITR dissolution after 4 h 
ranged from 83.20 ± 0.06 % (two weeks) to 98.46 ± 3.92 % (six months). The 
low results after two weeks and one month had to be ascribed to the high de-
termined ITR contents (111.68 ± 6.56 % and 105.12 ± 6.51 %). The remaining 
three dissolution curves showed natural fluctuations. The same held true for the 
dissolution results in closed containers. Here, dissolution after 4 h spanned from 
80.99 ± 0.56 % (one month) to 97.89 ± 2.39 % (start of the stability study). 
After six months, 95.86 ± 1.06 % of ITR dissolution was achieved. Results of the 
ITR content evaluation were also reflected in this dissolution analysis, especially 
in dropping down the curve for one month (ITR content 107.39 ± 1.25 %). Apart 
from this sample, all other dissolution curves reached 80 % of dissolution after 
90 min.  
 
 
Figure IV.69. - Dissolution results of HMG Trial B stored in open containers dur-
ing the stability study; n = 2; error bars = min/max. 
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Figure IV.70. - Dissolution results of HMG Trial B stored in closed containers 
during the stability study; n = 2; error bars = min/max. 
Figure IV.71. and Figure IV.72. present the dissolution profiles of HMG Trial HP 
stored in open and closed containers. The previously described curve fluctuations 
might have been proclaimed as minor. This, however, was not the case for 
HMG Trial HP. Dissolution in open and closed containers ranged from 
73.66 ± 3.99 % (three months) and 66.00 ± 1.66 % (six months) to 
91.31 ± 0.35 % (one month) and 87.29 ± 8.23 % (one month), respectively. 
This could not solely be explained by segregation within the storage container or 
falsely determined ITR content. It rather seemed as if the previously described 
results regarding the high ITR crystallinity as well as suspected inhomogeneities 
influenced these dissolution results.  
The ITR content evaluation after one month in the open container had shown a 
high sd (6.16 %). This had indicated inhomogeneity of the sample and might 
have been the reason why this dissolution profile was always above all the other 
dissolution curves. It was probable that the assumed content for calculating the 
dissolution curve had been too low. No trend could be observed throughout the 
six months that would have suggested further ITR recrystallisation or degrada-
tion as causes for decreasing dissolution.  
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Figure IV.71. - Dissolution results of HMG Trial HP stored in open containers 
during the stability study; n = 2; error bars = min/max. 
 
 
Figure IV.72. - Dissolution results of HMG Trial HP stored in closed containers 
during the stability study; n = 2; error bars = min/max. 
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The dissolution results of HMG Trial SOLU are shown in Figure IV.73. and Fig-
ure IV.74. for open and closely stored samples, respectively. Regarding the dis-
solution rate, all samples were identical. Right from the start, there was rapid 
ITR dissolution with the plateau phase reached after 10 min. The situation of the 
plateau phase, however, varied strongly for the samples. ITR dissolution ranged 
from 109.62 ± 0.37 % (two weeks) to 81.90 ± 4.27 % (one month) for the 
openly stored samples and from 87.70 ± 3.40 % (two weeks) to 
100.44 ± 0.37 % (start) for the samples stored in closed containers.  
ITR dissolution after six months was determined to be 101.92 ± 2.76 % and 
98.62 ± 2.41 % after 4 h in open and closed containers, respectively. Even 
though content analyses had yielded high variations at some sampling points and 
had suggested too low results, the obtained dissolution curves could not be com-
pletely correlated to that. For example, the low ITR content after three months in 
the open PE bottle should have caused the dissolution curve to go up, however, 
this was the lowest dissolution curve. These results strongly hinted at inhomoge-
neities in the samples. The variabilities of the presented curves were more pro-
nounced for the openly stored samples.  
 
Figure IV.73. - Dissolution results of HMG Trial SOLU stored in open containers 
during the stability study; n = 2; error bars = min/max; start: n = 6. 
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Figure IV.74. - Dissolution results of HMG Trial SOLU stored in closed containers 
during the stability study; n = 2; error bars = min/max; start: n = 6. 
As presented before, HMG Trial SOLU was susceptible to water absorption. It is 
possible that this might have influenced the dissolution, e.g. by ITR recrystallisa-
tion in the dissolution vessel.  
Lastly, the marketed formulation, SEMP, was investigated for ITR dissolution 
during storage. Changes in ITR content were not taken into account. Fig-
ure IV.75. and Figure IV.76. present the dissolution curves for the openly and 
closely stored samples. The results of the samples stored in open containers only 
showed minor fluctuations of the curves which could be ascribed to slightly dif-
fering ITR content (e.g. faster dissolution rate after three months). No difference 
in lag time was observed during storage as might have been expected due to the 
cracks in the PEG seal coating as previously reported. ITR dissolution after 4 h 
ranged from 95.07 ± 0.73 % (one month) to 105.80 ± 1.37 % (three months) 
for the openly stored samples and from 94.05 ± 1.94 % (six months) to 
109.74 ± 3.92 % (three months) for the samples stored in the closed PE bottle. 
No trend regarding decreasing dissolution or solubility rate was observable. The 
ITR dissolution for the closed container differed more pronounced. However, no 
shortened lag time with longer storage could be observed.  
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Figure IV.75. - Dissolution results of SEMP stored in open containers during the 
stability study; n = 2; error bars = min/max; start: n = 6. 
 
 
Figure IV.76. - Dissolution results of SEMP stored in closed containers during 
the stability study; n = 2; error bars = min/max; start: n = 6. 
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The dissolution rate after two weeks and after three months appeared faster 
than for the rest of the samples, which could have indicated that a substantial 
amount of the pellets used in this analysis exhibited disrupted seal coatings. Still, 
both of these samples reached their plateau phase after 60 min and did not show 
a decrease in absolute ITR dissolution. The fact that the sample after three 
months exhibited such high ITR dissolution well above 100 % must have been 
ascribed to the used sample. Even the marketed formulation allows ITR content 
to be in a certain range for the product to be regarded as specified. The used ITR 
amount during this experiment must have exceeded the previously determined 
ratio that 464 mg equalled 100 mg of ITR. Generally, the hypothesis that the 
marketed formulation would still show acceptable dissolution results after storage 
of six months had been proven right. 
IV.10.3. Concluding Remarks about the Stability Study 
In the previous subsections, results of the stability study of four self-produced 
samples and SEMP were shown. As suspected, SEMP stayed stable the whole 
time and no recrystallisation of ITR could be detected in the DSC. ITR dissolution 
stayed on satisfactory levels. HMG Trial A and B did not show substantial aging 
over six months. Even though the dissolution curves fluctuated which could be 
correlated to high variations in the content analyses, no decreasing trend was 
visible over six months. This also held true for the remaining two samples. How-
ever, when evaluating HMG Trial SOLU and HP, variabilities were seen in the dis-
solution experiments that could not be correlated to ITR content examination. 
This indicated stronger inhomogeneities in these samples.  
Concluding the stability study, it can be said that both HMG Trial A and B 
proved to be the most stable of the self-produced samples. HMG Trial B showed 
higher dissolution fluctuations than HMG Trial A. However, the absolute dissolu-
tion of HMG Trial B was generally higher than of HMG Trial A, both in openly and 
closely stored samples. It could still be concluded that HMG Trial B, being pro-
duced at lower operating temperatures, seemed to be the most profitable binary 
βCD formulation in-vitro. Nonetheless, during this study, it was only possible to 
conduct content analyses in triplicate and dissolution experiments in duplicate. 
For statistically relevant results, this would have to be strongly expanded. That 
way, the vulnerability of the dissolution results to high content variations could 
be minimised. Moreover, it would allow obtaining valid statistical data.  
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Furthermore, the samples were all stored in PE bottles as bulk. It was possible 
that this had further enabled segregation during storage. Future stability studies 
should rather use pre-filled capsules or single doses (e.g. in sachets), to exclude 
this phenomenon from influencing later results. Moreover, it has to be added that 
a probable pharmaceutical product would most likely also be investigated for 
storage stability packaged in the chosen primary packaging as this is relevant for 
determining the later shelf life. 
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V. Comparative Summary and Overall Discussion 
The previous chapters presented the results obtained in this project as well as 
discussions about specific observations. After the preformulation studies and the 
development of an HMG procedure to produce binary βCD/ITR melt-granules 
containing solid ICs, different formulation approaches were presented. The aim 
of this was to further optimise the firstly created specimen. The following chapter 
will take up the most important of the previously described data and put them 
into a wider scientific perspective to allow an encompassing conclusion of this 
work as a whole. 
V.1. Hot-Melt Processes and Formulation Approaches 
The foremost goal of the present study was the development of a binary hot-
melt procedure that would yield solid ICs on the basis of βCD as matrix. Sec-
tions IV.2., IV.3. and IV.4. followed the development of this process, firstly, by 
employing HME with a self-built conical 6 mm die and secondly, by changing the 
focus to HMG which resulted in an equivalent product. It was presented that the 
HMG process was the most feasible procedure for this task. Different tempera-
ture profiles were investigated and HMG Trial B was chosen as the best compro-
mise between product properties and coldest applicable temperature. The maxi-
mum temperature in this procedure was 180 °C. HMG Trial B showed the highest 
ITR dissolution after 4 h. ITR was at least mostly amorphous in the samples. 
Even though ATR-FT-IR results were inconclusive, comparing the dissolution 
against PMaITR as reference clearly showed interactions between βCD and ITR. 
Additionally, it was presented that the highest relative enhancement in dissolu-
tion compared to crystalline ITR (86 %) had occurred for HMG Trial D, the sam-
ple processed at the coldest temperatures, below Tm of ITR.  
Sections IV.5., IV.6., IV.7. and IV.8. presented different approaches to opti-
mise the reference formulation HMG Trial B. The marketed formulation SEMP was 
also investigated for comparative reasons. Furthermore, HPβCD and SOLU were 
examined as alternative matrices in HMG. In section IV.9., different case studies 
were described, utilising xylitol, PEG 6000 and HPMC 4000 either as matrix or 
ternary addition of 10 % and 20 % in mass. Xylitol and PEG 6000 failed to show 
any additive or synergistic effect on the formulation. The sample containing a 
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10 % mass fraction of HPMC, however, showed substantially faster ITR dissolu-
tion compared to the reference HMG Trial B.  
Lastly, chosen samples underwent stability testing, presented in section IV.10.. 
Apart from segregation of the samples stored as bulk in PE containers, no sub-
stantial aging was observed.  
The development of HME and later HMG procedures proved to be challenging as 
βCD lacks thermoplastic behaviour. The results in this thesis showed that βCD 
did not melt at all during the experiments and was either present in the solid 
state or degraded. Nevertheless, the resulting HMG process has to be regarded 
as innovative. The general use of CDs in hot-melt processes can only be referred 
to as restricted. There is a 2002 US patent dealing with HME of CDs and APIs 
without the further use of polymers [172]. However, a few facts about this pa-
tent are interesting in regard to this project. Firstly, they clearly state that the 
term “melting” should be interpreted “broadly”, covering the possibility that one 
component does not melt. Secondly, even though βCD is directly mentioned, the 
presented practical examples in this patent only show the use of HPβCD and di-
methyl-βCD. Rambali et al. investigated HME properties with ITR but they also 
chose HPβCD as matrix [110]. Thiry et al. prepared ternary ICs with different 
CDs with an mTSE. Yet, they also did not use βCD and their binary IC examples 
were not prepared by HME/HMG [87]. Yano and Kleinebudde compared wet and 
hot extrusion of indomethacin/HPβCD mixtures. They found improved indometh-
acin dissolution for both formulations. They concluded that the dissolution en-
hancement of the HME sample was most likely caused by API amorphisation and 
stressed the importance of HPβCD for wet extrusion [173]. Interestingly, it has 
previously been reported that βCD showed a slightly higher CE than HPβCD for 
indomethacin [174]. Section IV.1. also showed that ITR exhibited a higher CE 
with βCD than with HPβCD. Still, somehow there seem to be restraints in regard 
to the application of βCD as matrix in hot-melt processes.  
Fukuda et al. investigated HME with sulfobutyl ether βCD (SBE7-βCD) and keto-
profen. For comparative processes, they also examined βCD and found that their 
SBE7-βCD extrudates showed a faster dissolution rate. However, as SBE7-βCD is 
a hygroscopic substance, they saw definite decreases in dissolution after only 
seven days storage in open containers at 40 °C/75 % RH [81]. Unfortunately, 
they did not explain much about the HME process operability. Nonetheless, simi-
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larities to the HME process described in this work could be found. The die size 
was also 6 mm and they employed molten API and solid βCD. However, the pro-
cess developed in this work is more industry-oriented. Apart from the fact that 
Fukuda et al. only used a mSSE, they also operated their procedure with a ScS of 
10 rpm which is considerably lower than 150 rpm as used for HMG Trial B. This 
comparative study between SBE7-βCD and βCD was the only attainable report 
about HME with unmodified βCD. To the author’s best knowledge, there are no 
reports about using βCD as sole matrix component in HMG. 
Miller et al. discussed practical considerations that formulators should be aware 
of when utilising CDs. They mentioned two basic methods for producing solid 
ICs, coprecipitation and kneading with subsequent drying. Additionally, they re-
ported two innovative approaches, dry grinding and steam granulation. However, 
they also stated that dry grinding has not proven to be a satisfactory technique 
in obtaining ICs [175]. This further highlights that the manufacturing of IC with-
out the addition of solvent is an unusual and inventive approach. Cavallari et al. 
steam-granulated piroxicam and βCD. They used a one-step mixer-granulator-
dryer with an electric boiler which supplied aqueous steam at a steady flow. By 
doing so, the additional use of water is not necessary. It is proposed that the 
steam diffuses faster into the powder and creates a better thermal balance dur-
ing a fastened drying step. They found improved piroxicam dissolution rate for 
the steam-granulated samples and concluded steam-granulation to be a water-
saving alternative to WG [176]. In some ways, the HMG procedure described in 
this thesis shared characteristics with steam-granulation. Water from the CD 
cavity was vaporised during HMG and also presented as steam before leaving 
mTSE. HMG Trial D, showing the highest relative dissolution enhancement, was 
produced at a maximum temperature of 100 °C. Although water vapour was not 
visible to the extent of the other samples, it might have had some effect. But, an 
important difference to steam-granulation is the complete lack of further addition 
of solvent and thus, no need for a drying step altogether. The developed HMG 
procedure must therefore be described as advancement to steam-granulation.  
Regarding only the HMG process, this work clearly demonstrates that it was 
possible to operate βCD as matrix and gain sufficient results. A continuous, easily 
up-scalable and stable manufacturing process was developed. Nonetheless, es-
pecially the experimentation with different powder blends and formulation ap-
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proaches indicated drawbacks of the used HMG equipment, such as the utilisation 
of only one volumetric feeding station.  
Apart from the development of a newly HMG process, another important objec-
tive of this work was to gain a product with sufficient characteristics which con-
tained ICs. Figure V.1. recaps all investigated samples in regard to their ITR dis-
solution after 4 h directly after production. Hereby, the amount of dissolved ITR 
after 4 h of the samples is juxtaposed with the respective dissolution reference 
as shown in the correlating sections. Samples processed above ITR Tm were 
evaluated against PMaITR, samples processed below ITR Tm against PM.  
 
Figure V.1. - Deviations of ITR dissolution after 4 h compared to the respective 
reference formulation (PM or PMaITR) for all investigated samples in this project. 
The presented overview cannot indicate the absolute solubility enhancement of 
ITR and also not give indications regarding the dissolution rate. In the results 
and discussion section, some produced samples were already shown to be effec-
tive for ITR dissolution. Figure V.2. summarises a selection of those samples as 
well as SEMP and PMaITR as references. The corresponding results sections 
showed that the determination of ICs with ATR-FT-IR was challenging if aITR was 
present. However, the synopsis of Figure V.1. strongly indicates ICF during HMG. 
All four binary HMG formulations HMG Trial A – D showed improved dissolution 
against their respective references. The same held true for HMG Trial HP and 
HMG Trial XYL20. The discrepancy in CE between βCD and HPβCD (see sec-
-100
-80
-60
-40
-20
0
20
40
60
80
100
D
iv
e
r
g
e
n
c
e
 i
n
 d
is
s
o
lu
ti
o
n
 r
a
te
, 
%
 
Comparative Summary and Overall Discussion 
 
 
176 
tion IV.1.) proved true as βCD showed further dissolution improvement than 
HPβCD. HMG Trial D showed distinct differences in ATR-FT-IR, further proving ICF.  
 
Figure V.2. - Dissolution results of PMaITR (n= 3) and SEMP (n= 6) as refer-
ences, HMG Trial A (n = 2), B (n = 2), HP (n = 2), and SOLU (n = 6) as well as 
from the HPMC case study (n = 3); error bars = min/max. 
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ITR has been extensively studied both in respect to ICF and hot-melt process-
es. Since ITR is a perfect candidate for solubility enhancing attempts, a plethora 
of techniques and excipients have been examined and promoted to be the best 
suitable formulation available. Very often, the concept of solid dispersions is ap-
plied. To only name a few, ITR dissolution rate has been improved by spray dry-
ing, media milling, ITR salt formation, HME with different polymers or by ICF uti-
lising supercritical carbon dioxide [46,150,177–182]. In recent times, one of the 
polymers most frequently used in these different research approaches is SOLU.  
Guth et al. showed improved ITR in-vitro dissolution and in-vivo absorption in 
beagle dogs from SOLU extrudates compared to Sempera® [85]. The presented 
dissolution rate of SOLU was slower than described in this project, probably due 
to different experimental settings such as slower paddle rotation speed. As visi-
ble in Figure V.2., HMG Trial SOLU exhibited the fastest dissolution rate of all 
samples which could lead to the assumption that this formulation was best suited 
for a later industrial process. Thiry et al. examined extrudates with SOLU in bina-
ry and ternary form (addition of HPβCD or superdisintegrant) in-vitro by a previ-
ously reported biphasic dissolution method and in-vivo in rats. They found that 
the CD formulation exhibited highest and fastest ITR release in-vitro, whereas 
the SOLU/ITR/disintegrant formulation was the most favourable 
in-vivo [182,183]. Linn et al. investigated solid solutions of SOLU and ITR and 
found increased ITR absorption both in Caco-2 cells as well as in beagle 
dogs [82].  
However, to the author’s best knowledge, in early 2018, there still is no market-
ed formulation available containing SOLU. This can be explained by SOLU’s regu-
latory status as a completely new pharmaceutical excipient. Even though there 
are toxicology studies ongoing, it is still hard to predict how regulatory agencies 
will respond to an application based on such a new substance. The very strong 
absorption enhancing and solubility enhancing properties of SOLU could prove to 
be disadvantageous in humans as is, for example, the case with methylated CDs. 
Depending on the amount of methylated groups, these CDs can be strongly cyto-
toxic, e.g. by extracting cholesterol from cell membranes [184]. Until there is no 
full toxicological profile of SOLU available or the substance has passed a regula-
tory inquiry, HMG Trial SOLU could not be regarded as the most favourable for-
mulation prepared in this project. This conclusion was also backed up by the fact 
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that the operability of HMG with SOLU was not as sufficient as with the binary 
ITR/βCD, especially regarding the sampling procedure at the granulation heel 
slide.  
Figure V.1. further stresses the failure of the investigated ternary additives xyli-
tol and PEG 6000. Apart from HMG Trial WG, these samples were the only ones 
showing negative deviations in regard to their reference. The only exception was 
HMG Trial XYL20 which showed the smallest increase of dissolution of all positive 
samples. The case study HPMC 4000, however, yielded interesting results. The 
addition of a 10 % mass fraction of HPMC 4000 to the binary βCD/ITR formula-
tion strongly increased the dissolution rate. The sample even showed faster dis-
solution than SEMP. This sample combined fast ITR dissolution with the coldest 
applicable HMG temperatures based on HMG Trial B. The fast dissolution was due 
to the combination of ITR amorphisation, ICF and improved wettability or possi-
bly complexation between ITR and HPMC 4000. Due to its size, it seemed unlike-
ly that HPMC 4000 (or parts thereof) had become included in the βCD cavity.  
Figure V.3. shows a magnification of the first 30 min of dissolution testing pre-
sented in Figure V.2.. Of all self-produced samples apart from HMG Trial SOLU, 
HMG Trial HP showed fastest dissolution during the first 15 min. 
HMG Trial HPMC10 exhibited higher ITR dissolution than SEMP during the whole 
30 min. Before interpreting these data regarding the definition of the most opti-
mal specimen produced during this work, the limitations of the presented results 
have to be considered. First of all, most dissolution studies could only be per-
formed in duplicate. Nevertheless, all samples underwent stability testing and 
since no substantial aging was detected, the dissolution of the samples in ques-
tion stayed on similar levels as presented in Figure V.2. and Figure V.3.. Second-
ly, all data provided only in-vitro information. The used dissolution method for 
ITR was a simple and traditional procedure. Even though it lacked complexity, it 
allowed discriminatory results. As mentioned previously, Thiry et al. developed a 
biphasic ITR dissolution method which supposedly should further mirror the 
GIT [183]. 
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Figure V.3. - Dissolution results of PMaITR (n= 3) and SEMP (n= 6) as refer-
ences, HMG Trial A (n = 2), B (n = 2), HP (n = 2), and SOLU (n = 6) as well as 
from the HPMC case study (n=3) during the first 30 min of the experiment; er-
ror bars = min/max. 
However, as described in section III.1.2., the bioavailability of Sporanox® is 
situated at about 55 % even though dissolution results have shown quantitative 
ITR release. ITR is strongly protein bound and causes unpredictable individual 
absorption not only in humans, but also in birds, horses, reptiles or arthro-
pods [185]. Yoo et al. investigated the different oral absorption of ITR in labora-
tory rats, rabbits and dogs and found strong variabilities [186]. Zimmermann et 
al. concluded after examining the influence of food on ITR absorption in humans 
that the influence was very strong but sometimes irregular and variable between 
individuals. Additionally, they found that ITR absorption was improved by long 
gastric retention times, low stomach pH, and a high fat content of the co-
administered meals [187,188].  
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The presence of CDs can further complicate the circumstances for the drug in 
the human body. Stappaerts and Augustijns conducted in-vitro gastrointestinal 
transfer studies of ITR in the presence of HPβCD and different bile salts. They 
found that in the intestinal milieu, ITR was supersaturated depending on the ex-
cipients. However, displacement of ITR from the HPβCD cavity caused by bile 
salts was also observed. The consequently following ITR precipitation was not 
always seen, probably because ITR was emulsified by the present bile salts. They 
concluded that the supersaturated amount of ITR was rapidly absorbed and that 
the presence of CDs as well as different endogenous substances definitely im-
pacted ITR absorption [167].  
Another interesting study about ITR behaviour in gastric and intestinal milieus 
was carried out by Brouwers et al. (part I) and Berben et al. (part II). They in-
vestigated GIT precipitation of ITR in human volunteers after administering 
Sporanox® capsules and solution which contains HPβCD. Additionally, they re-
viewed precipitation and supersaturation of ITR from Sporanox® solution after 
intake with and without water. Their findings included that the solution showed 
faster and higher ITR dissolution in the stomach. But, in the small intestine, pre-
cipitation occurred. Generally, they observed high variabilities between their sub-
jects. In part II of the study, they made the observation that even though ITR 
precipitation was higher after taking Sporanox® solution with water, the systemic 
exposure of ITR was nearly identical to the intake without water. They concluded 
that HPβCD in diluted form partially lost its encapsulation ability. But, even when 
more ITR was in solution, the included portion was not able to permeate through 
intestinal membranes [189,190]. This is a good example for the solubility-
permeability interplay of an API. Just because the drug is dissolved does not au-
tomatically mean that the absorption will be high.  
All these different case studies clearly show that it is almost impossible to pre-
dict ITR in-vivo behaviour after evaluation of in-vitro data, regardless of the in-
vestigated species. Also, they stress the individual variabilities of ITR absorption. 
This project majorly dealt with the general development of the βCD/ITR formula-
tion. Although the obtained in-vitro results do not allow a distinct prediction of 
physical ITR absorption, they can indicate the theoretical dissolving of ITR. This 
also holds strong value, especially as a specification for determining the product 
quality.  
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Notwithstanding, transferring the results of Berben et al. to the dissolution re-
sults obtained in this project for HMG Trials B, HP and HPMC10, it has to be con-
sidered that the faster dissolution rate in the 30 min window may lead to higher 
ITR dissolution in the stomach but also to higher precipitation and less absorp-
tion due to the complexation [190]. On the other hand, Loftsson et al. concluded 
after reviewing different oral formulations with CDs that the necessary mecha-
nism for drug absorption from the GIT should be dilution of the formulation to 
force the drug out of the IC and make it accessible to intestinal membranes. 
They strongly suggested that formulations should not contain excess CD as this 
would hamper dilution after intake [191]. This might explain the similar ITR 
plasma concentrations Berben et al. obtained for their two samples [190]. It ap-
peared as if the amount of precipitated ITR was not relevant in this study for the 
efficacy in the patient. Brouwers et al. however showed much higher plasma 
concentrations for the oral solution than the oral capsule [189]. Even though it 
was suboptimal to compare a solution and a capsule, these results still suggested 
that the formulation with CD was superior to the polymer-based formulation.  
Based on this, three self-produced formulations stood out to be potentially re-
garded as the most optimal exemplar, HMG Trial B, HP and HPMC10. 
HMG Trial HPMC10 showed the fastest absolute dissolution rate whereas 
HMG Trial HP showed the highest ITR dissolution in the first 15 min. Brouwers et 
al. showed tmax values for the Sporanox
® capsules and solution of 2.9 ± 1.6 h and 
2.5 ± 0.7 h, respectively [189]. This supported a scenario where the faster dis-
solution rate would not be that important for the absolute drug absorption when 
evaluating the 4 h experimental set-up presented in this work. Thus, as 
HMG Trial HP exhibited lower absolute ITR dissolution, CE was lower than for 
βCD, and as it is a much costlier excipient, this sample was ruled out as optimal 
formulation. This choice was also supported by the fact that HMG Trial HP was 
the only sample where a dissolution influence due to small particle size in com-
parison to the other specimen could not have been excluded. Thus, the only ad-
vantage of this sample compared to the other two might have been a mere result 
of smaller particles and not ICF. 
HMG Trial B and HPMC10 both reached nearly quantitative ITR dissolution after 
4 h with HMG Trial HPMC10 showing the faster dissolution rate. However, the 
mixture of HMG Trial HPMC10 differed more strongly in ITR content due to seg-
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regation. This forced the determined ITR dissolution above 100 %. With the used 
equipment, HMG Trial B had to be regarded as more stable. Nonetheless, provid-
ed different feeders were used, HMG Trial HPMC10 would be creatable in a more 
reproducible manner. Due to the presence of HPMC 4000, it was not possible to 
distinguish between ICF and dissolution improvement due to amorphisation or 
other mechanisms. Moreover, no stability data were obtained for the HPMC 4000 
case study. Even though HPMC based SEMP did not show much signs of aging 
regarding the dissolution tests, this still could not be extrapolated towards 
HMG Trial HPMC10.  
Therefore, taking into account all of the in-vitro results presented in this thesis, 
it could be confirmed that HMG Trial B entailed the best compromise between 
high ITR dissolution, low application temperature during HMG (maximum 180 °C) 
and storage stability. The product utilised a cost-effective, sustainable excipient. 
In ITR therapy against fungal infection with HMG Trial B (200 mg ITR/day), βCD 
intake would be 320 mg/day. Until October 2017, the NOAEL of βCD for adult 
humans was 500 mg/day. Then, the annex to the European Commission guide-
line on ‘Excipients in the labelling and package leaflet of medicinal products for 
human use’ was updated and proposed a limit of 20 mg/kg/day to be harm-
less [78,79]. This would also allow high dose ITR therapy in adults with 
HMG Trial B. 
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VI. Conclusion and Perspectives 
VI.1. Final Denouement and Scientific Significance of 
the Developed Formulation 
To finally conclude this work, it can be stated that it was possible to develop a 
novel polymer-free HMG process for binary βCD formulations. Simultaneously, it 
was possible to create ICs without addition of solvents.  
HMG Trial B with a maximum processing temperature of 180 °C was selected to 
be the most favourable HMG formulation manufactured in this project. The com-
prehensive presentation and discussion about the development of the HMG pro-
cedure are useful examples regarding the overall strategy when creating a new 
hot-melt process. In addition, it was shown that the change from HME to HMG 
does not have to coincide with loss of desired product properties. In the course 
of the process development, a new 6 mm conical die was developed. Insights in-
to the necessary inner die structures when operating without polymers are also 
of value for formulation scientists working in this field. 
The present thesis provides continuous manufacturing procedures for βCD that 
can either result in improved API dissolution by the combination of amorphisation 
and ICF or solely by ICF. The mere processing of ITR at a temperature of 
100 °C (HMG Trial D) showed the highest relative improvement in dissolution 
even though nearly no vaporisation of cavity water was observed.  
With the development of the HMG process as well as different optimisation ap-
proaches and the conducting of a stability investigation, all previously defined 
objectives have been met. A comprehensive summary of the positive properties 
of the developed HMG procedure is given in Table VI.1.. 
Finally, it can be confirmed that the present work combines the development of 
a new HMG technique from scratch as well as the thorough characterisation of 
the produced samples. Important conclusions could be drawn from the given da-
ta, both for the application of CDs and HME/HMG. Nonetheless, there are yet fu-
ture possibilities regarding the here-in presented research. These will be shortly 
discussed in the next subsection. 
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Table VI.1. - Favourable process characteristics of the developed HMG procedure. 
Favourable Process Characteristics 
 
Stable, solvent- and polymer-free process was operated which holds strong in-
dustrial potential. 
 
Continuous manufacturing process would allow 24/7 production of a formulation 
with higher drug load than SEMP. 
 Less production steps and excipients than SEMP as the binary product utilised 
only one cost-effective and sustainable excipient. 
 
ICF during HMG proven by dissolution results and by ATR-FT-IR for crystalline 
sample. 
 Additional effects by amorphisation of ITR and ICF with βCD were proven. 
 
ITR only employed as model substance; technique generally suitable for any API, 
possibly even without the use of high temperatures, since greatest relative dis-
solution enhancement for a crystalline sample prepared below the Tm of ITR. 
 
Process can be regarded as novel model technique for solvent-free ICF. HMG 
could be entrenched as additional method for ICF in the solid state. 
VI.2. Future Possibilities 
While reasonable explanations were found for emerging issues about the pre-
sented data, there were also some drawbacks defined which could be eradicated 
in future research. These are, mainly, the mTSE equipment as well as the statis-
tical significance of the results. It was described that the used mTSE was operat-
ed with a volumetric feeding system which made it impossible to fully determine 
the throughput of the material during processing. Furthermore, the use of one 
single hopper promoted mixture segregation. The use of separate gravimetric 
feeders would allow constant throughput monitoring. This would also lower pro-
duction costs as blending of the API with the matrix would not be necessary. Fol-
low-up studies with more suitable HMG/HME equipment should be carried out to 
improve reproducibility of the results.  
In addition, the sample characterisation should be conducted with a larger 
sampling size. In this work, statistical analyses of the results were left out due to 
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the small number of replications that were implementable. Additionally, the pre-
sented process should be conducted with different model APIs to gain far-
reaching insights into the binary HMG of unmodified βCD. As the patent protec-
tion of Sporanox® capsules has already expired and many different generic for-
mulations are available on the market, the realistic possibility for a new oral ITR 
formulation has to be considered slim. If ITR is authorised for additional indica-
tions such as the recently researched types of cancer (see section III.1.1.) this 
judgement may need to be revised. However, when considering ITR as model 
BCS class II API, it is likely that the innovative HMG process holds strong scien-
tific value in formulation design of different BCS class II APIs, mainly NCEs. The 
water-free ICF method could possibly allow investigations with hydrolysis-
sensitive drugs. 
Lastly, to fully fathom the clinical significance of the developed process and 
subsequent formulation, in-vivo studies should be carried out regarding drug ab-
sorption. For the oral use of βCD, no toxic effects have to be expected.  
Utilising parenterally harmless CDs in the HMG process such as HPβCD would 
be a possibility to continuously produce solids for later reconstitution and paren-
teral application. Having the right equipment at disposal, the new HMG process 
may be universally employed for a plethora of administrations, depending mostly 
only on the substances used. 
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VII. Appendices 
VII.1. Abbreviations, Units and Variables 
%  mass fraction 
[CD]t total cyclodextrin concentration in phase-solubility 
measurements 
°2θ  degree of diffraction angle in XRPD  
A  ampere  
A  surface 
ADI  acceptable daily intake 
aITR  amorphous itraconazole 
API  active pharmaceutical ingredient 
ATR-FT-IR attenuated total reflectance Fourier-transform in-
frared spectroscopy 
βCD  beta-cyclodextrin 
BCS  Biopharmaceutics Classification System 
CE  complexation efficiency 
Cs  saturation concentration 
D:CD  drug : cyclodextrin ratio 
d  diameter 
d  day 
D  extruder screw diameter  
D  diffusion coefficient 
DCS  Developability Classification System 
dem.  demineralised 
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DSC  differential scanning calorimetry 
Dt total drug concentration in phase-solubility meas-
urements 
DR  dissolution rate 
drug load  mass fraction of the API of a formulation 
  dX
dt
  dissolved drug (dX) over a time period (dt) 
EMA  European Medicines Agency 
EV  Einschlussverbindung(en) 
f1  difference factor 
f2  similarity factor 
FAO Food and Agriculture Organisation of the United 
Nations 
FB  formulation bulk 
FDA  US Food and Drug Administration 
GIT  gastrointestinal tract/Gastrointestinaltrakt 
GRAS  generally recognised as safe 
h  effective boundary layer thickness 
Hh  Hedgehog pathway 
HME  hot-melt extrusion 
HMG  hot-melt granulation 
HMG Trial A, B, C, D samples of different HMG temperature profiles 
HMG Trial HP  sample of HPβCD HMG case study 
HMG Trial HPMC/10/20 samples of HPMC 4000 HMG case study 
HMG Trial PEG/10/20 samples of PEG 6000 HMG case study 
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HMG Trial SOLU sample of Soluplus® HMG case study 
HMG Trial WG sample of HMG process after WG 
HMG Trial XYL/10/20 samples of xylitol HMG case study 
HPβCD  hydroxy-propyl-beta-cyclodextrin 
HPLC  high performance liquid chromatography  
HPMC  hydroxy propyl methyl cellulose  
i.v.  intravenous  
IC  inclusion complex 
ICF  inclusion complex formation 
IFB  increase in bulk formulation 
ITR  Itraconazole/Itraconazol 
IVIVC  in-vivo – in-vitro correlation 
IVIVR  in-vivo – in-vitro relationship 
JECFA  Joint FAO/WHO Committee of Food Additives 
KN  sample of kneading process 
L  length of extruder screws  
L/D ratio ratio between length and diameter of extruder 
screws 
M  mole per litre 
mg/kg · bw  milligram per kilogram body weight 
min  minute(s) 
mo  month(s) 
mPa · s  milli Pascal · second 
mSSE  melt-single screw extruder 
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mTSE  melt-twin screw extruder 
MWCD  molecular weight of cyclodextrin 
MWdrug  molecular weight of drug 
N  normality, 
molar concentration
equivalence factor
 
NCE  new chemical entity 
NIC  non-inclusion complex 
Nm  Newton metre  
PAT  process analytical technology 
PEG  Polyethylene glycol 
Ph.Eur.  Pharmacopoeia Europaea 
PM  physical mixture 
PMaITR   physical mixture with amorphous itraconazole 
PS  phase solubility 
PSD  phase solubility diagram(s) 
PSM  phase solubility measurements 
PVPVA  polyvinyl pyrrolidone vinyl acetate 
R2  regression coefficient 
H  relative humidity 
rpm  rounds per minute 
Rt  dissolution value of reference at time t 
s   second(s) 
ScS  screw speed 
sd  standard deviation 
SE  Schmelzextrusion 
Appendices 
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SEM  scanning electron microscopy 
SEMP   marketed formulation Sempera® 
SG  Schmelzgranulation 
SOLU  Soluplus® 
t  time point 
TGA  thermogravimetric analysis  
Tt  dissolution value of measurand at time t 
UK  United Kingdom 
US  United States of America 
US$ currency of the United States of America, US-
dollar 
USP  United States Pharmacopeia 
wt/v %  weight per volume per cent 
WG  sample of wet granulation process 
WHO  World Health Organisation 
WS  Wirkstoff 
V  volume 
V/V  volume per volume 
Xd  amount of dissolved drug 
XRPD  X-ray powder diffraction 
XYL  xylitol 
x̅  arithmetic mean 
yr/s  year/s  
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VII.2. Analyser Materials 
Material   Manufacturer  
Acetonitrile Honeywell Riedel-de HaënTM, Fisher 
Scientific GmbH, Germany 
Argon 5.0   Linde AG, Germany 
Bidistilled water freshly produced with in-house 
Finn Aqua 75, San-Asalo-Sohlberg 
Corp., Finland 
Citric Acid, mono hydrate Carl Roth GmbH & Co. KG, Germa-
ny 
Hydrochloric acid   AppliChem GmbH, Germany 
Methanol, HPLC Grade  Avantor Performance Materials Po-
land S.A., Poland 
Nitrogen 5.0   Linde AG, Germany 
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VII.3. Methods for Content Evaluation 
VII.3.1. HPLC Method for Itraconazole Content Evaluation 
Table VII.1. - HPLC method for ITR quantification 
HPLC system 
Agilent 1100 Series LC with diode array detector (Agilent 
Technologies Inc., US) 
Software HPChemstation (Agilent Technologies Inc.) 
Column 
LiChroCart® 125-4, LiChrospher® 100 RP18-5 (Merck KGaA, 
Germany) with precolumn 
Mobile phase 
80/20 V/V% acetonitrile/ bidistilled aqueous citric acid 1 %, 
pH adjusted to 3.2 - 3.3 
Flow rate 2 mL/min 
Oven temperature 20 °C 
Detection wavelength 264 nm 
Injection volume 100 µL 
Run time 3.5 min 
VII.3.2. HPLC Method for Cyclodextrin Content Evaluation 
Table VII.2. - HPLC method for quantification of βCD and HPβCD 
HPLC system 
Agilent 1100 Series LC (Agilent Technologies Inc.) with RI 
detector (Shodex RI-101, Shoko Scientific Co., LTD., Japan) 
Software 
ClarityTM Chromatography Station 6.1 (DataApex, Czech Re-
public)  
Column 
LiChroCart® 250-4, LiChrospher® 100 RP18-5 (Merck 
KGaA) with precolumn 
Mobile phase 10/90 V/V% methanol/bidistilled water 
Flow rate 0.8 mL/min 
Oven temperature 35 °C 
Detector temperature 35 °C 
Injection volume 100 µL 
Run time 15 min 
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VII.3.3. Comparison of Methods for Itraconazole Content Evaluation 
 
Figure VII.1. - Dissolution results of aITR measured by HPLC and UV spectros-
copy; n = 12; error bars = sd. 
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